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ABSTRACT 
 Staphylococcus aureus is known to cause severe systemic infection with high 
mortality rates. Antibiotics are the only approved therapy for patients, but the 
widespread prevalence of antibiotic-resistant strains limits treatment efficacy, and many 
patients succumb to the disease. Many probiotic agents are commercially available, but 
the mechanisms by which they benefit are not known. Understanding these mechanisms 
will help develop novel therapeutics that can improve healthcare, including systemic 
infections by S. aureus. 
 Bacillus subtilis is a probiotic bacterium that produces an exopolysaccharide 
(EPS) that induces anti-inflammatory macrophages (MΦ). We tested if EPS could be 
used for systemic S. aureus infections in mice and found that EPS-treated mice had 
improved outcomes, reducing bacterial load and inflammation. We tested for the 
mechanism behind this protection and found that EPS-induced MΦ, while they 
resemble anti-inflammatory M2 MΦ, restrict the growth of internalized S. aureus 
through reactive oxygen species like that of pro-inflammatory M1 MΦ. In addition, EPS-
induced MΦ retained their anti-inflammatory capacity to limit T cell activation in 
response to S. aureus superantigens, suggesting that EPS-induces a “hybrid” MΦ 
population with both M1- and M2-like qualities, limiting S. aureus growth. In vivo, we 
found that S. aureus induces interferon gamma (IFN-γ) production through natural 
killer (NK) cells, a way to manipulate the host immune system for its own pathogenesis. 
Furthermore, EPS-
 
 
xxi 
 
treated mice did not make IFN-γ in response to S. aureus, suggesting that EPS protects 
hosts from S. aureus also by limiting IFN-γ production. 
 We suggest that EPS primes the host immune system to bolster its antimicrobial 
activity and also limit inflammation, which prevents S. aureus from manipulating the 
host response for its own pathogenesis, leading to reduced disease burden and 
improving outcomes. By our understanding of EPS mechanism for protection, we have 
identified a potential strategy to help patients with systemic S. aureus infection. 
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CHAPTER ONE 
REVIEW OF LITERATURE 
A Brief History of Probiotics 
 Human beings come in contact with microbes ubiquitously throughout their 
daily lives. A common way by which people encounter microbes is through consumption 
of fermented food products, depicted even in ancient Egyptian hieroglyphs. Many 
cultures have adopted fermented food products in their diet, probably due to 
fermentation being used as a method for food storage. Today, a variety of different 
fermented food products are readily available due to extensive globalization. In addition, 
recent advances in our knowledge of the microbes that mediate fermentation have 
pointed to the potential health benefits of fermented food products, and with the 
emergence of the wellness industry, microbial encounter through consumption of 
fermented food products is more widespread than ever. 
 While the story of fermentation through microbes originates from early human 
history, the microbes that mediate host benefits were not appreciated until more 
recently. The first probiotic, microbes that benefit the host, was not conceptualized until 
Élie Metchnikoff associated lactic acid-producing bacteria, termed Bulgarian bacillus at 
the time, in yogurt with longevity of life in 1908 (Metchnikoff, 1908). The first accepted 
trial with probiotics was reported in 1922 when Leo Frederick Rettger and Harry A. 
Cheplin observed apparent improvements in chronic constipation, diarrhea, and eczema 
in 30 patients through administration of Lactobacillus acidophilus 
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(Rettger and Cheplin, 1921), though it should be noted that randomized clinical trials 
using placebos were not standard until about the 1950s. Since then, the number of 
publications and randomized clinical trials related to probiotics has surged, especially 
since the 2000s (McFarland, 2015). Today, a variety of probiotic products are readily 
available to the public commercially, behind an industry with an estimated value of $87 
billion (Stanton et al., 2001). Despite widespread use for apparent health benefits, the 
specific mechanisms that underlie these benefits are generally not clear, limiting the use 
of probiotics in mainstream healthcare settings since measuring efficacy and predicting 
potential adverse effects are difficult. Therefore, understanding the underlying biology 
of probiotics and their interactions with the host is critical for transforming beneficial 
microbes into a novel sector of healthcare innovations. 
Probiotic Mechanism of Action: Colonization Resistance 
Microbial Colonization of the Gastrointestinal Tract 
 Most studies of probiotics and their mechanisms of action focus on the 
gastrointestinal (GI) tract, as many probiotic organisms have been isolated from the GI 
tract and are administered orally such as Henry Tissier’s Bifidobacterium bifidum, 
Alfred Nissle’s Escherichia coli Nissle 1917, and Minoru Shirota’s Lactobacillus casei 
subspecies Shirota. The GI tract hosts a significant number of microbial cells, a number 
estimated to equal the number of human cells in the entire body (Sender et al., 2016). 
However, different sections within the GI tract provide diverse environmental 
conditions for which microbes must adapt. In the oropharyngeal lumen, salivary 
secretions contain a variety of digestive enzymes that dictate the kinds of nutrients that 
are available. In addition, saliva contains antimicrobial molecules such as lysozyme and 
peroxide, dictating what kind of microbes can survive within the oropharyngeal mucosa. 
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In the gastric tissue, parietal cells produce hydrochloric acid that lowers luminal pH to 1, 
a major adaptive barrier for microbes. In fact, a major quality of what is considered a 
“good” probiotic is the ability to survive passage through the acidic gastric lumen, so 
they could efficiently colonize the lower GI tract (Hill et al., 2014). The small intestine is 
subject to many digestive enzymes and molecules such as pancreatic secretions, bile 
secretions, and brush border enzymes intrinsic to the small intestines. Like in the 
oropharynx, these enzymes dictate the types of nutrients available and subsequently put 
selective pressure on microbes to adapt. In addition, bile acids can have antimicrobial 
activities (Binder et al., 1975), which put additional selective pressure on microbes. Also, 
the lower GI tract is under massive immune surveillance that the microbes must deal 
with to avoid elimination from the GI mucosa. As for the colon, a key distinguishing 
environmental feature is the low oxygen content, measured at below 1 millimeter 
mercury (mmHg) (Albenberg et al., 2014). Consequently, anaerobic bacteria are 
enriched in the microbiome of the colon (Hugon et al., 2015; The Human Microbiome 
Project Consortium, 2012). While the lower GI tract is the most densely colonized, it 
should be noted that microbes are not limited to the GI tract. In fact, the microbiome 
exists within other organs as well, including skin, upper and lower respiratory tracts, 
and genitourinary tract, each with its own environmental factors that require their own 
specific adaptations for microbial survival (The Human Microbiome Project Consortium, 
2012). The diversity of the microbiota is further enhanced because each organ harbors 
specialized spaces with distinct environments. While one would typically assume an 
oxygen-rich environment in the oropharyngeal mucosa as it shares space with the upper 
airways, certain places such as the deep crypts of tonsils harbor a robust community of 
anaerobic microbes (Brook, 1981), indicating an anaerobic microenvironment within the 
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tissue. In the gastric tissue, the lumen generally measures at low pH as discussed above, 
but it is thought that the pH may be less acidic in spaces juxtaposed to the gastric 
epithelium due to bicarbonate secretion by the non-parietal cells, assumed to be a 
mechanism to protect gastric epithelium from acidic damage (Flemström, 1977). This 
creates a microenvironment distinct from the lumen of the gastric tissue, where the pH 
is relatively less acidic and allows for bacteria to survive and colonize. These 
microenvironments are also subject to modulation by host physiology and behavior 
since neutralization of gastric acid often occurs in patients given proton pump inhibitor 
therapy which can cause a 104-fold increase in gastric luminal pH with just a single dose 
(Laine et al., 2008). Therefore, while a vast number of microbes colonize a variety of 
different parts of the human body, they do so specifically within given 
microenvironments, termed niches, with specific adaptations to the nutrients and other 
factors particular to that niche. As such, microbes must compete with other microbes, as 
well as with the host, for limited space and nutrients to survive. To this end, many 
probiotics have adapted specific strategies to outcompete other microbes, and through 
many of these mechanisms, probiotics can limit colonization of host by pathogens. The 
ability of the host and its microbiota to not allow colonization by pathogens is termed 
colonization resistance, the very first mechanism by which probiotics were thought to 
benefit the host as conceptualized by Metchnikoff, to prevent colonization by microbes 
that promoted putrefaction of the GI tract (Metchnikoff, 1908). 
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Direct Competition of Microbes 
 Today, there are many mechanisms described by which microbes compete 
against other microbes. Lactobacilli are the prototypic probiotic bacterium studied early 
on in the field, aptly named for their production of lactic acid through their metabolic 
processes, which gave the sour taste associated with probiotic-containing foods. Lactic 
acid production reduces pH, as low as pH 4.5 in the female genitourinary tract in 
humans (Andersch et al., 1986), which limits the growth of other bacteria not adapted 
for acidic conditions; presence of Lactobacilli and low pH in the female genitourinary 
tract was associated with reduced risk for bacterial vaginosis (Spiegel et al., 1980). This 
acid production or “souring” quality in milk was originally the quality associated with 
the beneficial activity (Rettger and Cheplin, 1921). Still, acid production is not the only 
mechanism by which Lactobacillus species can compete against other bacteria. 
Lactobacilli can use oxygen as the terminal electron acceptor for its metabolism through 
flavoproteins that catalyze the formation of hydrogen peroxide (H2O2) that can be toxic 
to other microbes (Eschenbach et al., 1989). The spent culture medium of Lactobacilli 
was demonstrated to have antibacterial activity on Staphylococcus aureus in vitro 
(Dahiya and Speck, 1968). This effect was ameliorated by treating the spent medium 
with catalase, an enzyme that converts H2O2 to water and oxygen, indicating that H2O2 
was responsible for the antibacterial activity of Lactobacilli. Though the specific 
molecules and modifications affected by H2O2 in target microbes are not known, it is 
generally thought that the oxidative damage from superoxide radicals derived from the 
peroxide disrupts cellular processes, leading to bactericidal or bacteriostatic activity 
(Dahiya and Speck, 1968; Thomas et al., 1994).   
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 Lactobacilli also produce other factors that confer a broad antibacterial activity 
in vitro, as L. acidophilus LA1 was shown to secrete molecules that inhibit growth of 
many gram positive and gram negative pathogens such as Listeria monocytogenes, S. 
aureus, Salmonella typhimurium, and Pseudomonas aeruginosa, though the molecules 
that mediate this antibacterial activity have not been identified (Bernet-Camard et al., 
1997). 
 Within the niche, microbes compete for nutrients against each other and against 
the host as well. The fiercest competitions occur over trace nutrients such as metals that 
serve as cofactors in many biological processes. Iron is the best studied of these and is 
actually one of the most abundant elements on Earth (Morgan and Anders, 1980), 
though most are inaccessible to biological entities. Many forms of life require relatively 
high concentrations of iron, but iron is quite insoluble under physiologic conditions. 
Ferric iron, the free aqueous form, have an estimated solubility at attomolar (aM, 10-18) 
concentrations. The host also requires iron for many physiologic processes, and 
therefore absorbs much of the dietary iron in the proximal small intestine and tightly 
regulates circulating iron levels to avoid toxicity. Therefore, iron is very limited in the 
extracellular space, which also serves as a host defense mechanism to limit bacterial 
overgrowth and virulence, and patients under iron overload conditions often fare worse 
during infection (Barry and Reeve, 1977). Bacteria have developed many iron acquisition 
systems designed to scavenge iron from the environment, with the best-characterized 
system being the siderophores. Siderophores are essentially metal-binding chelators 
secreted by the bacteria, with an affinity for iron that generally thought to exceed host 
iron chelators like transferrin (Fetherston et al., 2010). Once the iron-siderophore 
complex is formed, bacteria take up the iron through active transport using specific 
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transporter systems (Bäumler et al., 1998). By sequestering the trace iron from the 
environment, uptake of iron by a probiotic bacterium can contribute to iron limitation 
within the niche, potentially limiting the growth of pathogens. An example of this is 
demonstrated in E. coli Nissle 1917, a probiotic strain of E. coli isolated from a soldier 
who was thought to be resistant to an outbreak of diarrhea by Alfred Nissle in 1917. 
Administration of E. coli Nissle 1917, but not a mutant defective in iron-acquisition, 
reduced colonization by the enteric pathogen S. typhimurium in a murine model (Deriu 
et al., 2013), demonstrating an ability of a probiotic to outcompete an already 
established pathogen through iron sequestration. As discussed above, iron is not the 
only trace metal for which the bacteria compete. In the case of Campylobacter jejuni, a 
commensal bacterium in the GI tract of chickens, successful colonization depends on its 
zinc acquisition system in normal chickens but not in germ-free chickens, indicating 
that C. jejuni uses its zinc acquisition system for colonization when zinc is limited due to 
microbial competition (Gielda and DiRita, 2012). It should be noted that metal 
acquisition can have effects beyond the context of microbial competition, since in many 
pathogens the levels of intracellular metals dictate expression of virulence factors 
(Fetherston et al., 2010; Kirienko et al., 2013; Martin et al., 2013; Peralta et al., 2016). 
Therefore, one way probiotics could benefit hosts through metal sequestration may also 
be through suppressing virulence of pathogens by limiting their acquisition of metals. 
 There are also more direct mechanisms by which bacteria compete with others, 
such as bacteriocins that directly kill other bacteria. Bacteriocins are a broad group of 
peptides secreted by bacteria that kills targets but not the producer, due to the presence 
of immunity proteins. Due to their heterogeneous nature, the mechanisms of action for 
bacteriocins are quite diverse, though many mechanisms resemble those of current 
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antimicrobial agents such as inhibition of peptidoglycan synthesis, pore formation, 
inhibition of deoxyribonucleic acid (DNA) gyrase, and inhibition of protein synthesis 
(Diep et al., 2007; Kobayashi et al., 2010; Parks et al., 2007; Piper et al., 2009). 
Lactobacillus salivarius subspecies salivarius UCC118 is a probiotic that produces the 
bacteriocin ABP-118 that has antibacterial activity against L. monocytogenes in vitro 
(Flynn et al., 2002), demonstrating the potential for probiotic bacteriocin-mediated 
inhibition of a pathogen. Still, the most interesting aspect of bacteriocins is that they are 
genetically amenable for engineering, due to their proteinaceous nature. This potential 
is best demonstrated in heterologous expression of ABP-118 in other bacteria such as 
Lactobacillus plantarum and Lactobacillus lactis (Flynn et al., 2002), showing that 
probiotics could be engineered to produce bacteriocins to target specific pathogens. Still, 
the direct antibacterial activities of bacteriocins could give rise to resistant pathogens 
through mutations, primarily the same concern with any novel antimicrobial agents. In 
summary, probiotic bacteria use a variety of mechanisms to compete within the niches, 
and through these mechanisms, contribute to host resistance to colonization by 
pathogens. 
Competition in the Context of the Microbiota 
 Lactobacilli were the first probiotic embraced by the mainstream scientific 
community and have been studied for more than a century (Lee et al., 2019; Metchnikoff, 
1908; Rettger and Cheplin, 1921). The principal mechanism by which they benefit is 
thought to be by directly limiting the growth of pathogenic microbes through the ways 
described above. Under this scenario, orally administered Lactobacillus probiotic would 
survive the harsh conditions of the upper GI tract and colonize the lower GI tract with 
great efficiency where it would mediate its beneficial effects; this trait of a probiotic is 
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stressed even in the most recent definition of what constitutes a “good” probiotic (Hill et 
al., 2014). Initially, Lactobacilli were reported to represent the majority of the culturable 
bacteria from human feces (Rettger and Cheplin, 1921). Of course, anaerobic culture 
techniques were not developed until the 1960s, and studies after this era demonstrated 
that orally administered Lactobacilli species only form marginal populations within the 
human GI tract, at best estimated to be 0.01% of culturable bacteria (Dal Bello et al., 
2003; Finegold et al., 1974). This observation from multiple studies accounting for 
anaerobic bacteria seemed inconsistent with the idea that Lactobacilli exclude 
pathogens in the GI tract through direct competition, given that other bacteria made up 
the dominant population. Since then, many probiotics have been screened for 
colonization efficiency (Jacobsen et al., 1999). For example, specific strains of 
Lactobacillus probiotics with high colonization efficiency such as Lactobacillus 
rhamnosus GG have been identified, and have been the focus of probiotic studies 
(Canani et al., 2015; Jacobsen et al., 1999; Yan et al., 2016). 
 The GI tract harbors a complex community of microbes, collectively termed the 
microbiota, that in recent years gained appreciation for its ability to affect host 
physiology in virtually every organ system (Abrams and Bishop, 1967; Atarashi et al., 
2011; Furusawa et al., 2013; Mazmanian et al., 2008; Al Nabhani et al., 2019; Sharon et 
al., 2010; et al., 2015; Tyagi et al., 2018). The underlying mechanisms by which the 
microbiota affect host physiology are not entirely clear, but it is well accepted that the 
different composition of the microbiota correlates with the different physiologic 
conditions or processes, including colonization resistance against pathogens. Likely, 
host environmental contact plays a great role in the composition of the microbiota, as it 
would dictate what microbes are introduced into the system. Once exposed, host factors 
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such as barriers, nutrient availability, already existing microbes within the host, and 
immunity would select certain microbes for colonization in various niches. Within 
niches, individual microbial members compete with one another to dictate which would 
successfully occupy the niche, forming the microbiota. Some members of the microbiota 
could indirectly affect the microbial composition by affecting host physiology, altering 
the niche microenvironment. Therefore, a vast number of relatively simple mechanisms 
from individual microbes combine to form a complex network of interactions that likely 
dictate the overall composition of the microbiota within the host. In turn, this may 
suggest that the introduction of a relatively minor member such as a Lactobacillus 
probiotic into the GI tract could have profound downstream effects on pathogen 
exclusion through the change in microbial composition in response to Lactobacilli or 
other probiotics. Of course, the exact composition of the microbiota responsible for 
pathogen exclusion is not known, and how probiotics specifically alter the composition 
of the microbiota has not been extensively studied. For now, there is an interest in using 
a combination of probiotic organisms to benefit hosts such as VSL#3 (Gionchetti et al., 
2000) that is commercially available, with the idea that by providing multiple agents of 
supposedly “good” bacteria, more beneficial mechanisms could be deployed, and better 
host colonization resistance against pathogen could be achieved. Understanding the 
dynamics of microbial composition in the context of host resistance to pathogens will be 
needed to understand better the full range of ways probiotics could promote exclusion of 
pathogens. 
 Ironically, the most successful form of microbial therapy designed to alter the 
microbial composition is one of the oldest: fecal transplantation. Fecal transplantation 
involves the transfer of fecal matter and its microbial content from a healthy donor to a 
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recipient in an attempt to treat disease and is supposedly documented in a 4th-century 
traditional Chinese medicine textbook (Zhang et al., 2012). In the modern era, fecal 
transplantation is most often used to treat Clostridium difficile infection (CDI), a severe 
diarrheal disease in patients after antibiotic use due to GI dysbiosis. CDI patients are 
initially treated with antibiotics which is efficacious, but this perpetuates the GI 
dysbiosis that allows for C. difficile colonization in the first place, and many patients 
experience recurrent infections (McDonald et al., 2018). 
 In a clinical trial, fecal transplantation was attempted on patients suffering from 
recurrent CDI with the idea that resolving the dysbiosis by the transfer of a “healthy” 
microbiota will restore colonization resistance to the pathogen and cure disease. 
Compared to vancomycin, the standard therapy, fecal transplantation was so much 
more efficacious that the study, although controversial, was stopped early with the 
conclusion that fecal transplantation is the superior therapy (Van Nood et al., 2013). 
Currently, fecal transplantation is recommended for patients with more than two 
recurrent CDI episodes (McDonald et al., 2018). Still, what constitutes a “healthy” 
microbiota is unclear, let alone the methods to standardize the criteria for selecting 
“healthy” donors for obtaining transplant material. In addition, fecal transplantation 
has been extensively used in animal models to transfer physiologic traits to demonstrate 
the role of microbiota in host processes, including obesity (Ridaura et al., 2013). Thus, 
fecal transplantation has the potential to be therapeutically useful in many conditions, 
but without a complete understanding of how specific microbial compositions affect 
physiology, unintended consequences such as transfer of metabolic syndromes could 
occur (Alang and Kelly, 2015). Nevertheless, a key mechanism by which probiotics could 
benefit the host is through competition for nutrients and niches for survival, which can 
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directly or indirectly limit colonization of the host by pathogens. Probiotics also possess 
these mechanisms to outcompete pathogens, and the potential to use microbes directly 
for therapy is demonstrated in one of the oldest therapies. A better understanding of 
how members of the microbiota confer host colonization resistance to pathogens will 
help develop specific microbial therapies that are efficacious and result in adverse 
effects that are predictable and manageable. 
Probiotic Mechanism of Action: Manipulation of the Host Barrier 
The Gastrointestinal Epithelial Barrier, the Host-Microbe Interface 
 The key feature of the host immune system is the ability to selectively respond 
against foreign pathogenic antigens but not innocuous self- or non-self-associated 
antigens. This challenge is perhaps best represented within host mucosal surfaces, 
especially the GI tract, where the host is in perpetual contact with the members of the 
commensal microbiota. Here, mounting an inappropriate response against food or 
commensal antigens would result in an inflammatory response that could impede 
normal functions of the GI tract essential for life. Such dysregulation of GI immune 
homeostasis is thought to cause GI disorders such as inflammatory bowel disease (IBD) 
and colon cancer (Feng et al., 2015; Al Nabhani et al., 2019; Willing et al., 2009). The 
immune system harbors a complex array of mechanisms to maintain immune 
homeostasis, especially at mucosal sites (Chung et al., 2011; Coombes et al., 2007; Craig 
and Cebra, 1971; Gabanyi et al., 2016; Sakaguchi et al., 1995). However, failure to 
respond to potentially invasive pathogens can lead to dissemination of the pathogen. 
Thus, the mucosal immune system must harbor mechanisms to tightly regulate 
immunity and strike a delicate balance to ensure host survival. This process generally 
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starts at the point of contact between the host and microbes, the intestinal epithelial 
barrier. 
 The GI tract is the most significant barrier surface, lined by a single layer of 
columnar epithelial cells that are designed to absorb nutrients while restricting 
translocation of microbes from the lumen. To prevent inappropriate triggering of 
immune responses against commensals within the lumen, intestinal epithelial cells 
generally sequester some of their pattern recognition receptors (PRR) to surfaces in 
deep crypts or on the basolateral side of the cell, especially in the colon where microbes 
most heavily colonize (Chabot et al., 2006; Vamadevan et al., 2010). 
 The intestinal epithelial cells are supported by an array of immune and non-
immune cells within the GI mucosa and within the gut-associated lymphoid tissues 
(GALT) that play important roles such as excluding luminal pathogens, suppressing 
inappropriate inflammation, responding against invading pathogens, and promoting 
wound healing to maintain the intestinal barrier functions (Cario et al., 2007; Coombes 
et al., 2007; Kim et al., 2018; Lycke et al., 1987; Silvey et al., 2001). Loss of this barrier 
function leads to increased non-specific translocation of GI luminal contents including 
the microbes, which could trigger PRRs on epithelial cells and mucosal immune cells to 
induce inflammation, leading to GI tract disorders such as IBD. Because of their nearly 
ubiquitous presence amongst many host organisms from Drosophila to humans, GI 
tract commensals are thought to have co-evolved with the host and are thought to 
harbor many mutually beneficial processes such as promoting gut barrier functions and 
maintaining immune homeostasis. This is highlighted by the observations that immune 
disorders such as IBD are associated with dysbiosis (Willing et al., 2009), although the 
mechanism behind the phenomena is not clear. While there are a lot of mechanisms by 
14 
 
 
 
which commensals probably do this, the majority of the studies on probiotics have 
focused on three major mechanisms the host utilizes to maintain the gut barrier that 
commensals are able to reinforce: strengthening the epithelial tight junctions, 
promoting mucus and antimicrobial secretions, and modulating IgA responses as 
described in Table 1. 
Modulation of Epithelial Cell Barrier Functions 
 As previously described, the GI lumen is lined by a single layer of intestinal 
epithelial cells that are joined together by tight junctions, adherens junctions, and 
desmosomes. Desmosomes, or macula adherens, are cell-cell junction plaques that 
anchor intracellular intermediate filaments between cells, providing structural integrity 
for the epithelial monolayer. Adherens junctions, or zonula adherens, are actin-
anchoring cell-cell junctions that utilize calcium-dependent cadherin-catenin 
interactions that not only join neighboring cells together but also promote apical and 
basolateral polarization of the intestinal epithelium. Lastly, tight junctions, or zonula 
Table 1: Major Mechanisms by which Probiotics can Exclude Pathogens in 
the GI Tract. 
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occludens, are the most apical of the cell-cell adhesions that facilitate selective transport 
of ions and solutes and also prevent translocation of microbes and toxins. Of the 
adhesive junctions, tight junctions are the best characterized and have been the subject 
of studies related to probiotics. Probiotics can enhance the functions of tight junctions, 
which would strengthen the epithelial barrier integrity. Overall functions of tight 
junctions can be estimated in vitro by measuring electrical resistance across the 
epithelial monolayer, or transepithelial resistance (TER). For example, probiotic strains 
of L. acidophilus and Streptococcus thermophilus slightly increased TER in Caco-2 cells, 
a human colonic epithelial cell line (Resta-Lenert and Barrett, 2003). In the same study, 
the probiotics helped HT-29 cells, another human colonic cell line, maintain TER levels 
during infection with enteroinvasive E. coli (EIEC), which normally results in a 3-fold 
loss in TER within 24 hours. This correlated with a reduction in the number of EIEC 
colony forming units (CFU) that passed through the epithelial cells, suggesting that the 
probiotics help keep the invasive pathogen at bay by strengthening the epithelial tight 
junctions (Resta-Lenert and Barrett, 2003). Tight junctions consist of four families of 
proteins: occludins, claudins, junctional adhesion molecules, and tricellulins (Furuse et 
al., 1993; 1998; Ikenouchi et al., 2005; Stevenson et al., 1986). Occludins are regulated 
through phosphorylation that helps localize these proteins to the tight junctions to link 
the junction to the actin cytoskeleton (Andreeva et al., 2001). Treatment of HT-29 cells 
with L. acidophilus and S. thermophilus resulted in an increase in occludin and zona 
occludens protein 1 (ZO-1) phosphorylation suggesting that the probiotics function 
through modulation of tight junction proteins (Resta-Lenert and Barrett, 2003). Live 
probiotics were required for these effects implying that there are some effector 
molecules produced by the probiotics, but the molecules remain unidentified. In 
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addition, these probiotics induced phosphorylation of extracellular signal-regulated 
kinases 1 and 2 (ERK1 and ERK2) (Resta-Lenert and Barrett, 2003), but how the 
probiotics influence this pathway and what other pathways are influenced remain to be 
elucidated. It should be noted that there is no evidence yet for these probiotics 
influencing tight junctions in vivo. One concern for these probiotics is that spent 
medium from L. acidophilus and S. thermophilus cultures were unable to influence tight 
junctions in vitro, suggesting a requirement for close contact of live bacteria to the 
epithelial cells (Resta-Lenert and Barrett, 2003). In the GI tract, the majority of 
commensals are thought to be spatially separated from the epithelium with a layer of 
mucus secreted by the goblet cells (Johansson et al., 2008), and it is unclear if probiotics 
could come in close contact with the epithelial cells and affect tight junctions in vivo. A 
mucus-producing clone of HT-29 cells (HT-29-MTX) is available (Gagnon et al., 2013) 
and could be used to determine if a probiotic could affect tight junctions in the presence 
of host mucus. 
 Barrier dysfunctions have been well-documented in many inflammatory 
conditions of the mucosa (Johansson et al., 2014; Meddings et al., 1999), and 
inflammatory mediators such as interferon gamma (IFN-γ) and tumor necrosis factor 
alpha (TNF-α) have been demonstrated to increase epithelial monolayer permeability 
and decrease TER in many epithelial cell lines (Fish et al., 1999; Madara and Stafford, 
1989; Schmitz et al., 1999). Bifidobacterium infantis is a probiotic present in the VSL#3 
formulation and B. infantis-conditioned medium prevented TER loss induced by IFN-γ 
and TNF-α in T84 cells, another human colon cancer cell line (Ewaschuk et al., 2008). B. 
infantis-conditioned medium did this using a similar mechanism as L. acidophilus: 
increase in TER, increased levels of claudins and occludins, and phosphorylation of 
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ERK1 and 2. Ewaschuk and colleagues were able to assess the effects of B. infantis in 
vivo by measuring ex vivo tissue permeability of colons isolated from mice treated with 
B. infantis. They found that B. infantis reduced intestinal permeability and that these 
effects correlated with beneficial effects, as B. infantis reduced colitis due to interleukin-
10 (IL-10)-deficiency (Ewaschuk et al., 2008). However, splenocytes from B. infantis-
treated mice produced reduced levels of IFN-γ, and colonic IFN-γ levels were indeed 
reduced as well, making it difficult to know if the reduction in colitis by B. infantis 
administration was due to direct improvement on tight junction functions or due to a 
decrease in inflammatory cytokines. Modulation of immunity by probiotics is a subject 
of further discussion, but this study demonstrates that a probiotic can reinforce tight 
junction functions in vivo to benefit hosts during inflammation-induced colitis 
(Ewaschuk et al., 2008). 
 Some mechanisms by which probiotics reinforce the intestinal barrier functions 
do not necessarily involve the tight junctions. The intestinal epithelial cells are subject to 
high rates of turnover, constantly being shed from the luminal surface, and then 
replaced by proliferation and differentiation of the stem cells found in the crypts 
(Bjerknes and Cheng, 1981). Noxious stimuli such as inflammation can cause death of 
GI epithelial cells to disrupt the barrier and trigger an inflammatory reaction that 
further increases intestinal permeability. Specifically, TNF induces epithelial cell 
apoptosis, a programmed form of cell death, in cell lines and in mouse colon explants 
which can be prevented by conditioned medium from L. rhamnosus GG (Yan et al., 
2007). L. rhamnosus GG does this by activating protein kinase B (Akt) that mediates 
cellular pro-survival signals, and this activity was attributed to two unidentified proteins 
of 75 and 40 kilodaltons (kDa) in size (Yan et al., 2007). There are many mechanisms by 
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which probiotics can limit epithelial permeability, and through these, probiotics can 
help exclude pathogens from invasion. Still, the specific molecules that mediate these 
effects remain mostly unidentified, and elucidating the mechanisms, especially the 
signaling pathways by which epithelial barriers are reinforced, would help identify 
targets for therapies in many inflammatory GI conditions. 
Modulation of Epithelial Secretions 
 It is essential to recognize that the epithelium is not just a physical barrier, but 
also an active participant in regulating the intestinal microbiota. To this end, the 
epithelial layer hosts specialized cell types that serve specific functions. Goblet cells, first 
noted by Friedrich Henle in 1837 and noted for mucus production by Franz von Leydig 
in 1857, are one such cell type, forming a gel-like layer that covers the luminal surface of 
the GI epithelium. In the colon, the mucus layer is divided into the inner and outer 
layers. The inner layer is anchored to the goblet cells and is generally thicker, with 
estimated pore sizes around 0.5 μM, which prevent penetration by most bacteria 
(Johansson et al., 2008). About 50 μM (mice) or 200 μM (humans) away from the 
epithelium, the mucus is converted, through proteases, into a thinner outer layer that 
allows penetration by bacteria. This two-layer system is thought to prevent most 
bacteria from coming in direct contact with the epithelium, preventing intestinal 
inflammation. The mucus layers consist of about 50 proteins, and mucin 2 (Muc2) is the 
most critical, as Muc2-deficient mice lack colonic mucus (Johansson et al., 2014). Muc2 
is heavily polymerized and glycosylated, eventually forming a massive web-like structure 
that gives mucus the sticky nature with pore sizes designed to limit bacterial penetration 
(Ambort et al., 2012). Muc3 is another mucin protein of the small intestine thought to be 
large and heavily glycosylated as well (Gum et al., 1997), though the exact function is not 
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known. Germ-free mice have inner mucus layers that are penetrated by microbe-sized 
beads (Johansson et al., 2015), demonstrating that commensals are essential for proper 
formation of the mucus layer. Probiotics can reinforce this mucus layer, which would 
help exclude pathogens from invading the intestinal mucosa. Multiple probiotic 
Lactobacillus species have been shown to increase expression of Muc3 in HT-29 cells, 
which correlated with reduced enteropathogenic E. coli (EPEC) adherence to the cells 
(Mack et al., 2003). VSL#3, a probiotic formulation of multiple organisms, including 
several Lactobacilli (Gionchetti et al., 2000), also increased expression of multiple 
mucin components by HT-29 cells (Otte and Podolsky, 2004). In this study, 
pharmacologic inhibition of mitogen-activated protein kinase (MAPK) prevented this 
increase, indicating that the probiotic mixture affects mucin production through specific 
signals. However, it is not clear how VSL#3 activates the MAPK pathway, and it is not 
clear if any other pathways are involved. It should be noted that no probiotics to date 
have been assessed for their ability to influence goblet cell functions. While intestinal 
cell lines are notorious for being heterogeneous and mucus-producing clones of these 
cell lines have been identified (Gagnon et al., 2013), the major mucus-producing cell 
type is the goblet cell, and this warrants further study. In addition, the ability of specific 
probiotics to influence the mucus layer in vivo has not been assessed. Goblet cells are 
known to be heavily regulated by the immune system (Oeser et al., 2014; Turner et al., 
2013), and given the influence of commensals on immune homeostasis, it would not be 
surprising if probiotics can modulate goblet cell functions through immune modulation 
in vivo. 
 Mucus is not the only secretion at the GI epithelial barrier. Antimicrobial 
peptides (AMP) are oligopeptides with antimicrobial activity, produced by members 
20 
 
 
 
from all kingdoms of life. Since their discovery (Dubos, 1939), more than 5,000 AMPs 
have been discovered or synthesized (Zhao et al., 2013), and a variety of mechanisms 
exist by which they exhibit antimicrobial activity. In the human colon, β-defensins are 
the best characterized AMPs. The human genome encodes 33 β-defensins, of which β-
defensin 1, 2, and 3 are the most extensively studied. β-defensins are small cationic, 
cysteine-rich peptides of about 4 to 5 kDa in size with multiple disulfide bridges between 
the cysteine pairs (Klüver et al., 2005; Schibli et al., 2002). Because of their cationic 
nature, β-defensins preferentially bind to microbial membranes that are negatively 
charged; mammalian cell membranes tend to be more electroneutral. Once bound to the 
microbial surface, β-defensins penetrate through the lipid bilayer, forming a pore 
through which intracellular contents leak, resulting in cell death (Lehrer et al., 1989). 
Probiotics could act by inducing host secretion of AMPs to reinforce antimicrobial 
defenses at the gut barrier. E. coli Nissle 1917 and other probiotic strains of E. coli have 
been demonstrated to increase fecal levels of β-defensin 2 in humans after 3 weeks of 
probiotic administration, and also induced expression of β-defensin 2 messenger RNA 
(mRNA) in Caco-2 cells in vitro (Möndel et al., 2008). While this demonstrates that 
probiotics have the potential to reinforce host antimicrobial defenses through AMPs, it 
is not clear if AMP secretion is responsible for the exclusion of pathogens from the GI 
tract in vivo. In addition, probiotic strains of E. coli are also susceptible to β-defensins, 
and the induction of β-defensin in humans by probiotics is transient, as β-defensin 
levels in feces start to return to baseline by about 9 weeks after treatment (Möndel et al., 
2008). Still, probiotics have the ability to promote host secretions, including mucus and 
AMPs, and through these mechanisms, they can help exclude pathogens from invading 
the mucosal surfaces. 
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Modulation of Secretory IgA 
 The third major mechanism by which probiotics can promote gut barrier 
functions involves a major component of the mucosal immune system, secretory IgA 
(sIgA). In the serum, IgA is primarily in its monomeric form. In the mucosa, IgA is 
primarily in its dimeric form: two monomers joined together by the J chain (Halpern 
and Koshland, 1970; 1973). IgA is the most abundant antibody class, representing about 
70% of antibodies made by mammals (Chodirker and Tomasi, 1963). To this end, the GI 
tract is lined ubiquitously with GALT such as Peyer’s patches in the ileum important for 
the development of IgA-producing cells (Craig and Cebra, 1971). The IgA-secreting 
plasma cells then populate the GI lamina propria, where they are thought to produce 
IgA. The dimeric IgA is bound by the polymeric Ig receptor (pIgR) expressed on 
epithelial cells that mediates basolateral to apical transcytosis of dimeric IgA 
(Brandtzaeg, 1974; Brandtzaeg and Prydz, 1984; Tomasi et al., 1965; Tourville et al., 
1969). Close to the luminal surface, IgA is then released from the pIgR and secreted 
from the epithelium as sIgA, associated to a part of the pIgR known as secretory 
component (Brandtzaeg, 1974; Tourville et al., 1969). Canonically, it is believed that 
sIgA serves as the first-line defense against mucosal pathogens, neutralizing microbial 
toxins and contributing to pathogen exclusion by binding to microbes and limiting their 
penetration through the mucus layer (Boullier et al., 2009; Lycke et al., 1987; Silvey et 
al., 2001). Commensals are important for the production of IgA since germ-free mice 
had no detectable serum IgA and slightly reduced cecal sIgA levels that was restored to 
levels found in conventional mice once commensals were introduced (Benveniste et al., 
1971). Germ-free mice also had reduced numbers of IgA plasma cells in the duodenum 
that were also restored to conventional levels by introducing certain microbes (Moreau 
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et al., 1978), indicating that the microbes stimulate sIgA production by promoting the 
development of IgA-producing cells. Certain probiotics such as L. casei have been 
demonstrated to increase IgA levels in the GI tract by increasing the number of IgA+ 
cells in the small intestines after about a week (Galdeano and Perdigón, 2006). However, 
this IgA was not specific to the administered probiotic, suggesting that L. casei generally 
increases IgA levels rather than inducing an antigen-specific antibody response 
(Galdeano and Perdigón, 2006). By reinforcing sIgA production in the GI tract, 
probiotics have the potential to protect hosts from invading pathogens. 
 While it is important to note that sIgA mediates important canonical functions 
within the GI tract such as neutralization of microbial toxins and exclusion of 
pathogenic microbes (Boullier et al., 2009; Lycke et al., 1987; Silvey et al., 2001), how a 
non-specific increase in sIgA levels would benefit hosts is not immediately clear. In 
addition, it is not clear what mechanisms actually drive increased sIgA levels in 
response to commensals or probiotics. A potential explanation for how probiotics could 
protect hosts through IgA stems from a recent appreciation for how commensals 
influence the IgA repertoire. The diversity of antibody specificities is generated in large 
part by the action of activation-induced cytidine deaminase (AID) in activated B cells 
(Muramatsu et al., 2000). AID functions by converting deoxycytidines to deoxyuracil in 
DNA of the Ig variable (V) genes, which results in the introduction of a transition 
mutation from a cytidine-guanine pair to a thymine-adenine pair, or error-prone 
excision repair of the deoxyuracil, that introduces mutations, diversifying the V gene 
pool as B cells proliferate (Petersen-Mahrt et al., 2002); this process is called somatic 
hypermutation (SHM). AID is also responsible for class switch recombination, which is 
required to generate different antibody classes, including IgA (Muramatsu et al., 2000). 
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Commensal microbes increase the levels of sIgA in the gut (Benveniste et al., 1971), but 
this is only one aspect of what commensals do to influence sIgA production. In germ-
free mice, the level of sIgA is decreased, but also decreased is the frequency of SHM, 
indicating that commensals also influence the generation of sIgA diversity (Lindner et 
al., 2012). The ability to diversify the sIgA repertoire is likely more important than 
increasing sIgA levels to maintain gut homeostasis, since AID mutant mice that have 
defective AID functions had levels of fecal sIgA comparable to that of wild-type (WT) 
mice but had reduced sIgA diversity that correlated with expanded intestinal bacterial 
population and increased invasion by Yersinia enterocolitica during infection (Wei et al., 
2011). The reduction in SHM frequency is also observed in T cell-deficient mice in 
conventional housing, indicating that commensals drive sIgA diversification through T 
cells (Lindner et al., 2012). Generally, microbes are sampled through specialized 
epithelial cells called microfold (M) cells that bring in luminal microbes through 
transcytosis to the associated immune cluster (Bockman and Cooper, 1973; Owen and 
Jones, 1974). Here, antigen presenting cells such as dendritic cells (DC) take up the 
microbe and activate T cells that coordinate germinal center reactions to give rise to 
antibody responses (Alpan et al., 2001). 
 Activated T cells can differentiate into T follicular helper (TFH) cells that are 
critical for selective survival of high-affinity B cells and the maintenance of germinal 
centers (Breitfeld et al., 2000). The germinal center also is home to T follicular 
regulatory (TFR) cells that regulate the germinal center reactions (Chung et al., 2011). 
These follicular T cells help shape the sIgA repertoire against intestinal microbes, as 
evidenced by the change in the profile of IgA-coated intestinal microbes by the transfer 
of follicular T cells into immunodeficient mice (Kawamoto et al., 2014). Therefore, 
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probiotics could promote the development of antigen-specific sIgA responses that could 
target pathogens for exclusion. An example of this is observed with B. bifidum and B. 
infantis that reduce rotavirus-induced diarrhea in mice which correlates with increased 
levels of virus-specific mucosal sIgA levels (Qiao et al., 2002). 
 The specific mechanisms for how the administration of probiotics leads to the 
generation of antibody responses against seemingly unrelated pathogens are not clear, 
but two possibilities seem feasible. For one, the probiotics could harbor some antigens 
that bear a resemblance to those found on pathogens, therefore driving a probiotic-
specific sIgA response that also targets pathogens with similar epitopes, a phenomenon 
that could be described as molecular mimicry. However, probiotics do not usually 
induce a sIgA response targeting itself, as the administration of L. casei increased sIgA 
responses but none that targeted L. casei itself (Galdeano and Perdigón, 2006). Another 
possibility is that, by stimulating GALT immune cells including DCs and follicular T cells, 
overall mucosal antibody responses may be heightened, increasing the likelihood of 
generating antigen-specific antibody responses against others, perhaps pathogens like 
rotavirus. Unfortunately, the increase in sIgA by probiotics is a generally accepted (and 
marketed) benefit that needs further mechanistic understanding, and how it would 
actually be beneficial remains to be studied. 
 A recent observation about sIgA is that a part of the sIgA repertoire is innate-like, 
enriched for polyreactive antibodies, and thought to serve as a first-line defense 
mechanism (Bunker et al., 2017). The natural sIgA arises through a T cell-independent 
process and is not affected by the absence of germinal center reactions or SHM (Bunker 
et al., 2015). The natural IgA coats specific members of the commensal microbiota 
(Bunker et al., 2015; 2017), though what functional outcome this has on host physiology 
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is not clear. However, sIgA can enter the Peyer’s patches in both in vitro and in vivo 
models, where they can be internalized by DCs (Rey et al., 2004), though functional 
outcomes on DCs or germinal center reactions were not assessed in this study. This 
suggests that sIgA-coated commensal microbes could selectively be transported to the 
GALT where they could interact with immune cells to affect host physiology. IgA-coated 
probiotic L. rhamnosus can stimulate DCs isolated from Peyer’s patches to induce 
regulatory T cells (Treg) through IL-10 and transforming growth factor beta (TGF-β) 
(Mikulic et al., 2016). While the ability of IgA-coated L. rhamnosus to enter Peyer’s 
patches in vivo or ex vivo was not assessed, this study suggests that sIgA, given that a 
part of its repertoire selectively binds to commensals, could mediate uptake of 
probiotics into the GALT where it can influence immune homeostasis. A similar 
phenomenon has been described for invasion-deficient Salmonella as well. While 
invasion-deficient Salmonella is avirulent, it is generally not considered a probiotic. Still, 
in vivo administration of IgA-coated invasion-deficient Salmonella by direct injection 
into the duodenum of mice resulted in increased presence of bacteria within the Peyer’s 
patches compared to injection of uncoated bacteria, and this led to the generation of an 
antigen-specific IgA response (Fransen et al., 2015), demonstrating that IgA can 
mediate selective uptake of GI bacteria to promote antigen-specific IgA responses. 
Further investigation into the relationship between sIgA, commensals, and the overall 
IgA repertoire will be needed to understand the basis by which probiotics can protect 
hosts from pathogens through sIgA.  
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Probiotic Mechanism of Action: Immune Homeostasis 
Microbes and Immune Homeostasis 
 While a substantial number of studies have focused on ways probiotics confer 
protection against pathogens through exclusion, it is essential to note that this is not the 
only way probiotics can benefit hosts. In fact, probiotics are currently marketed with 
claimed health benefits that span the entire human body: improved digestion, 
strengthened immune system, reduced allergy, improved cardiovascular functions, and 
even improved psychological health. One particular benefit that is becoming a major 
focus of multiple research disciplines is the effect of the microbiota on immune 
homeostasis. Mucosal surfaces, especially the GI tract, are in constant contact with 
microbes that need to be regulated by host immunity. Failure to regulate the intestinal 
microbes can leave the host vulnerable to pathogenic invasion (Wei et al., 2011). 
However, inappropriate activation of immunity has detrimental effects for the host, as 
evidenced by inflammatory diseases caused by dysregulation of host immunity such as 
IBD (Hugot et al., 2001; Kühn et al., 1993). Therefore, a delicate balance between the 
need to restrict microbes and to limit inflammation must be achieved. To this end, many 
host mechanisms exist to regulate immune responses tightly. We have already discussed 
the influence of the microbiota on host physiology, but the relationship between host 
and commensal microbes is suspected to be more intertwined. One evidence for this is 
the observation that the development of the different arms of the immune system, 
especially adaptive immunity, coincides with the evolutionary appearance of organisms 
that host a complex microbiota (Pancer et al., 2004; Zuo et al., 2017). Therefore, it is 
perhaps not surprising to see that the microbiota exerts its influence on just about every 
major host immunoregulatory mechanisms. Probiotics also target these 
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immunoregulatory mechanisms, mainly those described in Table 2. By reinforcing the 
immunoregulatory mechanisms, probiotics have the ability to promote immune 
homeostasis and prevent inflammatory diseases. 
 
Modulation of Regulatory T Cells 
 The major immune cell type that mediates regulation of immunity is the Treg cell, 
generally defined by the expression of the master transcription factor, forkhead box 
protein P3 (Foxp3) (Fontenot et al., 2003; Hori et al., 2003). Foxp3 expression by Treg 
cells is critical to maintain tolerance to self-antigens, as Foxp3-deficient mice experience 
systemic autoimmune disease and die by about 4 weeks of age (Fontenot et al., 2003). 
In humans, mutations in FOXP3 gene are linked with the systemic autoimmune disease 
known as immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome 
(IPEX) (Bennett et al., 2001). There are two main subtypes of Treg cells, natural Treg 
(nTreg) cells and inducible Treg (iTreg) cells. nTreg cells develop from the thymus through 
the host-intrinsic mechanism and generally mediate central tolerance against self-
antigens upon release into the periphery. Certain peripheral naïve T cells can be induced 
into iTreg cells, which then can mediate tolerance against both self- and foreign-antigens. 
Table 2: Major Mechanisms by which Probiotics Promote Immune 
Homeostasis 
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Unlike nTreg cells, iTreg cells are heavily influenced by the local cytokine milieu, especially 
TGF-β, which is thought to help maintain Foxp3 expression in Treg cells (Zheng et al., 
2010). The canonical anti-inflammatory cytokine IL-10 is also known to potentiate iTreg 
differentiation (Hsu et al., 2015). The GI tract is perhaps the most critical place to 
maintain immune homeostasis, and the balance of effector T cells and Treg cells is critical. 
This was experimentally demonstrated by the transfer of naïve T cells, defined by the 
expression of cluster of differentiation (CD) markers as CD4+CD45RBhigh, to 
immunodeficient mice which recreated a Treg cell-deficient host and resulted in pan-GI 
tract inflammation (Read et al., 2000), assumed to be due to unchecked T cell activation. 
In this model, co-transfer of the CD4+CD25+CD45RBlow compartment, known to be 
enriched for Treg cells, ameliorated inflammation in the GI tract (Read et al., 2000), 
suggesting that Treg cells are important to maintain homeostasis in the GI tract. In the 
colon, the majority of the Treg cells are iTreg cells (Atarashi et al., 2011; Geuking et al., 
2011; Lathrop et al., 2011), and since they are influenced by environmental signals, they 
are thought to be the cells interacting with the microbiota to maintain immune tolerance. 
The microbiota is known to play a role in promoting or maintaining Treg cell population 
within the GI tract since germ-free mice harbor reduced numbers of Treg cells in the 
colonic lamina propria (Geuking et al., 2011). Not surprisingly, a significant way 
probiotics are thought to function in homeostasis is to reinforce the Treg cell 
compartment. Chronic administration of Bifidobacterium breve Yakult strain to mice 
ameliorated colitis in the naive T cell transfer model, and this is thought to be due to an 
increase in the number of colonic Treg cells that produce IL-10 (Jeon et al., 2012). It 
should be noted here that B. breve-induced IL-10+ Treg cells did not express Foxp3, a 
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phenotype consistent with a subset of Treg cells called type 1 Treg cell (Tr1) (Groux et al., 
1997). 
 The effect of microbes on immune homeostasis and Treg cells is often studied in 
the context of the GI tract, but the effects are not necessarily confined locally. Certain 
Clostridium species of the GI tract microbiota are known to be sufficient to induce IL-
10-producing, Foxp3+ Treg cells in the colon in germ-free mice (Atarashi et al., 2011). 
Supplementation of these Clostridia species to normal mice under specific pathogen-
free (SPF) conditions limited colitis induced by the chemical irritant, dextran sodium 
sulfate (DSS) (Atarashi et al., 2011), indicating that the local induction of Treg cells by the 
microbe helps limit inflammation. However, mice supplemented with these Clostridia 
species were also resistant to allergic sensitization as well, as these mice had reduced 
serum levels of ovalbumin- (OVA) specific IgE following systemic immunization with 
OVA (Atarashi et al., 2011). 
 The mechanisms by which microbes in the GI tract can have systemic 
immunomodulatory effects are not clear, but two main possibilities exist. For one, 
locally induced Treg cells, or any other immune cell, could mediate systemic effects either 
by the production of systemic immunoregulatory mediators or by redistribution to other 
tissues. The other possibility is that the mediator molecules of microbes drain into the 
circulation and directly affect immune cells in other tissues. In Clostridia-supplemented 
mice, splenocytes produced higher levels of IL-10 upon stimulation, which suggests that 
IL-10+ Treg cells are present systemically (Atarashi et al., 2011). Still, it is not clear if this 
increased IL-10 production even comes from Treg cells, nor is it clear if these cells 
originated from the GI tract. However, there is compelling evidence for microbial 
products directly affecting tissues outside the GI tract. 
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 Short chain fatty acids (SCFA) are byproducts of microbial fermentation of 
carbon sources, often those that cannot be processed by the mammalian hosts such as 
dietary fiber. Administration of SCFAs to germ-free mice resulted in an increase in 
intestinal Treg cells and protected mice from colitis in the T cell transfer colitis model 
(Smith et al., 2013), indicating that microbes promote immune homeostasis by inducing 
Treg cell differentiation through SCFAs. SCFAs are known to directly promote Treg cell 
differentiation in vitro through G-protein coupled-receptors (GPCR) (Smith et al., 2013), 
and SCFAs can be detected in the human circulation (Cummings et al., 1987), suggesting 
that, by getting into the circulation, SCFAs could directly engage T cells for Treg cell 
differentiation in distant tissues. Indeed, one study demonstrated that administration of 
L. rhamnosus GG to mice resulted in an expansion of SCFA-producing Clostridia, which 
increased Treg cells in the bone marrow to promote bone homeostasis (Tyagi et al., 2018). 
Therefore, by enhancing the Treg compartment, probiotics can help maintain immune 
homeostasis within the local environment and beyond. 
 While probiotics promote Treg cell differentiation, they do not necessarily target 
T cells directly. In fact, the best-characterized probiotics have been found to exert their 
functions through a mediator cell type, generally of the myeloid lineage, which can 
promote Treg cell differentiation. The classic example is an anaerobic member of the 
microbiota, Bacteroides fragilis. B. fragilis is known to ameliorate colitis in multiple 
murine models, and as in many other probiotic agents, this is mediated through the 
induction of IL-10-producing Treg cells (Mazmanian et al., 2008). This protective effect 
requires polysaccharide A (PSA), a zwitterionic polysaccharide that forms the bacterial 
capsule that recapitulates protection from colitis when administered as purified PSA 
(Baumann et al., 1992; Mazmanian et al., 2008). PSA inhibits the production of TNF-α 
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induced by infection with Helicobacter hepaticus in in vitro co-cultures of bone 
marrow-derived DCs (BMDC) and T cells in a Toll-like receptor 2 (TLR2)-dependent 
manner (Mazmanian et al., 2008). In vivo protection from colitis also requires TLR2 
(Mazmanian et al., 2005; Round and Mazmanian, 2010; Wang et al., 2006), indicating 
that PSA exerts its effects in part through TLR2 on DCs. Other probiotics also go 
through mediator cells to induce Treg cells. B. breve Yakult strain induces Tr1 cells in the 
colon and in vitro during co-culture of intestinal CD103+ DCs and splenic CD4+ T cells, a 
process that requires TLR2 signaling in the DCs (Jeon et al., 2012). Non-immune cells 
can also be the mediator cell type for promoting Treg cell differentiation. In the case of 
SCFA-producing microbes, SCFAs can act on pancreatic β cells, the insulin-producing 
cell, to induce production of cathelicidin-related AMP (CRAMP) which promotes anti-
inflammatory polarization of macrophages (MΦ), leading to increased Treg cell 
differentiation that correlates with protection from autoimmune diabetes (Sun et al., 
2015). 
Modulation of Macrophages 
 Other immune cells can also be targeted by microbes to promote immune 
homeostasis. In particular, MΦs are a diverse group of cells of the mononuclear 
phagocyte (MNP) system and tissue resident cells that perform homeostatic functions in 
virtually all tissues (Broug-Holub et al., 1997; Fox et al., 1987; Gautier et al., 2012; 
Geissmann et al., 2003; Mackaness, 1962; Nahrendorf et al., 2007; Nimmerjahn et al., 
2005; Udagawa et al., 1990). Classically, MΦs can be characterized in two major 
categories, classically activated M1 MΦs that mediate pro-inflammatory type I responses 
and alternatively activated M2 MΦs that mediate pro-fibrotic type II responses (Mills et 
al., 2000). Under in vitro conditions, MΦs can be polarized into M1 and M2 MΦs in 
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response to the type I cytokine IFN-γ and a microbial ligand or type II cytokines IL-4 
and IL-13, respectively (Doherty et al., 1993; Held et al., 1999; Murray et al., 1985; 2014; 
Stein et al., 1992). M1 MΦs are best known for their antimicrobial functions and their 
expression of inducible nitric oxide synthase (iNOS). M1 MΦs phagocytose microbes 
and kill them by producing toxic molecules like reactive nitrogen species (RNS) through 
iNOS and reactive oxygen species (ROS) through the action of nicotinamide adenine 
dinucleotide phosphate hydrogen (NADPH) oxidase, a process characterized as the 
respiratory burst (Sbarra and Karnovsky, 1959; Segal, 1987; Xie et al., 1992). M2 MΦs 
are typically associated with immunoregulation and anti-parasite responses, typically 
defined by the expression of arginase 1 (Arg-1) (Munder et al., 1998). M2 MΦs have been 
studied often in tumor environments, specifically designated tumor-associated MΦs 
since these cells are now recognized as a distinct subtype, with robust suppressive 
activity against tumor-specific T cells (Curiel et al., 2004; Kuang et al., 2009; Torroella-
Kouri et al., 2009). M2 MΦs are thought to suppress T cell functions by three different 
mechanisms: inhibitory cytokines, inhibitory cell surface ligands, and local depletion of 
arginine (Curiel et al., 2004; Huber et al., 2010; Modolell et al., 2009; Pesce et al., 2009; 
Taylor et al., 2006). Both iNOS and Arg-1 use arginine as the substrate, and this is 
thought to drive polarization of MΦs since these enzymes mutually exclude the action of 
the other by competing for the same substrate (Munder et al., 1998). However, it is not 
known how these enzymes contribute to differential polarization of MΦs, and there are 
other processes known to influence this polarization such as β-oxidation of fatty acids, a 
process important for M2 polarization (Huang et al., 2014). The designation of MΦs into 
M1 and M2 originally fit well with the two classes of T cell responses (Mills et al., 2000), 
but this likely represents an oversimplified view of MΦs. In fact, other signals that 
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activate MΦs such as IL-10, TGF-β, and glucocorticoids did not fit with the original 
descriptions of M1 and M2 MΦs, and since these signals induced mostly 
immunoregulatory functions like that of M2 MΦs, the M2 MΦs were proposed to be 
further subdivided into subsets based on activating signals (Anderson and Mosser, 2002; 
Edwards et al., 2006; Ehrchen et al., 2007). Still, the factors that affect MΦ phenotypes 
are a seemingly endless list, including salt concentrations (Binger et al., 2015) and even 
cell shape (McWhorter et al., 2013), and attempts to subdivide MΦs into more subsets 
would be equally complex. This is further complicated in vivo due to the different 
developmental ontogeny of MNPs, including MΦs in vivo. The circulating MNP 
progenitors, monocytes, arise from the bone marrow and differentiate into MΦs and 
DCs upon being recruited to tissues (Tamoutounour et al., 2013; Volkman and Gowans, 
1965). However, different tissues harbor resident MΦs that are thought to arise from 
progenitors during fetal and yolk sac lymphopoiesis (Ghosn et al., 2010; Ginhoux et al., 
2010; Hoeffel et al., 2012; De Schepper et al., 2018; Tamoutounour et al., 2013). Given 
the recent appreciation of the complex nature of MNPs in vivo, the most appropriate 
view is likely that MΦs exist in a dynamic spectrum of specialized cells with differing 
ontogeny that constantly modulate their functions in response to environmental cues. 
 The GI tract harbors many MΦs, typically expressing C-X3-C chemokine receptor 
1 (CX3CR1) (Geissmann et al., 2003). The mucosal layer receives constant input from 
the circulating monocytes that replenish the MΦ pool while the deeper muscle layers 
have tissue resident MΦs that self-renew (De Schepper et al., 2018). Based on 
localization, it is thought that the mucosal MΦs mediate interactions with the 
microbiota while MΦs in the muscularis layer interact with the enteric neurons to 
support digestive functions of the GI tract (Gabanyi et al., 2016; De Schepper et al., 
34 
 
 
 
2018). In fact, ablation of GI tract MΦs resulted in increased GI tract transit time, 
indicative of decreased GI motility (De Schepper et al., 2018). Intestinal MΦs play an 
important role in coordinating immune responses against microbes in the GI tract, as 
depletion of CX3CR1+ MNPs resulted in increased T cell responses against intestinal 
pathogens (Kim et al., 2018), indicating that these cells limit inflammation under 
homeostatic conditions. The microbiota is known to influence these MΦs, since 
depletion of the same CX3CR1+ MNPs resulted in decreased T cell responses against 
intestinal pathogens in antibiotic-treated mice (Kim et al., 2018), suggesting that under 
certain conditions, intestinal MΦs promote antimicrobial responses instead. Specific 
microbes can exploit MΦs to promote homeostasis as well. We already discussed SCFAs 
that induce pancreatic CRAMP to modulate MΦs and promote Treg cell differentiation, 
preventing autoimmune diabetes. CRAMP-induced pancreatic MΦs take on an 
immunoregulatory phenotype with high TGF-β production and expression of aldehyde 
dehydrogenase (ALDH), an enzyme involved in retinoic acid (RA) production, which is 
linked with Treg cell differentiation (Sun et al., 2015). Still, it should be noted that this 
study did not assess if CRAMP-induced regulatory MΦs were responsible for Treg cell 
differentiation, and the mechanism by which CRAMP confers this MΦ phenotype is not 
known. Another example is H. hepaticus, which was demonstrated to produce large 
polysaccharides that modulate MΦs to express an anti-inflammatory gene expression 
profile through TLR2, which prevented exacerbation of colitis (Danne et al., 2017). This 
study assessed signaling pathways needed for H. hepaticus polysaccharide in vitro, but 
these pathways were not confirmed in vivo. Nonetheless, these studies demonstrate that 
microbes target MΦs to reinforce their homeostatic functions and prevent inflammatory 
disease. 
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Modulation of Invariant Natural Killer T Cells 
 Another cell type of interest is invariant natural killer T (iNKT) cells, tissue 
resident lymphocytes that recognize lipid antigens presented by the major 
histocompatibility complex (MHC) class I-like molecule, CD1d (Bendelac et al., 1995; 
Kawano et al., 1997). iNKT cells are distributed across many tissues, but they have been 
best characterized in mucosal tissues and adipose tissues. Like the T helper cell 
compartment, iNKT cells develop from the thymus and differentiate into IFN-γ-
producing iNKT1, IL-4-producing iNKT2, IL-17-producing iNKT17, follicular helper 
iNKT, and IL-10-producing regulatory iNKT10 compartments to coordinate different 
immune responses (Georgiev et al., 2016). In the liver, the site where iNKT cells are the 
most frequent, iNKT cells continuously patrol the liver sinusoids (Geissmann et al., 
2005). During infection, the patrolling iNKT cells get activated and become stationary at 
the infective focus, producing pro-inflammatory mediators like IFN-γ (Velázquez et al., 
2008). iNKT cells are thought to then coordinate antimicrobial responses by other cells 
like Kupffer cells, the liver resident MΦs, and help clear pathogens (Lee et al., 2010). 
However, one study demonstrated that during sterile focal liver injury induced by heat, 
iNKT cells get to the injury site but make a 180° turn from the injured focus and settle at 
the edge of injury site (Liew et al., 2017). There, iNKT cells produce IL-4 and not IFN-γ, 
supposedly in response to self-lipid antigens. This was proposed to coordinate the 
differentiation of recruited monocytes to wound healing MΦs through IL-4, as IL-4 
blockade prevented wound healing (Liew et al., 2017). This suggests that under certain 
circumstances, iNKT cells promote wound healing in response to lipid antigens. 
 In the GI tract, iNKT cells represent about 1% of the lymphocyte population 
(Matsuda et al., 2000). Microbes have been suggested to influence the iNKT population 
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within the GI tract, as germ-free mice had increased numbers of colonic iNKT cells 
compared to mice in SPF conditions (Olszak et al., 2012). Specific microbes can have 
similar effects, as the administration of B. fragilis to germ-free mice was sufficient to 
reduce colonic iNKT cell numbers to levels found in mice under SPF conditions (An et 
al., 2014). B. fragilis does this through a specific sphingolipid molecule, GSL-Bf717, 
which limits iNKT cell activation in vitro and is required for reduced iNKT cell numbers 
in vivo (An et al., 2014). iNKT cells are known to drive allergic inflammation in the gut 
through the production of IL-13 in a chemical-induced allergy model (Heller et al., 
2002), and SPF mice and B. fragilis monocolonized mice had reduced inflammation 
during oxazolone-induced colitis compared to germ-free mice (An et al., 2014; Olszak et 
al., 2012), suggesting that microbes reduce inflammation by modulating the gut iNKT 
cells. On the other hand, iNKT cells from germ-free mice are hyporesponsive, and 
exposure to Sphingomonas yanoikuyae was sufficient to restore iNKT maturity 
(Wingender et al., 2012), suggesting that certain microbes instead promote proper 
maturation of iNKT cells to reinforce host defenses. It should be noted that for common 
probiotic organisms, their effects on iNKT cells have not been explored. Since iNKT cells 
play roles in both host defenses and immunoregulation in response to microbes, they 
represent prime targets for probiotic therapy that remains to be explored. 
Bacillus subtilis, the Probiotic 
Exposure to Bacillus subtilis 
 B. subtilis is a gram positive, spore-forming bacterium ubiquitously found in the 
environment, in particular in the soil (Siala et al., 1974). Human exposure to B. subtilis 
is thought to occur through contact with soil and as a part of the diet in many cultures. 
Fermented soybean food products contain B. subtilis, the most widely recognized being 
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natto, a Japanese dish prepared by fermentation of cooked soybeans with a pure culture 
of B. subtilis var. natto (Ashiuchi et al., 1998). As a spore-forming bacterium that has 
been extensively studied by the scientific community, B. subtilis possesses qualities that 
give significant advantages as a potential probiotic product. Bacterial endospores are a 
dormant form of the cell that are generally formed under nutrient-depleted conditions. 
Once formed, spores can persist indefinitely, and can withstand a variety of extreme 
conditions including heat in excess of 100°C and even ultraviolet radiation (Alderton 
and Snell, 1969; Nicholson et al., 2005), which makes long-term storage of B. subtilis as 
a product fairly simple. Upon oral administration of spores, B. subtilis is known to 
complete its life cycle within the GI tract, from germination into a vegetative state to 
endospore formation prior to passage from the gut (Hoa et al., 2001). To date, oral 
administration of B. subtilis has not been associated with any adverse outcomes in 
immunocompetent individuals (Hoa et al., 2001), and B. subtilis has been safely 
consumed as part of fermented soybean products for a long time in certain regions of 
the world, making B. subtilis a durable probiotic easily administered orally, and safe for 
human consumption. 
 As an orally administered probiotic, B. subtilis-containing products have been 
tested for their potentially beneficial effects, though the specific mechanisms have not 
been elucidated. Like many other probiotics, some have suspected that B. subtilis can 
alter colonization of pathogens through competitive exclusion. One study tested if oral 
administration of B. subtilis PY79 spores could alter colonization by the murine enteric 
pathogen, Citrobacter rodentium, and found that B. subtilis-colonized mice had 
reduced the number of C. rodentium CFU by 75% and reduced diarrheal disease 
(D’Arienzo et al., 2006). A more recent study observed in a study in rural Southeast Asia 
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that people colonized with B. subtilis were not colonized with the opportunistic 
pathogen, S. aureus (Piewngam et al., 2018). This study then tested if B. subtilis 
prevents colonization by S. aureus by orally administering spores of B. subtilis NCIB 
3610 to mice and found that this prevented intestinal colonization by S. aureus. This 
exclusion activity was attributed to B. subtilis production of fengycin, a cyclic 
lipopeptide, which interfered with S. aureus accessory gene regulator (Agr) quorum 
sensing critical for expression of various virulence factors (Ji et al., 1995; Piewngam et 
al., 2018). 
Immune Modulation by Bacillus subtilis 
 Another way B. subtilis is thought to benefit hosts is through immune 
modulation. One study treated RAW264.7 MΦs with B. subtilis PY79 spores and found 
that the spores were taken up by the MΦs, which had slightly increased IL-6 gene 
expression (Duc et al., 2004). The authors also administered spores to mice orally and 
found an increase in gene expression of IFN-γ and TNF-α in intestinal tissues and in 
GALT, suggesting that B. subtilis spores stimulate the immune system. In another study, 
B. subtilis A109 spores orally administered to mice were shown to result in increased 
MΦ oxidative burst activity when stimulated, and increased natural killer (NK) cell 
killing activity (Kosaka et al., 1998), indicating that B. subtilis stimulates multiple 
immune cells in vivo. Rhee and colleagues investigated the role of microbes in GALT 
development in rabbits and found that specific members of the microbiota, including B. 
subtilis, promote GALT development that is important for antibody repertoire 
diversification (Rhee et al., 2004). For the development of rabbit GALT, factors 
associated with stress responses in B. subtilis were required, though the mechanism 
behind this was not clear. In fact, how B. subtilis stimulates immune cells in all of the 
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studies discussed above is not known. Understanding how B. subtilis modulates the 
immune system, by identifying bacterial immunomodulatory factors and the 
corresponding host response pathways, will be critical for developing B. subtilis into a 
therapy that could be used in many clinical settings. 
Bacillus subtilis Exopolysaccharide 
 Our group was interested in understanding the mechanism by which B. subtilis 
benefits hosts, especially in the context of disease processes. The group initially chose 
the C. rodentium-induced murine colitis model where B. subtilis had been 
demonstrated to be protective (D’Arienzo et al., 2006), and confirmed the beneficial 
effect of B. subtilis in C. rodentium infection using an undomesticated, biofilm-forming 
strain of B. subtilis, NCIB 3610 (Jones and Knight, 2012). Bacterial biofilms are a 
community of bacterial cells encased within a self-produced extracellular matrix 
composed of carbohydrates, proteins, and nucleic acids. B. subtilis biofilms are also 
composed of a complex matrix, and the two major components are the protein TasA and 
the polysaccharide EPS produced by the products of the 15 gene eps operon, encoding 
epsA through epsO (Branda et al., 2001; 2006). Administration of a B. subtilis epsH 
mutant that fails to produce EPS could not protect mice from C. rodentium-induced 
colitis, suggesting that EPS is required for protection (Jones and Knight, 2012). Biofilm-
associated bacteria are thought to be more persistent (Anwar et al., 1992), and it may be 
that biofilm formation by B. subtilis is needed to prevent C. rodentium pathology by 
better excluding the pathogen through competition. However, pre-treatment of mice 
with B. subtilis PY79 only mildly reduced the number of C. rodentium CFU in the colon 
in the original study (D’Arienzo et al., 2006), and no difference in C. rodentium CFU or 
any alteration in colonization in B. subtilis NCIB 3610-treated mice was observed in the 
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studies by Jones and colleagues (Jones and Knight, 2012; Jones et al., 2014), indicating 
that the assumption that B. subtilis protects through exclusion of C. rodentium from the 
GI tract may not be correct. It should be noted that a few key differences between 
studies by the two groups could explain the differences observed. One is that B. subtilis 
PY79 is a domesticated laboratory strain that does not form robust biofilms as B. subtilis 
NCIB 3610 does under in vitro conditions (Branda et al., 2001), which may affect the 
way B. subtilis colonizes the GI tract. Another is that D’Arienzo and colleagues infected 
suckling NIH Swiss mice with 103 CFU C. rodentium while Jones and Knight used 
C57BL/6J mice infected with 5 x 108 CFU C. rodentium, so perhaps with the increased 
pathogen inoculum, B. subtilis was not able to compete against C. rodentium as well in 
the study by Jones and Knight. Also, the sIgA repertoire is known to be different 
between different strains of mice, which leads to differences in microbial composition 
(Fransen et al., 2015) that could affect how B. subtilis and C. rodentium interact within 
the GI tract. The other possibility is that B. subtilis exerts its protective effect through 
modulation of host processes through EPS. Jones and colleagues tested if B. subtilis 
reinforces host barrier integrity during C. rodentium infection, which would reduce 
pathogen translocation into host tissues and reduce triggering of inflammatory 
responses that drive disease. However, B. subtilis-treated mice did not have reduced gut 
leakiness during C. rodentium-infection, as measured by the translocation of orally 
administered fluorescein isothiocyanate (FITC)-labeled dextran into serum (Jones et al., 
2014), indicating that B. subtilis did not alter host barrier functions. The pathology of C. 
rodentium-induced colitis depends on CD4+ T cells recruited to the GI tract, which 
mediate pro-inflammatory responses that drive IBD-like pathologies such as crypt 
hyperplasia, loss of goblet cells, and increased pro-inflammatory cytokine levels 
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(Higgins et al., 1999). When assessing C. rodentium-induced disease in B. subtilis-
treated mice, it was observed that B. subtilis reduced crypt heights and levels of pro-
inflammatory cytokines and that the goblet cells were left intact (Jones and Knight, 
2012; Jones et al., 2014), suggesting that B. subtilis protects hosts by altering host 
inflammatory processes. Jones and colleagues hypothesized that B. subtilis EPS might 
have immunomodulatory properties that mediate protection, and indeed, systemic 
administration of purified EPS from B. subtilis recapitulated protection from C. 
rodentium-induced colitis by B. subtilis spores (Jones et al., 2014). This suggested that 
B. subtilis exerts protection by producing EPS, an immunomodulatory polysaccharide 
that prevents inflammation. (Jones et al., 2014). 
 Host recognition of microbial molecules generally starts with PRRs. Studies of 
other probiotics that work through immunomodulation found that signaling through 
TLR2 was required for their beneficial effects (Danne et al., 2017; Jeon et al., 2012; 
Round and Mazmanian, 2010). Based on this, it was hypothesized that EPS also alters 
the immune system by first engaging a PRR. Indeed, EPS failed to protect TLR4-
deficient mice from C. rodentium-induced colitis as well as mice deficient in myeloid 
differentiation primary response protein 88 (MyD88), the adaptor protein critical for 
multiple TLR signaling pathways (Jones et al., 2014), indicating that EPS exerts its 
effects through TLR4 signaling. TLR4 is best characterized as the mediator of signaling 
induced by lipopolysaccharide (LPS), a microbial ligand found mostly on Gram-negative 
bacteria (Hoshino et al., 1999). However, the process by which the signal initiates is 
quite complex. Upon release from the microbe, LPS is first bound to LPS-binding 
protein, an acute phase protein in the serum (Tobias et al., 1986). LPS is then delivered 
to CD14, a glycosylphosphatidylinositol (GPI)-anchored glycoprotein found on the 
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surface of MNPs (Hailman et al., 1994). Originally, CD14 was thought to be crucial for 
the recognition of LPS since CD14-deficient mice were insensitive to lethal challenge 
with LPS and cells from these mice failed to produce pro-inflammatory cytokines TNF-α 
and IL-6 in response to LPS, though limited production could be detected at high LPS 
concentrations (Haziot et al., 1996). However, CD14 does not mediate intracellular 
signaling, and further studies suggested that CD14 brings LPS to TLR4 where signaling 
is initiated. Transfer of LPS from CD14 to TLR4 was recently confirmed (Ryu et al., 
2017). Myeloid differentiation factor 2 (MD-2) is the major protein that binds LPS when 
complexed with TLR4 (Akashi et al., 2003), and this complex initiates signaling through 
the intracellular Toll-IL-1 receptor homology (TIR) domains of TLR4 (Poltorak et al., 
1998). The signal is amplified by the adaptor protein, MyD88, and leads to downstream 
activation of the transcription factor nuclear factor kappa light chain enhancer of 
activated B cells (NF-κB), which drives gene expression of pro-inflammatory cytokines 
(Kawai et al., 1999). It is not clear how TLR4 signaling contributes to EPS-induced 
protection from C. rodentium-induced colitis, given that the activation of TLR4 is 
generally associated with pro-inflammatory responses while EPS decreased 
inflammation during disease. Nonetheless, understanding both in vitro and in vivo 
pathways of EPS-induced activation of TLR4 signaling, and the resulting host responses 
will be key to understanding the therapeutic potential of B. subtilis EPS. 
Anti-Inflammatory Effect of Bacillus subtilis Exopolysaccharide 
 Intraperitoneal (i.p.) administration of EPS is sufficient to confer protection in 
murine C. rodentium-induced colitis (Jones et al., 2014). Under homeostatic conditions, 
the peritoneal cavity myeloid compartment is dominated by MΦs. There are two subsets 
of peritoneal MΦ: large peritoneal MΦs (LPM, defined by CD11bhighF4/80high) that 
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represent the majority, and small peritoneal MΦs (SPM, defined by CD11b+F4/80+) that 
represent the minority (Ghosn et al., 2010). Upon stimulation with i.p. LPS injection, 
the peritoneal cavity becomes dominated instead by SPMs, which show enhanced 
antimicrobial nitric oxide (NO) production compared to the LPM counterparts (Ghosn 
et al., 2010). LPMs are thought to be the long-term residents of the peritoneal cavity but 
disappear after i.p. LPS injection; LPMs are hypothesized to be recruited to different 
nearby tissues for various purposes. For example, it was recently demonstrated that 
during sterile liver injury, LPMs, defined by their unique expression of GATA-binding 
factor 6 (GATA-6), were recruited directly from the peritoneal cavity to the liver surface 
through the mesothelium to mediate wound healing (Wang and Kubes, 2016). Since 
LPMs are the major innate immune cell within the peritoneal cavity and MΦs are well 
known to sense microbial products to mediate various functions, EPS was hypothesized 
to alter the functions of LPMs to exert its protective functions. Indeed, EPS failed to 
protect mice from C. rodentium infection when mice were depleted of peritoneal MΦs 
through the administration of clodronate-loaded liposomes, indicating that MΦs are 
required for protection by EPS (Paynich et al., 2017). MΦs are described in a spectrum 
between two polarization states ranging from pro-inflammatory to anti-inflammatory 
functions. Since EPS reduces inflammation during C. rodentium infection that is 
primarily thought to be driven by T cells (Higgins et al., 1999), EPS was proposed to 
drive an anti-inflammatory polarization of MΦs that limit inflammation during C. 
rodentium-induced colitis. Paynich and colleagues compared the CD11bhighF4/80high 
LPM compartment between phosphate buffered saline solution (PBS)- and EPS-treated 
mice 3 days after i.p. injection and found that the LPMs resembled M2 MΦs in EPS-
treated mice, showing increased expression of M2 markers, including CD206 and Arg-1 
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(Paynich et al., 2017). These EPS-induced MΦs limited splenic T cell activation in vitro, 
suggesting that EPS induces anti-inflammatory M2 MΦs that suppress T cell functions 
(Figure 1A) (Paynich et al., 2017). 
 Although M2 MΦs can inhibit T cell activation by depletion of arginine through 
the action of Arg-1 expressed by EPS-induced M2 MΦs, supplementation of L-arginine 
did not restore T cell activation in co-cultures with EPS-induced M2 MΦs. However, 
neutralization of the inhibitory cytokine TGF-β and blockade of the inhibitory cell 
surface molecule programmed death-ligand 1 (PD-L1) using antibodies in vitro restored 
T cell activation, suggesting that EPS-induced M2 MΦs inhibit T cells through TGF-β 
and PD-L1 (Paynich et al., 2017). In addition, co-cultures of EPS-induced M2 MΦs with 
splenocytes resulted in an increase in CD4+CD25+Foxp3+ Treg cells, and there was an 
Figure 1: Established Model for the Anti-Inflammatory Effect of B. subtilis 
EPS. A. EPS drives anti-inflammatory M2 polarization of MΦs. B. EPS-induced M2 
MΦs limit T cell activation and promote Treg differentiation. C. EPS limits systemic T 
cell activation, limiting disease due to inflammation. Adapted from Paynich and 
colleagues, Journal of Immunology, 2017. 
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increased percentage of Foxp3+ T cells in the peritoneal cavity of EPS-treated mice in 
vivo, which suggests that EPS-induced M2 MΦs promote Treg cell differentiation 
(Figure 1B) (Paynich et al., 2017). Also, cells from the mesenteric lymph nodes (mLN) 
of EPS-treated mice were hyporesponsive to stimulation with phorbol 12-myristate 13-
acetate (PMA) and ionomycin, indicating that EPS limits T cell functions in vivo 
(Figure 1C) (Paynich et al., 2017). Finally, transfer of these EPS-induced MΦs to 
recipient mice was sufficient for protection from C. rodentium-induced colitis (Paynich 
et al., 2017), indicating that B. subtilis EPS protects hosts from colitis in large part 
through these anti-inflammatory M2 MΦs that modulate T cell activation during disease 
in vivo, limiting inflammation and improving disease outcomes. 
 Administration of EPS results in anti-inflammatory M2 MΦs in the peritoneal 
cavity, but it is not known if EPS has similar effects in other tissues; after all, i.p. 
injection is considered a systemic route of administration (Turner et al., 2011). EPS-
treated mice had reduced levels of T cell effector cytokines in the serum after in vivo 
administration of anti-CD3ε antibodies that activate T cells (Paynich et al., 2017), 
indicating that i.p. administration of EPS affects T cells systemically. Consistent with 
this view, orally administered B. subtilis spores, but not the epsH mutant spores, 
prevented allergic inflammation in the lung in a house dust mite-induced eosinophilic 
inflammation model (Swartzendruber et al., 2019), indicating that the anti-
inflammatory effect of EPS is systemic, and can reduce inflammation in tissues beyond 
the GI tract. To date, the structure and composition of EPS remain unknown. 
 In summary, B. subtilis is a probiotic bacterium that produces EPS, a component 
of its biofilm that has systemic anti-inflammatory properties. B. subtilis has been 
consumed by humans for many years and is not known to cause disease in 
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immunocompetent individuals. Additionally, it can be easily administered as durable 
spores by the oral route, and there is a potential to use purified EPS as a pharmacologic 
agent. This anti-inflammatory property of B. subtilis is likely to benefit many patients 
suffering from various diseases with inflammatory pathophysiology, and to this end, the 
specific mechanisms by which EPS modulates host responses in other inflammatory 
disease conditions remain to be elucidated. Here, we present our study on exploring the 
potential to use EPS for one such disease with a systemic inflammatory pathology, 
sepsis, one of the most severe manifestations of systemic infection. 
Sepsis and Staphylococcus aureus 
Sepsis Epidemiology and Pathophysiology 
 Sepsis is defined as a life-threatening organ dysfunction caused by a 
dysregulated host response to infection (Singer et al., 2016). Sepsis is one of the most 
severe manifestations of ongoing infection with mortality rates approaching 50% in 
some cases (Angus et al., 2001). Sepsis accounted for about 6% of all US adult 
hospitalizations in 2014, estimated to be over a million cases a year (Rhee et al., 2017). 
While controversial, sepsis is considered the most expensive condition to manage in the 
US (Torio and Andrews, 2006). Sepsis is generally thought to start when microbial 
ligands engage host immune cells, setting off a pro-inflammatory response designed to 
clear microbial pathogens: activation of innate immune cells, production of cytokines 
and chemokines to recruit and activate additional immune cells, and activation of 
complement cascades to further support pro-inflammatory responses. While many 
processes are thought to contribute to the pathophysiology of sepsis, the most clinically 
concerning is the loss of endothelial integrity. Recruitment of additional immune cells to 
tissues generally occur from the circulation. Initially, the local pro-inflammatory 
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mediators activate the nearby endothelial cells and induce their expression of leukocyte 
adhesion molecules such as vascular cell adhesion protein 1 (VCAM-1) (Bevilacqua et al., 
1987; Osborn et al., 1989). Circulating immune cells are captured by leukocyte adhesion 
molecules and start rolling along the endothelial surface until activated by chemokines 
through GPCRs (Atherton and Born, 1972; Kim et al., 2003). This leads to the 
expression of integrins such as intercellular adhesion molecule 1 (ICAM-1) on 
endothelial cells that mediate adhesion between immune cells and the endothelium 
(Dustin and Springer, 1988; Dustin et al., 1986). Finally, the adhered immune cell 
crawls to a junction between endothelial cells (Phillipson et al., 2006) where it squeezes 
through to the basolateral side to enter the tissue, a processes defined as diapedesis. 
This process is accommodated in part by the loosening of the endothelial junctions by 
the increase in intracellular free calcium ions in response to cross-linking of adhesion 
molecules, which activates myosin light chain kinases and subsequent actin-myosin 
fiber contractions (Hixenbaugh et al., 1997; Huang et al., 1993). This results in a small 
separation of endothelial cells that immune cells can squeeze through, which increases 
vascular permeability. Increased leakiness of the endothelium is generally maintained 
locally, but under severe systemic conditions such as sepsis, vascular permeability is 
increased systemically, and intravascular fluid is lost into the tissues. This makes 
maintaining blood pressure difficult, and perfusion of organs can become limited due to 
cardiovascular collapse, leading to multi-organ failure. Another major complication 
during sepsis that stems from endothelial dysfunction is related to the coagulation 
system. Coagulation is mediated by a complex cascade involving plasma coagulation 
factors and platelets, designed for deposition of fibrin at sites of tissue damage to 
prevent leakage of blood contents. Many aspects of inflammation are known to activate 
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the coagulation cascade, but the most prominent way sepsis is thought to initiate the 
coagulation cascade is the tissue factor that is produced as a result of tissue and 
endothelial damage (Osterud and Rapaport, 1977). It should be noted that microbial 
ligands like LPS have been shown to directly activate platelets as well (Andonegui et al., 
2005), though the contribution of such activation to sepsis is not clear. Due to the 
systemic nature of the disease, sepsis can initiate widespread activation of coagulation 
cascades within the vasculature, a condition known as disseminated intravascular 
coagulation (DIC). DIC is thought to precipitate two major issues: widespread 
microvascular thrombosis that blocks blood flow resulting in organ dysfunctions, and 
rapid depletion of platelets that further complicates endothelial dysfunction and 
maintenance of blood pressure for organ perfusion (Akca et al., 2002; Toh and Alhamdi, 
2013). DIC is a common complication of severe sepsis and is often associated with 
mortality (Ogura et al., 2014). Despite extensive clinical studies, sepsis remains an often 
lethal challenge that is difficult for physicians to identify, diagnose, and manage. 
Table 3: Evaluation of Sepsis in Patients. As recommended by Singer and 
colleagues, Journal of the American Medical Association, 2016. 
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 Clinically, patients suspected of sepsis are evaluated using a sepsis-related organ 
failure assessment (SOFA) score. SOFA score system evaluates functions of major organ 
systems, determining a score for estimated organ damage (Singer et al., 2016). For 
example, mean arterial pressure (MAP) greater than or equal to 70 mmHg, considered 
relatively normal in terms of overall cardiovascular function, is given a score of 0 while 
MAP less than 70 mmHg would be given a score of 1. Higher scores would be given if 
pharmacologic agents had to be used to maintain MAP. Functions of other systems such 
as renal, hepatic, respiratory, and coagulation systems are evaluated and given scores, 
and a cumulative score is determined to diagnose sepsis, along with microbiologic 
evidence of infection. Increased serum lactate levels in patients, a sign of metabolic 
acidosis due to severe illness, with hypotension resistant to fluid resuscitation has been 
associated with much higher mortality rates, so these criteria are used additionally to 
diagnose septic shock (Singer et al., 2016). Since many patients often present with vague 
symptoms, and since sepsis is a rapidly developing condition, physicians are encouraged 
to use a broad screening tools such as quick SOFA (qSOFA) scoring, a much simpler 
version of the SOFA score, to identify suspected patients and subsequently evaluate for 
sepsis, as outlined in Table 3. However, many patients with modest dysfunctions 
according to SOFA scores can rapidly deteriorate, and the diagnostic criteria for sepsis 
remain controversial (Singer et al., 2016), making the diagnosis of sepsis a challenge. 
Treatment of sepsis patients focuses on two primary approaches. 
 The best highlighted is antimicrobial therapy to reduce inflammatory stimuli. 
The other is to limit host responses, especially on maintaining MAP and preventing 
platelet depletion. Due to high mortality rates, sepsis patients are often aggressively 
treated: broad-spectrum antimicrobial therapy initiated within one hour, aggressive 
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testing to identify the infectious source, immediate intravascular fluid resuscitation, 
vasopressors, and more invasive interventions such as blood or platelet transfusions and 
mechanical ventilation if necessary (Rhodes et al., 2017). Despite aggressive 
management, mortality rates for sepsis remain high (Angus et al., 2001; Rhee et al., 
2017), highlighting a critical need for novel strategies to manage and treat sepsis 
patients. For a majority of sepsis cases, the causative organism is not identified, though 
some of this is presumably attributed to early initiation of broad-spectrum antimicrobial 
therapy that could impede detection of organisms through traditional culture methods 
(Vincent et al., 2009). Of the cases for which the causative organism is documented, S. 
aureus remains the top etiologic agent of sepsis, accounting for about 20% of all cases 
(Vincent et al., 2009). 
Clinical Considerations for Staphylococcus aureus Infections 
 S. aureus is a gram positive bacterium found on the skin and anterior nares of 
colonized individuals. About 30% of the general population is thought to be colonized 
with S. aureus without apparent disease, and S. aureus is considered a part of the 
healthy microbiota of the skin (Gorwitz et al., 2008). However, upon breaching 
epithelial barriers, S. aureus can seed into underlying soft tissue and cause disease 
generally described by a cutaneous abscess; S. aureus is the primary cause of skin and 
soft tissue infections (SSTI), estimated to be about 3.4 million emergency visits in 2005 
(Pallin et al., 2008). While SSTIs are the most common form of S. aureus infection, S. 
aureus can penetrate into deeper tissues and cause severe diseases including necrotizing 
fasciitis, necrotizing pneumonitis, osteoarthritic infections, infective endocarditis, and 
bacteremia, to name a few. 
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 Like many infectious diseases, S. aureus bloodstream infections are aggressively 
managed with antibiotics designed to reduce the inflammatory stimuli (Liu et al., 2011). 
Historically, penicillin was introduced in the 1940s, that successfully reduced case 
fatality rates due to S. aureus bacteremia (Blair and Carr, 1960; Fleming, 1929). 
However, penicillin resistance was reported only a few years later, and within a decade, 
antibiotic-resistant S. aureus, harboring a plasmid-encoded penicillinase, became 
widely prevalent (Blair and Carr, 1960). A penicillinase-resistant β-lactam antibiotic, 
methicillin, was introduced in the late 1950s to combat these resistant S. aureus strains, 
but the medical community was met with methicillin-resistant S. aureus (MRSA) by 
1961 (Barber, 1961), which limited treatment efficacy. Antibiotic resistance continues to 
be a significant problem today, where strains resistant to a variety of standard 
antimicrobial agents are reported, including vancomycin-resistant strains (Hiramatsu et 
al., 1997; Liu et al., 2011; Weigel et al., 2003), making treatment of S. aureus infections 
a challenge. Several novel antimicrobial agents are in the development pipeline 
(Holubar et al., 2016), but resistance can and will likely arise as resistance is often 
conferred through mobile genetic elements that are easily acquired, and that will 
perpetuate the process of developing antimicrobials and resistances. Therefore, novel 
strategies to combat S. aureus infections are critically needed. A major goal of 
antimicrobial therapy during sepsis is to reduce the inflammatory stimuli by targeting 
the pathogens for removal. However, an alternative approach may be to target the host 
to limit overt inflammation and promote survival. To this end, understanding host 
responses against S. aureus during bloodstream infection is critical.  
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Host Responses to Staphylococcus aureus Infection 
 As in other bacterial infections, the initial host response against S. aureus is 
induced through recognition of microbial molecules through PRRs: for S. aureus, 
recognition of lipopeptides through TLR2 is the primary sensor mechanism (Hashimoto 
et al., 2006; Takeuchi et al., 2000). 
This recognition results in the production of signals and chemokine gradients to recruit 
neutrophils to the site of infection, which is critical for initial containment of the 
pathogen. Depletion of neutrophils results in increased mortality in an animal model of 
S. aureus bacteremia (Alonzo III et al., 2012), and patients with defective neutrophil 
functions are predisposed to infections, predominantly S. aureus (Marciano et al., 2015). 
Once at the site of infection, neutrophils phagocytose S. aureus and try to kill the 
Figure 2: Histology of S. aureus-Induced Murine Renal Abscess. A female 
C57BL/6J mouse was systemically infected with S. aureus USA300 (LAC) and kidneys 
were assessed 2 days post infection (d.p.i) for histopathologic features. A. Hematoxylin 
and eosin (H&E) stained section of a S. aureus renal abscess. 400x magnification. B. 
Schematic representation of histopathologic features of the S. aureus renal abscess 1. 
Surrounding renal tissue. 2. Fibrous capsule surrounded by additional immune cells like 
macrophages and T cells. 3. Damaged tissue with necrotic cells and neutrophils. 4. 
Infected focus of S. aureus. Image by Paik and colleagues. 
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pathogen through a complex intracellular process involving endosomal acidification, 
production of RNS and ROS, and release of AMPs. In addition, neutrophils can release 
DNA and toxic granules known as neutrophil extracellular traps as they undergo cell 
death (NETosis) which traps bacteria for killing (Brinkmann et al., 2004). S. aureus 
harbors many mechanisms to withstand the actions of neutrophils, requiring additional 
host mechanisms for immunity such as MΦs and T cells. Monocytes, which differentiate 
into MΦs within tissues, are generally the first cell type recruited after neutrophils to 
augment anti-bacterial immunity (Volkman and Gowans, 1965). MΦs use similar 
mechanisms as neutrophils to contain pathogens but have the additional capacity to 
present antigens and coordinate subsequent immune responses mediated by the 
adaptive arm of immunity. T cells of the adaptive immune system can then augment 
bacterial killing through the production of pro-inflammatory cytokines, which help 
recruit more neutrophils and monocytes and increase their killing capacities (Held et al., 
1999). These cells typically constitute the classical pathological feature of S. aureus 
infections characterized as abscesses. Abscesses form as neutrophils arrive at the 
infected site and employ its antimicrobial defenses. S. aureus withstands neutrophils 
while tissue damage occurs, creating a core containing bacteria, necrotic debris, and 
neutrophils. The additional immune cells recruited are thought to contain the infection 
by promoting the development of the fibrous capsule at the edge of the infected foci, 
forming a mature abscess structure, as outlined in Figure 2. 
Staphylococcus aureus Evasion of Host Immunity: Recognition 
 Unfortunately, S. aureus has numerous mechanisms to interfere with the host 
immune response at multiple levels, as described in Table 4. For one, S. aureus can 
interfere with host recognition, mainly by counteracting TLR2 signaling. One way S. 
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aureus does this is through a lipoylated E2 subunit of the pyruvate dehydrogenase (E2-
PDH), an essential metabolic enzyme complex, which is also secreted. 
The lipoylated protein has structural similarities with TLR1-2 agonists and is thought to 
limit TLR2 signaling through direct antagonism, interfering with TLR2 signaling 
induced by S. aureus lipopeptides, resulting in limited host response in vivo and 
promoting bacterial survival (Grayczyk et al., 2017). S. aureus can also do this by 
Staphylococcal superantigen-like protein 3 (SSL3), which binds to TLR2 and 
antagonizes signaling induced by TLR2 agonists in cells in vitro (Bardoel et al., 2012). 
By limiting activation by TLR2, S. aureus evades recognition by the host to promote 
bacterial survival. Another mechanism by which S. aureus can subvert host responses is 
by impairing immune cell recruitment, that depends on immune cell recognition of 
chemokine ligands through chemokine receptors. Chemotaxis inhibitory protein of S. 
aureus (CHIPS) is a protein secreted by S. aureus that binds to phagocytes to interfere 
with chemokine-induced migration (Haas et al., 2004). Similarly, Staphopain A is a 
protease that cleaves C-X-C motif chemokine receptor 2 (CXCR2) on the surface of 
Table 4: Major Mechanisms of Immune Evasion by S. aureus. 
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neutrophils, limiting neutrophil homing to infective tissues. (Laarman et al., 2012). 
Through these mechanisms, S. aureus limits immune cell recruitment to infected sites, 
promoting bacterial survival. 
Staphylococcus aureus Evasion of Immunity: Withstanding the Killing 
 Once the host recognizes pathogens and recruits MNPs to the infected site, 
bacterial clearance is thought to occur through phagocytosis of bacteria for intracellular 
killing. One mechanism by which the host enhances phagocytosis of pathogens is 
through antibody- and complement-mediated opsonization. Opsonization is the process 
by which antibodies and complement deposit on bacterial surfaces, enhancing uptake by 
phagocytes that recognize the deposited antibodies or complement through antibody 
fragment crystallizable region (Fc) receptors and complement receptors, respectively 
(Caron and Hall, 1998). Protein A is a molecule produced by S. aureus that binds 
immunoglobulins and blocks their opsonic activity (Forsgren and Quie, 1974), which 
would reduce Fc receptor-mediated phagocytosis of bacteria. On the side of complement, 
Staphylococcal complement inhibitor (SCIN) is a C3 convertase inhibitor that prevents 
complement activation and subsequent deposition on bacterial surfaces, limiting 
opsonization and uptake by human neutrophils (Rooijakkers et al., 2005). Even when S. 
aureus is taken up by phagocytes, S. aureus harbors mechanisms to resist phagocyte-
mediated killing. Staphyloxanthin is a carotenoid pigment that gives S. aureus the 
hallmark golden color, but it is also an antioxidant that allows S. aureus to withstand 
neutrophil-mediated killing through the production of RNS and ROS (Liu et al., 2005). 
S. aureus also encodes two superoxide dismutases, SodA and SodM, which inactivate 
superoxide radicals to resist phagocyte-mediated killing (Karavolos et al., 2003). 
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Through these mechanisms, S. aureus subverts the host phagocytic responses, 
promoting its persistence within hosts. 
Staphylococcus aureus Evasion of Immunity: Killing Immune Cells 
 S. aureus also harbors more sinister mechanisms to counteract the host immune 
response, a deleterious challenge to the immune system through toxins. S. aureus 
produces seven different pore-forming toxins, some of which target immune cells. These 
leucocidins bind to a specific host cell receptor and subsequently recruit another subunit 
for oligomerization on the cell surface, forming a pore through the host cell membrane 
and killing it (Finck-Barbançon et al., 1993; Noda et al., 1982; Woodin and Wieneke, 
1963; 1967). The most notorious leucocidin is Panton-Valentine leucocidin (PVL), which 
recognizes human complement C5a receptor (C5aR) to kill neutrophils (Spaan et al., 
2013). Neutrophils are not the only cells to be targeted by leucocidins, as leucocidin ED 
(LukED) had been demonstrated to have a broad repertoire of cells it kills by targeting 
C-C motif chemokine receptor 5 (CCR5), CXCR1, and CXCR2 on T cells, NK cells, 
neutrophils, monocytes, and DCs (Alonzo III et al., 2012a; 2012b; Reyes-Robles et al., 
2013). In the context of abscesses, monocytes are additionally recruited to reinforce 
neutrophil-mediated antimicrobial defense, but S. aureus also harbors ways to target 
MΦs for killing. A study demonstrated that S. aureus could produce deoxyadenosine 
from extracellular DNA released by neutrophils during NETosis to kill U937 cells, a MΦ 
cell line (Thammavongsa et al., 2013; Winstel et al., 2018). S. aureus mutants deficient 
in nuclease and adenosine synthase, nuc and adsA respectively, failed to exclude F4/80+ 
MΦs from the core of renal abscesses (Thammavongsa et al., 2013), suggesting that S. 
aureus utilizes DNA released by neutrophils through NETosis to kill MΦs, promoting 
bacterial survival within abscesses. It should be noted that the killing of U937 MΦs by S. 
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aureus-produced deoxyadenosine was very mild, and that stressing the DNA processing 
system using pentostatin, a purine analog, was required for robust killing of MΦs. It is 
not clear if such stress would occur in vivo, but S. aureus mutants incapable of 
producing deoxyadenosine could not exclude MΦs from the abscesses, indicating that 
the killing of MΦs likely occurs in vivo. By targeting multiple immune cells for killing, S. 
aureus is able to evade a variety of host responses to establish itself within various host 
tissues. 
Staphylococcus aureus Evasion of Immunity: Superantigens 
 The cells of the adaptive immune system can additionally be targeted for killing 
through activation-induced cell death, which is mediated by superantigens (SAg) 
produced by S. aureus. Staphylococcal enterotoxins and enterotoxin-like proteins (SE 
and SEl) and related SAgs are secreted proteins that bind to both the Vβ region of the T 
cell receptor (TCR) complex and MHC class II on antigen presenting cells, activating up 
to 20% of the T cell repertoire (Fraser, 1989; Peavy et al., 1970; White et al., 1989). This 
polyclonal activation of T cells results in massive production of pro-inflammatory 
cytokines, which can cause a phenomenon called cytokine storm that causes toxic shock 
syndrome, an often fatal complication (Todd et al., 1978). Concurrently, the 
inappropriately activated T cells can impede proper adaptive immune responses, either 
by activation-induced cell death that removes specific T cells from the repertoire and by 
limiting activation of T cells through presented antigens (White et al., 1989; Xu et al., 
2014; Ziegler et al., 2011). Similarly, the other arm of adaptive immunity can be targeted 
by protein A which has SAg activity against B cells that results in apoptotic removal of B 
cells from the repertoire, limiting antibody responses (Goodyear and Silverman, 2004). 
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By targeting different immune cells for destruction, S. aureus is able to impede immune 
effector cell functions directly, promoting its survival. 
Concluding Remarks 
 During infection, S. aureus utilizes many mechanisms to perturb the immune 
response at multiple levels, resulting in a suboptimal host response not sufficient for 
bacterial clearance. This allows the pathogen to persist and, in the case of systemic 
infection, overt systemic inflammation occurs as a prolonged attempt to clear the 
pathogen. This perturbed inflammation can often result in the manifestation of sepsis 
and lethality, despite aggressive antimicrobial therapy to reduce bacterial burden. 
Therefore, an optimal approach to managing patients with systemic S. aureus infections 
is to bolster host antimicrobial defenses to reduce the bacterial burden while limiting 
inflammation to reduce the tissue damage and prevent the development of lethal 
complications such as sepsis. B. subtilis EPS is a probiotic-derived agent with potentially 
systemic anti-inflammatory properties. We reasoned that this anti-inflammatory agent 
could be used to limit inflammation during S. aureus bloodstream infections, reducing 
the host burden of disease. Herein, we focused our studies on tests of the protective 
potential of EPS against S. aureus bloodstream infection using a murine model, and to 
elucidate the specific mechanisms by which protection occurs, with the hope that these 
insights will help develop novel strategies to manage sepsis and reduce patient suffering.
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CHAPTER TWO 
MATERIALS AND METHODS 
Mice 
 All studies utilizing animals were reviewed and approved by the Institutional 
Animal Care and Use Committee at Loyola University Chicago Health Sciences Division 
(Maywood, IL). Unless otherwise specified, all mice were bred in house at the 
Comparative Medicine Facility at Loyola or purchased from Jackson Laboratories (Bar 
Harbor, ME). ND4 Swiss Webster mice were purchased from Envigo (Indianapolis, IN). 
Founder mice for in house breeding were purchased from Jackson Laboratories. All 
mice were housed at the Comparative Medicine Facility at Loyola and fed standard 
sterile chow. All mice used for this study is listed in Table 5. Unless otherwise noted, 
C57BL/6J mice were used. 
Table 5: Mice Used in This Study. 
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Common Reagents 
 All bacteriologic media were purchased from BD Biosciences (San Jose, CA). All 
cell culture media components were purchased from Thermo Fischer Scientific 
(Waltham, MA). Fetal bovine sera (FBS) for cell culture were purchased from Atlanta 
Biologicals (Flowery Ranch, GA). Modified Roswell Park Memorial Institute (RPMI) 
medium was used for all cell culture experiments (RPMI base medium supplemented 
with 2.4 mM L-glutamine, 1x minimal essential medium (MEM) vitamins solution, 50 
U/mL penicillin, 50 μg/mL streptomycin, 0.5 μg/mL amphotericin B, 0.5x non-essential 
amino acids, 0.5x essential amino acids, 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 1 mM sodium pyruvate, 0.195 % sodium 
bicarbonate (NaHCO3), 30 μg/mL gentamicin, 3.5 x 10-4 % 2-mercaptoethanol, 10% 
heat-inactivated FBS). For antibiotic-free RPMI medium, penicillin, streptomycin, and 
gentamycin were excluded. All antibodies were purchased from BioLegend (San Diego, 
CA) unless otherwise specified. All chemical reagents were purchased from 
MilliporeSigma (Burlington, MA) unless otherwise specified. 
Preparation of B. subtilis-Derived EPS 
 EPS was isolated from culture supernatants of B. subtilis DS991 (overproduces 
and secretes EPS) or DK4623 (DS991 derivative with lytic genes (Wang et al., 2014) 
deleted) grown to stationary phase in 1% tryptone phosphate broth (1% tryptone, 25 mM 
phosphate, 0.1 M sodium chloride (NaCl)) or minimal salts glutamate glycerol (Msgg) 
medium. Alternatively, EPS was prepared from B. subtilis DK6251 (Isopropyl β-D-1-
thiogalactopyranoside (IPTG)-inducible eps operon with gamma-polyglutamic acid (γ-
PGA) deficiency) grown as a lawn on Luria Bertani (LB, Miller formulation) agar (1.5%) 
plates with 1 mM IPTG. For ΔEPS, B. subtilis DS5187 (DS991 derivative that cannot 
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make EPS) was used. All bacterial strains used in this study are listed in Table 6. EPS 
was extracted by precipitation with 75% ethanol at -20°C. The precipitate was pelleted 
by centrifugation at 13,700 x g at 4°C for 30 min, resuspended in 0.1 M pH 8 Tris buffer, 
and treated with 67 μg/mL DNase and 330 μg/mL RNase at 37°C for 2 hours (hr), 
followed by digestion with 40 μg/mL proteinase K at 55°C for 2 hr. EPS was then 
purified on diethylaminoethyl (DEAE)-cellulose (GE Healthcare, Chicago, IL) ion 
exchange column chromatography or gel filtration on Sephacryl S-500 (GE Healthcare). 
Carbohydrate-positive fractions were identified, and total carbohydrate content was 
estimated using a modified phenol sulfuric acid assay (Albalasmeh et al., 2013; Masuko 
et al., 2005). All EPS preparations were assessed for the lack of protein and nucleic acid 
content by spectrometry and also for their ability to induce peritoneal M2 MΦ as 
previously described (Paynich et al., 2017) prior to use. All three strains of WT mice in 
this study were capable of generating peritoneal M2 MΦs in response to i.p. EPS 
administration as described previously (Paynich et al., 2017). 
Preparation of S. aureus Cultures 
 Starter cultures of all S. aureus strains were prepared in tryptic soy broth (TSB) 
medium, cultured at 37°C overnight. S. aureus LAC and AH1263 (plasmid-cured 
derivative of LAC (Boles et al., 2010)) were used in many studies interchangeably, but 
we did not observe noticeable differences in outcomes. Transposon (Tn) insertion 
mutant library strains from the University of Nebraska Transposon Mutant Library (Fey 
et al., 2013) were used for SAg studies. For bloodstream infection experiments, starter 
cultures were freshly diluted 1:100 into TSB and cultured at 37°C to exponential phase 
for 3 hr. Inoculum was prepared by washing the subculture three times in 10 mL PBS, 
normalized to an inoculum of 108 CFU/mL in PBS on the day of infection using optical 
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density (OD) measurements on Genesys 10S UV-Vis spectrophotometer (Thermo 
Fischer Scientific), to OD600 nm ~ 0.323. 
Statistical Analyses 
 Data were analyzed using GraphPad Prism 5 (GraphPad Software, San Diego, 
CA). Unpaired, two-tailed Student’s t-test was used to determine statistical significance 
unless otherwise noted.  
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Table 6: Bacterial Strains Used in This Study. All B. subtilis strains were 
generously provided by Dr. Daniel B. Kearns of Indiana University. S. aureus LAC was 
from Dr. Victor J. Torres at New York University. AH1263 is from Boles and colleagues, 
PLoS ONE, 2010. All the Tn library strains are from Fey and colleagues, mBio, 2013. 
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Murine Model of Bloodstream Infection by S. aureus 
 Four to eight week-old C57BL/6J mice were treated with 3 to 6 mg/kg EPS in 
PBS by i.p. injection one day prior to and one day after systemic infection with S. aureus. 
For infection, mice were first anesthetized by i.p. injection with 250 mg/kg Avertin 
(MilliporeSigma), then injected with 107 CFU S. aureus in 100 μL PBS through the 
retro-orbital venous plexus. Mice were monitored for signs of disease daily. For survival 
analysis, any mice that lost more than 20% body weight were considered dead to avoid 
utilizing any subjective criteria for assessing mortality. To assess bacterial burden, 
tissues were harvested from euthanized mice into 5 mL PBS and homogenized using a 
Polytron Brinkmann PT 10/35 homogenizer (Brinkmann Instruments, Westbury, NY). 
The homogenates were plated on tryptic soy agar (TSA, 1.5% agar) plates for 12 hr at 
37°C to enumerate bacteria. Cleared tissue homogenate supernatants were collected by 
centrifugation at 3,000 x g to assess levels of local cytokine and chemokine levels. Blood 
samples were collected from submandibular facial veins to determine bacterial burden 
or to determine serum levels of cytokines and chemokines. 
Cytokine and Chemokine Measurements 
 Levels of cytokines and chemokines were determined using the cytometric bead 
array (CBA) flex set for IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-
17A, keratinocyte-derived chemokine/C-X-C motif chemokine ligand 1 (KC/CXCL1), 
monocyte chemoattractant protein 1/C-C motif chemokine ligand 2 (MCP-1/CCL2), MΦ 
inflammatory protein 1 alpha (MIP-1α/CCL3), MIP-1β/CCL4, regulated on activation, 
normal T cell expressed and secreted (RANTES/CCL5), granulocyte-MΦ colony 
stimulating factor (GM-CSF), granulocyte CSF (G-CSF), IFN-γ, and TNF-α (BD 
Biosciences), according to manufacturer’s specifications. Samples were analyzed using 
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LSRFortessa or FACSCantoII flow cytometers (BD Biosciences) and data were analyzed 
using FCAP array v3.0 or FlowJo V10 (BD Biosciences). 
S. aureus Growth Assay 
 Starter cultures of S. aureus were subcultured 1:100 into 200 μL TSB containing 
EPS at various concentrations in a Falcon 96-well flat bottom tissue culture plate 
(Corning, Corning, NY). The plate was incubated at 37°C on a 250 round per minute 
(rpm) shaker. Growth was monitored at various time points by measuring OD550 nm 
using a BioTek ELx800 absorbance microplate reader (BioTek, Winooski, VT). 
S. aureus Uptake and Growth Restriction by Immune Cells 
 Starter culture of S. aureus was washed three times in 10 mL PBS then 
normalized to 108 CFU/mL by OD600 nm ~ 0.323. S. aureus inoculum was serum-
opsonized for 30 min using 10% fresh mouse serum at 37°C. Four- to eight-week-old 
mice were treated with 3 to 6 mg/kg EPS by i.p. injection and peritoneal cells were 
harvested by lavage with 300 mL/kg RPMI medium. For MΦ depletion studies, 200 μL 
clodronate- or PBS-loaded liposomes (VU Medisch Centrum, Amsterdam, Netherlands) 
were administered to ND4 Swiss Webster mice by i.p. injection 1 day prior to EPS 
administration. F4/80+ and F4/80- peritoneal cells were purified from mice 3 days after 
EPS injection using the BD IMag cell separation system (BD Biosciences) according to 
manufacturer’s specifications after incubation with anti-CD16/32 (93, BD Biosciences) 
and biotinylated anti-F4/80 (BM8) antibodies for 15 min on ice. F4/80+ macrophages 
or F4/80- cells (5 x 105), or total peritoneal cells (106) were infected with opsonized S. 
aureus at MOI 1 in antibiotic free RPMI medium and incubated in rotating microfuge 
tubes at 37°C for 30 min. To enumerate internalized S. aureus, cells were washed three 
times with 1 mL PBS then lysed with 0.1% saponin (MilliporeSigma) and plated on TSA 
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plates for 12 hr at 37°C. Restriction of S. aureus growth was assessed by culturing the 
washed cells for 2 to 6 hr followed by quantifying S. aureus CFU after lysis with 0.1% 
saponin and plating on solid medium. For ROS experiments, 2 μM 
diphenyleneiodonium (DPI, MilliporeSigma) was included in medium during the assay. 
To assess peritoneal cell composition, cells were first incubated with anti-CD16/32 (93) 
antibody for 15 min then stained with anti-CD11b-allopyocyanin (APC, M1/70), anti-
F4/80-APC/cyanine 7 (APC/Cy7, BM8), anti-Ly6C-pycoerythrin (PE, HK1.4), anti-
Ly6G-FITC (1A8) antibodies for flow cytometric analysis using FACSCanto II. Data were 
analyzed using FlowJo V10. 
Measurement of Reactive Oxygen Species Levels 
 Total peritoneal cells from PBS- or EPS-treated mice were harvested by lavage 
with 300 mL/kg RPMI medium 3 days after i.p. EPS injection. Cells (106) were infected 
with opsonized S. aureus at MOI 1 for 30 min at 37°C in rotating microfuge tubes in the 
presence of 1.25 μM CellROX Green (Thermo Fischer Scientific). For mitochondrial ROS 
(mtROS) measurements, 2.5 μM MitoSOX Red (Thermo Fischer Scientific) was used 
instead. Cells were washed three times in 1 mL PBS then incubated with anti-CD16/32 
(93) antibody for 15 min. Cells were subsequently stained with anti-CD11b-APC (M1/70) 
and anti-F4/80-APC/Cy7 (BM8) for flow cytometric analysis using LSRFortessa 
(CellROX Green) or FACSCanto II (MitoSOX Red). Data were analyzed using FlowJo 
V10, and median fluorescence intensity (MFI) of ROS indicators were determined after 
gating on CD11bhighF4/80high LPMs. 
Preparation of S. aureus Culture Supernatants 
 Overnight starter cultures of S. aureus AH1263, JE2, sek::erm, seq::erm, 
sex::erm, USA300_1559::erm were prepared in 5 mL antibiotic-free RPMI medium. 
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Starter cultures were diluted 1:100 into antibiotic-free RPMI medium and cultured for 9 
hr at 37°C on a 250 rpm shaker. Supernatants were harvested by centrifugation at 3,000 
x g and sterilized by passing it through a 0.2 μm filter. 
Measurement of Reactive Nitrogen Species by Griess Test 
 Peritoneal F4/80+ cells from PBS- and EPS-treated mice were harvested and 
purified using BD IMag cell separation system 3 days after i.p. EPS injection. Cells (105) 
were seeded into Falcon 96-well flat-bottom tissue culture plate in 200 μL RPMI 
medium per well and stimulated with 10% S. aureus AH1263 culture supernatant for 24 
hr. Supernatant (50 μL) from the stimulated cultures were mixed with equal volume 1 % 
sulfanilamide (Thermo Fischer Scientific) and equal volume 0.1 % 
naphthylethylenediamine dihydrochloride (MilliporeSigma) and OD550nm were 
measured using a BioTek ELx800 absorbance microplate reader (BioTek, Winooski, VT). 
RNS levels were estimated using a sodium nitrite standard. 
Superantigen-Induced Splenic T Cell Proliferation 
 Total splenocytes from naïve, PBS-treated, or EPS-treated mice were labeled 
with 5 μM CellTrace Violet (CTV, Thermo Fischer Scientific) according to 
manufacturer’s specifications. CTV-labeled cells (3.5 x 105) were seeded into a Falcon 
96-well flat-bottom tissue culture plate in 200 μL RPMI medium per well. Cells were 
stimulated with 33% S. aureus culture supernatants for 4 days. For peritoneal MΦ co-
cultures, F4/80+ cells (5 x 104) from PBS- or EPS-treated mice, purified using the BD 
IMag cell separation system, were added to the wells. To assess for T cell proliferation 
and activation, cells were stained with anti-CD4-APC (GK1.5), anti-CD8a-PE/Cy7 (53-
6.7), anti-CD25-APC/Cy7 (PC61), and anti-CD44-PE (IM7) and analyzed using 
LSRFortessa or FACSCanto II. Data were analyzed using FlowJo V10. 
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Analysis of Peritoneal Macrophage Phenotype by Flow Cytometry 
 Peritoneal cells were harvested from PBS- and EPS-treated mice by lavage with 
300 mL/kg RPMI medium 3 days after i.p. EPS injection. Cells were incubated with 
anti-CD16/32 antibody for 15 min on ice and stained with anti-CD11b-APC (M1/70), 
anti-F4/80-APC/Cy7 (BM8), and anti-CD206-Brillian Violet 421 (BV421, C068C2). 
Cells were fixed and permeabilized using BD Cytofix/Cytoperm solution (BD 
Biosciences) and stained with anti-iNOS-PE/eFluor 610 (CNXFT, Thermo Fischer 
Scientific) and anti-Arg-1-FITC (polyclonal Sheep IgG, Bio-Techne, Minneapolis, MN). 
Cells were analyzed using a LSRFortessa and the data were analyzed using FlowJo V10 
by first gating on CD11bhighF4/80high cells. 
Stimulation of Splenocytes with Heat-Killed S. aureus 
 Starter cultures of S. aureus strains were washed three times in 10 mL PBS then 
normalized to 109 CFU/mL by OD600 nm ~ 1.200. S. aureus was then diluted in PBS to 3.5 
x 108 CFU/mL and heat-killed at 65°C for 1 hr. Splenocytes from naïve WT or MyD88 
KO mice were harvested and seeded (3.5 x 105 cells per well) into a Falcon 96-well flat-
bottom tissue culture plate in 200 μL RPMI medium. For cell depletion experiments, 
target cells were incubated with anti-CD16/32 antibody for 15 min on ice, then stained 
with biotinylated anti-CD3ε (145-2C11), biotinylated anti-NK1.1 (PKC136), or 
biotinylated anti-CD11b (M1/70) antibodies prior to cell separation using the BD IMag 
cell separation system. Cells were stimulated by adding 10 μL heat-killed S. aureus 
preparation to MOI 10 for 24 hr. For SAg-based stimulation, cells were stimulated with 
33% S. aureus culture supernatant for 24 or 96 hr. For neutralization experiments, 1 
μg/mL anti-IL-12p40 (17.8), 10 μg/mL anti-IL-18 (YIGIF74-1G7, Bio X Cell, West 
Lebanon, NH), or 10 μg/mL Rat IgG2a κ isotype control (RTK2758) antibodies were 
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included in the medium during stimulation. Culture supernatants were collected and 
assessed for cytokines and chemokine levels by CBA using LSRFortessa. 
EPS Stimulation of Peritoneal Macrophages In Vitro 
 Peritoneal cells from naïve BALB/cJ mice were harvested by lavage with 300 
mL/kg RPMI medium. Cells were incubated with anti-CD16/32 (93) antibody for 15 min 
on ice, then stained with biotinylated anti-F4/80 (BM8) antibody prior to purification 
using BD IMag cell separation system. F4/80+ cells (5 x 105) were seeded into a Falcon 
96-well flat-bottom tissue culture plate in 200 μL RPMI medium and stimulated with 1 
or 5 μg/mL EPS or 10 ng/mL S. enterica LPS (MilliporeSigma). At 24 hr, supernatants 
were assessed for levels of cytokines and chemokines by CBA using LSRFortessa. 
Measurement of NF-κB Activation 
 RAW 264.7 NF-κB/AP-1-secreted embryonic alkaline phosphatase reporter cell 
line (RAW-SEAP) was obtained from Dr. Jay Radke at Idaho Veterans Research and 
Education Foundation in Boise, ID. RAW-SEAP cells (105) were seeded into Falcon 24-
well tissue culture plate (Corning) in 500 μL RPMI medium 1 day prior to stimulation 
with 0.1-1 μg/mL EPS, 0.5-5 μg/mL ΔEPS, or 10 ng/mL S. enterica LPS. At 24 hr, 
culture supernatants were collected, and the endogenous alkaline phosphatase activity 
was heat-inactivated at 68°C for 30 min. The SEAP activity in supernatants were 
measured by mixing the supernatant with equal volume (50 μL each) 1-step para-
nitrophenyl phosphate (PNPP) substrate solution (Thermo Fischer Scientific) and 
measuring absorbance at 405 nm using a BioTek ELx800 absorbance microplate reader. 
Analysis of IL-4Rα Expression by Peritoneal Macrophages 
 Total peritoneal cells (3 x 105) from C57BL/6J mice were seeded into Falcon 48-
well tissue culture plate (Corning) in 400 μL modified RPMI and stimulated with 5 
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μg/mL EPS or ΔEPS in the presence or absence of 5 μg/mL neutralizing anti-IL-10 
(JES5-16E3) antibody or Rat IgG1 κ isotype (RTK2071) antibody. Cells were scraped 24 
hr later and incubated with anti-CD16/32 (93) antibody for 15 min on ice. Cells were 
then stained with anti-CD11b-APC (M1/70), anti-F4/80-APC/Cy7 (BM8), and anti-IL-
4Rα-PE (I015F8) antibodies and analyzed by flow cytometry using FACSCantoII or 
LSRFortessa. Data were analyzed using FlowJo V10. 
In Vivo Cytokine Neutralization 
 For IL-10 and TNF-α neutralization experiments, mice were treated with 250 μg 
neutralizing anti-IL-10 (JES5-2A5, Bio X Cell) or 500 μg neutralizing anti-TNF-α 
(XT3.11, Bio X Cell) antibodies by i.p. injection 1 day prior to EPS i.p. injection. 
Flow Cytometric Characterization of Splenic Myeloid Compartment 
 WT or TLR4 KO mice were treated with PBS or EPS by i.p. injection. Splenocytes 
were harvested the next day and incubated with anti-CD16/32 (93) antibody for 15 min 
on ice. Cells were stained with anti-CD11b-APC/Cy7 (M1/70), anti-CD11c-APC (N418), 
anti-Ly6C-PE (HK1.4), and anti-Ly6G-FITC (1A8). Cells were analyzed using 
LSRFortessa. Data were analyzed using FlowJo V10. 
Stimulation of Bone Marrow Neutrophils 
 Mouse tibias and femurs were flushed with 3 mL RPMI medium to harvest bone 
marrow cells. Bone marrow cells were layered over a Histopaque gradient established 
using Histopaque 1077 layered over Histopaque 1119 (MilliporeSigma). Neutrophils 
were isolated by centrifugation at 800 x g for 30 min at room temperature without 
brakes. The interface layer containing bone marrow neutrophils (BM-PMNs) were 
carefully collected and washed twice in 10 mL modified RPMI medium. BM-PMNs (105) 
were seeded into Falcon 96-well flat-bottom plate in 200 μL modified RPMI and 
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stimulated with 5 μg/mL EPS or ΔEPS, or 10 ng/mL S. enterica LPS for 24 hr. Culture 
supernatants were collected and assessed for cytokine and chemokine levels using CBA. 
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CHAPTER THREE 
RESULTS 
B. subtilis-derived EPS Attenuates Bloodstream Infection by S. aureus 
 To test our hypothesis that EPS could limit inflammation during systemic 
infections to improve outcomes, we administered EPS to mice one day prior to, and one 
day following infection with S. aureus USA300 LAC, a clone of an epidemic community-
acquired (CA)-MRSA strain from Los Angeles County (Miller et al., 2005), through the 
retro-orbital venous plexus. This mimics direct seeding of the bloodstream as it could 
occur during invasive surgical procedures or intravenous (IV) drug use. We found that 
whereas all PBS-treated mice died by 3 d.p.i., more than 50% of EPS-treated mice 
survived (Figure 3A). 
Figure 3: Effect of EPS on S. aureus Bloodstream Infection Outcomes in 
Mice. Mice were treated with EPS on -1 and 1 d.p.i. and infected systemically with S. 
aureus. A. Survival analysis. Any mice with more than 20% body weight loss were 
considered dead. Data analyzed using Mantel-Cox test. B. % body weight. Error bars 
represent standard deviation (SD). N = 19 (PBS), 21 (EPS). Data pooled from 6 
independent experiments. ****P<0.0001. Adopted from Paik and colleagues, Infection 
and Immunity, 2019. 
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We also found that EPS-treated mice lost less weight compared to PBS-treated mice 
(Figure 3B), suggesting that the overall burden of disease was reduced.  
Figure 4: Effect of EPS on Systemic Inflammation During S. aureus 
Bloodstream Infection at 1 d.p.i. Serum levels of cytokines and chemokines were 
measured in PBS- or EPS-treated mice after systemic S. aureus infection on 1 d.p.i. using 
CBA. Each triangle represents one mouse. Bars represent mean. N = 12. Data pooled from 
3 independent experiments. *P<0.05. **P<0.01. ***P<0.001. ****P<0.0001. Adopted 
from Paik and colleagues, Infection and Immunity, 2019. 
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We could notice the beneficial effect of EPS even with a single dose early during disease, 
since even at 1 d.p.i., before the second dose of EPS was administered, EPS-treated mice 
had lost less weight compared to PBS-treated mice (Figure 3B). This suggests that pre-
treatment with EPS reduces the burden of disease induced by systemic S. aureus 
infection, increasing host survival. 
 Given that EPS has anti-inflammatory properties (Paynich et al., 2017), we 
assessed the levels of serum cytokines and chemokines in EPS-treated mice. Indeed, 
serum levels of IL-1α, IL-12p70, IFN-γ, MCP-1, MIP-1α, MIP-1β, and TNF were reduced 
in EPS-treated mice compared to PBS-treated mice at 1 d.p.i. (Figure 4), indicating 
that EPS limits systemic inflammation early during disease. We did not observe any 
differences in serum IL-6 and KC levels, and we could not detect IL-2 at this time (data 
not shown). At 3 d.p.i., time-point representing peak disease, the serum levels of KC 
and TNF were reduced while serum levels of MCP-1 trended lower as well (Figure 5). 
No differences in serum levels of IL-6, IL-12p70, MIP-1α, and MIP-1β could be observed, 
and IFN-γ was not detectable at this time (data not shown). This suggests that a 
single dose of EPS reduces systemic inflammation during systemic S. aureus infection. 
Figure 5: Effect of EPS on Systemic Inflammation During S. aureus 
Bloodstream Infection at 3 d.p.i. Serum levels of cytokines and chemokines were 
measured in PBS- and EPS-treated mice after systemic S. aureus infection on 3 d.p.i. 
using CBA. Each dot represents one mouse. Bars represent mean. N = 10 (PBS), 11 (EPS). 
Data pooled from 3 independent experiments. *P<0.05. **P<0.01. Adopted from Paik 
and colleagues, Infection and Immunity, 2019. 
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While EPS did not alter pathogen colonization in the C. rodentium-induced colitis 
Figure 6: Effect of EPS on S. aureus Burden in Organs During Systemic 
Infection. S. aureus burden in organs were assessed by determining CFU S. aureus in 
organ homogenates by dilution plating, from PBS- and EPS-treated mice following 
systemic infection. A. CFU S. aureus at 1 d.p.i. Data pooled from 2 independent 
experiments. N = 8. B. CFU S. aureus at 3 d.p.i. Data pooled from 2 (spleen) or 6 (liver 
and kidney) independent experiments. N = 8 (spleen), 18 (liver), 17 (kidney). C. CFU S. 
aureus in blood at 6 h.p.i. Each triangle represents one mouse. Bars represent mean. 
Data pooled from 2 independent experiments. N = 9 (PBS), 10 (EPS). *P<0.05. 
**P<0.01. ****P<0.0001. Adopted from Paik and colleagues, Infection and Immunity, 
2019. 
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model (Jones et al., 2014), we still tested if EPS alters S. aureus colonization during 
infection by assessing bacterial load within organs. To our surprise, EPS-treated mice 
had 8-fold reduced CFU S. aureus in the spleen and 3-fold reduced CFU S. aureus in the 
liver at 1 d.p.i. (Figure 6A), suggesting that EPS reduces bacterial burden. A 3-fold 
decrease in CFU S. aureus was noted in the liver at 3 d.p.i., although not statistically 
significant (Figure 6B). No difference in the bacterial load was observed in the spleen 
at 3 d.p.i., and in the kidney at all time points assessed (Figure 6A and B). Since the 
beneficial effect of EPS was noted as early as 1 d.p.i., we tested if EPS-treated mice have 
reduced bacterial burden at an earlier time point by assessing the circulating numbers of 
S. aureus. We found that EPS-treated mice had 3-fold lower CFU S. aureus in the blood 
as early as 6 hours post infection (h.p.i.) (Figure 6C). Together, these data suggest that 
EPS reduces bacterial burden early during systemic infection by S. aureus. 
EPS Protection from S. aureus Bloodstream Infection Through TLR4 
 EPS protects mice from C. rodentium-induced colitis through the inhibition of T 
cell activation that drives disease, and any changes in pathogen colonization could not 
be observed in that model (Jones et al., 2014). In S. aureus bloodstream infection, EPS-
treated mice had reduced bacterial burden in multiple organs (Figure 6), indicating 
that in this model, EPS had an antimicrobial effect. B. subtilis has been demonstrated to 
produce bacteriocins, including those with antimicrobial activity against Gram-positive 
pathogens like L. monocytogenes and S. aureus (Liu et al., 2015; Shelburne et al., 2007). 
Therefore, one possibility for the reduced bacterial load in EPS-treated mice is that our 
EPS preparations contain antimicrobial properties. We tested this by culturing S. aureus 
in the presence of EPS in vitro and found that EPS did not affect S. aureus growth 
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(Figure 7), suggesting that the EPS preparation does not have direct antimicrobial 
activity against S. aureus. 
 The other possible explanation for EPS reducing pathogen burden during 
infection is through indirect mechanisms, by modulating the host immune system, for 
example. The protection from C. rodentium-induced colitis by EPS requires TLR4 and 
MyD88 (Jones et al., 2014; Paynich et al., 2017), suggesting that EPS modulates host 
immunity through TLR4-MyD88 signaling. To test if protection from S. aureus 
bloodstream infection by EPS occurs through immune modulation, we asked whether 
TLR4 is required for EPS protection using TLR4-deficient mice. We treated wild-type 
and TLR4 KO mice with EPS one day prior to systemic infection with S. aureus and 
found that while EPS-treated wild-type mice lost less weight compared to PBS-treated 
mice at 1 d.p.i., this difference was not observed between PBS- and EPS-treated TLR4 
KO mice (Figure 8A).   
Figure 7: Effect of EPS on S. aureus Growth In Vitro. Overnight culture of S. 
aureus AH1263 was subcultured 1:100 in TSB containing noted concentrations of EPS 
and growth was monitored over time. Error bars represent SD. N = 3. 
78 
 
 
 
We also assessed the bacterial burden within organs and found that while EPS-treated 
WT mice had reduced CFU S. aureus in spleen and liver at 1 d.p.i., EPS-treated TLR4 
KO mice did not have such a reduction in splenic bacterial burden and no difference in 
hepatic CFU S. aureus compared to PBS-treated TLR4 KO mice (Figure 8B). As before, 
we did not see any difference in CFU S. aureus in kidney between all groups (Figure 
8B). These data suggest that the reduction of the bacterial burden during systemic S. 
aureus infection depends on the modulation of host immunity by EPS through TLR4.   
Figure 8: Role of TLR4 on EPS Protection from S. aureus Bloodstream 
Infection. Wild-type (WT) or TLR4 KO mice were treated with PBS or EPS one day 
before S. aureus bloodstream infection. A. % body weight at 1 d.p.i. Data pooled from 4 
independent experiments. N = 13 (TLR4 KO PBS), 14 (all groups). B. CFU S. aureus in 
organ homogenates at 1 d.p.i. Each triangle represents data from one mouse. Bars 
represent mean. Data pooled from 2 independent experiments. N = 8 (WT), 7 (TLR4 KO 
PBS), 9 (TLR4 KO EPS). *P<0.05. **P<0.01. 
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We also tested if EPS affects inflammation during disease in a TLR4-dependent manner 
Figure 9: Role of TLR4 on EPS Inhibition of Early Systemic Inflammation 
During S. aureus Bloodstream Infection. WT or TLR4 KO mice were treated with 
EPS 1 day prior to systemic S. aureus bloodstream infection. Serum levels of cytokines 
and chemokines were determined using CBA. Each triangle represents data from one 
mouse. Bars represent mean. Data pooled from 3 independent experiments. N = 8 
(TLR4 KO PBS, IL-12p70), 9 (all groups, IL-12p70), 11 (TLR4 KO PBS, all groups), 12 
(all groups). *P>0.05. **P>0.01. ***P>0.001. ****P>0.0001. 
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by measuring serum levels of cytokines and chemokines from the infected mice in 
Figure 8. The levels of pro-inflammatory cytokines and chemokines IL-12p70, IFN-γ, 
KC, and TNF were reduced in EPS-treated WT mice, but not in EPS-treated TLR4 KO 
mice (Figure 9), indicating that the reduction in systemic inflammation by EPS during 
systemic S. aureus infection requires TLR4. Together, these data indicate that EPS 
protects hosts from systemic S. aureus infection by modulating the host immune 
response through TLR4, resulting in both reduced bacterial burden and systemic 
inflammation. 
Anti-Bacterial Activity of EPS-Induced Peritoneal Macrophages 
 The initial host response to S. aureus infection is characterized by an influx of 
innate immune cells, particularly neutrophils and MΦs, designed for phagocytosis of 
invading pathogens and intracellular killing. EPS protects mice from systemic S. aureus 
infection, reducing bacterial load early during disease through modulation of host 
immunity through TLR4. In addition, EPS is known to exert its functions through MΦs 
in C. rodentium-induced colitis, albeit through the anti-inflammatory polarization of 
MΦs (Paynich et al., 2017). Therefore, we hypothesized that EPS might reduce bacterial 
burden during infection by bolstering the two primary antimicrobial functions of innate 
immune cells: by increasing bacterial uptake or by increasing intracellular killing. We 
first incubated total peritoneal cells from PBS- and EPS-treated mice with opsonized S. 
aureus for 30 min to assess bacterial uptake and found no difference between the 
number of S. aureus CFU taken up by cells (Figure 10), indicating that EPS did not 
affect bacterial uptake by immune cells.   
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To test if EPS enhances immune cell-mediated killing of internalized S. aureus, we 
continued to culture washed cells and found that by 4 hr, cells from EPS-treated mice 
had less CFU S. aureus then PBS-treated mice (Figure 10), suggesting that EPS 
enhances immune cell restriction of S. aureus growth. 
 The two principal immune cells that mediate phagocytic killing of bacteria are 
neutrophils and MΦs. Protection from C. rodentium-induced colitis by EPS requires 
MΦs, since i.p. administration of clodronate-loaded liposomes to deplete MΦs negated 
the protective effects of EPS (Paynich et al., 2017). Therefore, we took the same 
approach to test if MΦs were responsible for the restriction of S. aureus growth in EPS-
treated mice. We administered clodronate-loaded liposomes to mice prior to PBS or EPS 
treatment which resulted in a reduction in percent peritoneal CD11b+F4/80+ cells (MΦs) 
in both PBS- and EPS-treated mice (Figure 11). We also observed an increase in the 
percent CD11b+Ly6G+F4/80- cells (PMNs) in EPS-treated mice and in both clodronate-
Figure 10: Effect of EPS on Peritoneal Cell Restriction of S. aureus Growth. 
Peritoneal cells (106) from PBS- or EPS-treated Balb/cJ mice were infected ex vivo with 
opsonized S. aureus at MOI 1. CFU internalized S. aureus was assessed at 30 min after 
washing cells of free bacterium (left). Washed cells were further cultured and CFU S. 
aureus was assessed at 4 hr (right). Each triangle represents data from one mouse. Bar 
represents mean. N = 4 (PBS), 5 (EPS). ****P>0.0001. 
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loaded liposome treated mice (Figure 11). We infected these cells with opsonized S. 
aureus to test their capacity to restrict S. aureus growth as before and found that while 
cells from mice treated with EPS and control liposomes had lower CFU S. aureus by 5 hr, 
cells from mice with EPS and clodronate-loaded liposomes did not (Figure 12), 
indicating that peritoneal MΦs are required for restriction of S. aureus growth in vitro. 
 
 
 
 
Figure 11: In Vivo Depletion of Peritoneal Macrophages Using Clodronate-Loaded Liposomes. ND4 Swiss 
Webster mice were given 200 μL PBS- or clodronate-loaded liposomes by i.p. injection 1 day prior to i.p. EPS injection. 
Peritoneal cells were harvested 1 day later and analyzed by flow cytometry. Representative data from 2 experiments. 
8
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 EPS is thought to polarize MΦs into the anti-inflammatory M2 phenotype, which 
in turn limits the activation of T cells to protect hosts from inflammatory diseases such 
as C. rodentium-induced colitis (Paynich et al., 2017). Generally, M2 MΦs are not 
associated with antimicrobial functions. In fact, Arg-1-expressing MΦs have been found 
associated with S. aureus persistence in a murine model of catheter-associated biofilm 
infection (Thurlow et al., 2011). Therefore, we hypothesized that two reasons underlie 
the apparent anomaly of EPS-induced MΦs restricting S. aureus growth ex vivo. For one, 
EPS-induced M2 MΦs are typically detectable 3 days after i.p. EPS injection (Paynich et 
al., 2017), so at earlier time points, the MΦs may take on pro-inflammatory 
characteristics like antimicrobial activity. The other is that since MΦs modulate their 
functions in response to environmental cues, the EPS-induced M2 MΦs may increase 
their antimicrobial activity in response to infection by S. aureus. To test this, we isolated 
Figure 12: Effect of EPS on Restriction of S. aureus Growth in the Absence 
of MΦs. Peritoneal cells (106) were harvested from EPS-treated ND4 Swiss Webster 
mice, depleted of MΦs by pre-treatment with clodronate-loaded liposomes 1 day before 
treatment with EPS, 1 day after EPS and were infected with opsonized S. aureus at MOI 
1. After washing, growth of internalized S. aureus was monitored over time. Error bars 
represent SD. Data pooled from 4 independent experiments. N = 4. *P<0.05. 
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peritoneal F4/80+ MΦs from PBS- or EPS-treated mice at 3 days after i.p. EPS injection 
and tested their capacity to restrict S. aureus growth ex vivo. We found that whereas 
peritoneal F4/80+ cells from EPS-treated mice had lower CFU S. aureus than F4/80+ 
cells from PBS-treated mice by 5 hr, F4/80- cells from PBS- and EPS-treated mice did 
not show any difference in CFU S. aureus (Figure 13), confirming that EPS-induced 
peritoneal MΦs, previously demonstrated to be anti-inflammatory M2 MΦs (Paynich et 
al., 2017), restrict S. aureus growth. 
 A classic mechanism by which phagocyte kill bacteria or restrict their growth 
internally is the production of ROS and RNS. After uptake, phagocytes use NADPH 
oxidase that catalyzes the reaction of NADPH and O2 to generate O2-, which is then used 
to generate a variety of reactive oxidants that damage microbial processes (Sbarra and 
Karnovsky, 1959; Segal, 1987; Xie et al., 1992).   
Figure 13: Effect of EPS on Peritoneal MΦ-Mediated Restriction of S. aureus 
Growth. Peritoneal F4/80+ and F4/80- cells (5 x 105) harvested from PBS- or EPS-
treated mice 3 days after EPS injection were infected with opsonized S. aureus at MOI 1. 
After washing, growth of internalized S. aureus was assessed over time. Error bars 
represent SD. Data pooled from 4 independent experiments. N = 7 (F4/80+ PBS), 8 
(F4/80+ EPS), 5 (F4/80- PBS), 6 (F4/80- EPS). *P<0.05. **P<0.01. Adopted from Paik 
and colleagues, Infection and Immunity, 2019. 
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To determine if EPS-induced MΦs use ROS to restrict the growth of internalized S. 
aureus, we measured ROS levels in EPS-induced MΦs after infection with opsonized S. 
aureus ex vivo using a fluorescent ROS indicator, CellROX Green. There was no 
difference in CellROX Green staining between CD11bhighF4/80high MΦs from PBS- and 
EPS-treated mice freshly isolated, but upon infection with S. aureus ex vivo, MΦs from 
EPS-treated mice had increased CellROX Green staining compared to MΦs from PBS-
treated mice, which failed to increase CellROX staining (Figure 14A). This suggests 
that EPS-induced MΦs, while not increased in ROS levels at baseline, can increase ROS 
during infection. Another source of ROS is the mitochondria, thought to be produced 
through mitochondrial respiratory metabolic processes (Boveris et al., 1976; Turrens 
and Boveris, 1980).   
Figure 14: Effect of EPS on Peritoneal MΦ Production of ROS. Peritoneal cells 
were harvested from PBS- or EPS-treated mice 3 days after EPS injection. Cells (106)s 
were incubated with A. CellROX Green or B. MitoSOX Red ROS indicators in the 
presence of absence of infection with opsonized S. aureus at MOI 1. MFI of ROS 
indicators on CD11bhighF4/80high cells were assessed by flow cytometry. Each triangle 
represents data from one mouse. Bars represent mean. Data pooled from 5 (CellROX) or 
2 (MitoSOX) independent experiments. N = 9 (CellROX), 5 (MitoSOX, PBS), 6 
(MitoSOX, EPS). *P<0.05. **P<0.01. ****P<0.0001. Adopted from Paik and colleagues, 
Infection and Immunity, 2019. 
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This mtROS can be used to augment phagocyte antibacterial activity (West et al., 2011), 
and mtROS was recently reported to play a role in MΦ responses against S. aureus 
(Abuaita et al., 2018). M2 MΦs are associated with mitochondrial metabolic processes 
compared to M1 MΦs that rely more on glycolysis (Huang et al., 2014; 2016; Rodríguez-
Prados et al., 2010), and tissue-derived mtROS was demonstrated to promote 
differentiation of M2 MΦs in vivo (Formentini et al., 2017). Given this, we hypothesized 
that EPS-induced peritoneal MΦs might harbor increased levels of mtROS. To test this, 
we stained the peritoneal cells as in Figure 14A with MitoSOX Red mtROS indicator 
and found that CD11bhighF4/80high LPMs from EPS-treated mice had higher levels 
MitoSOX Red staining compared to PBS-treated mice at baseline (Figure 14B), 
indicating that EPS-induced MΦs have increased mtROS.   
Figure 15: Restriction of S. aureus Growth by EPS-Induced Peritoneal MΦs 
and ROS Production. Peritoneal F4/80+ cells (5 x 105) from PBS- or EPS-treated 
mice were harvested 3 days after i.p. EPS. Cells were infected with opsonized S. aureus 
at MOI 1, then monitored for S. aureus growth after washing in the presence or absence 
of 2 μM DPI in the medium. Error bars represent SD. Data pooled from 4 independent 
experiments. N = 6. *P<0.05. **P<0.01. Adopted from Paik and colleagues, Infection 
and Immunity, 2019. 
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Both cells had increased MitoSOX Red staining upon infection with S. aureus beyond 
baseline levels, and EPS-induced MΦs had mtROS levels that were even higher (Figure 
14B), consistent with the previous reports that mtROS plays a role in MΦ responses to S. 
aureus infection. To confirm that this increase in ROS production was responsible for 
restriction of S. aureus growth by EPS-induced MΦs, we repeated the restriction assay 
as in Figure 13 in the presence of DPI, a general ROS inhibitor (Cross and Jones, 1986). 
We found that in the presence of DPI, restriction of S. aureus growth by EPS-induced 
MΦs was abrogated (Figure 15). We also measured RNS production from EPS-induced 
MΦs using the Griess test. However, supernatants from the MΦ cultures from S. aureus 
infection ex vivo from Figure 13 did not have detectable RNS levels (data not shown). 
We then stimulated F4/80+ peritoneal cells from PBS- and EPS-treated mice with 
culture supernatants of S. aureus to compare their RNS-producing capacity and found 
Figure 16: Effect of EPS on MΦ Production of RNS. F4/80+ cells (105) from 
PBS- and EPS-treated mice were stimulated with 10% S. aureus culture supernatant 
and RNS levels were determined using the Griess test. Each triangle represents data 
from one mouse. Bars represent mean. Data pooled from 2 independent experiments. 
N = 4. 
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no difference in RNS production (Figure 16), suggesting that an increase in RNS 
production is likely not responsible for increased restriction of S. aureus growth ex vivo. 
Together, these data suggest that EPS reduces bacterial burden by inducing MΦs that 
restrict S. aureus growth through ROS. 
Effect of EPS-Induced Macrophages on S. aureus Superantigen-Induced 
Activation of T Cells 
 EPS was previously demonstrated to induce anti-inflammatory M2 MΦs that 
limit T cell activation (Paynich et al., 2017). Here, we found that these MΦs restrict S. 
aureus growth through ROS production, a feature classically associated with pro-
inflammatory M1 MΦs. We reasoned that this apparent paradox could be explained by 
the flexible nature of MΦs, constantly modulating their functions according to 
environmental cues (Gautier et al., 2012; Murray et al., 1985). If this is the case, we 
hypothesized that EPS-induced M2 MΦs, when infected with S. aureus, may convert to 
pro-inflammatory M1 MΦs to deal with the bacterial infection. It is thought that M1 and 
M2 MΦ polarization is mutually exclusive because of the competition of the two M1- and 
M2-defining enzymes, iNOS and Arg-1, for the same substrate (Munder et al., 1998). To 
test this idea, we took advantage of the fact that S. aureus secretes both lipopeptides 
that trigger pro-inflammatory responses through TLR2 (Hashimoto et al., 2006) and 
SAgs that drive polyclonal activation of T cells (Peavy et al., 1970). We first tested a 
system for SAg-driven splenic T cell activation in vitro using culture supernatants from 
S. aureus AH1263. When C57BL/6J splenocytes were stimulated with 33% S. aureus 
AH1263 culture supernatants for 4 days, we found that both CD4+ and CD8a+ T cell 
proliferated, as measured by the dilution of CellTrace Violet proliferation tracking dye 
(Figure 17). S. aureus LAC makes three SAgs: SEl-K, SEl-Q, and SEl-X encoded by sek, 
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seq, and sex, respectively. It also harbors a gene annotated as a putative type A 
enterotoxin, USA300_1559. We also stimulated the splenocytes with culture 
supernatants from transposon mutants deficient in each one of these SAgs and found 
that while the wild-type (JE2) stimulated proliferation of both CD4+ and CD8a+ 
splenocytes, mutant deficient in SEl-Q failed to stimulate proliferation (Figure 17).   
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Figure 17: Effect of S. aureus SAg on Splenic T Cell Proliferation In Vitro. 
Splenocytes (3.5 x 105) from mice were stimulated with 33% culture supernatant from S. 
aureus for 4 days. Proliferation of CD4+ and CD8a+ splenocytes were assessed by CTV 
dilution by flow cytometry. Proliferative index = % events within the “proliferated” gate. 
A. Representative flow cytometry plots showing CD4+ splenocytes. B. Error bars 
represent SD. Data pooled from 4 independent experiments. N = 4 (NT), 6 (all others). 
Data analyzed using 1-way ANOVA with Bonferroni’s multiple comparisons test. 
***P<0.001. Adopted from Paik and colleagues, Infection and Immunity, 2019. 
 
  
 
 
Figure 18: Effect of EPS-Induced Peritoneal MΦs on S. aureus SEl-Q-Mediated Proliferation and 
Activation of T Cells. Splenocytes (3.5 x 105) from naïve mice were co-cultured with peritoneal F4/80+ cells (5 x 104) 
from PBS- or EPS-treated mice 3 days after i.p. EPS. Cultures were stimulated with 33% S. aureus culture supernatant for 
4 days. A and B. Representative flow cytometry plots showing CD8a+ splenocytes. C. T cell proliferation. D. % 
CD25+CD44+ activated T cells. Each triangle represents data from individual mouse. Bars represent mean. Data pooled 
from 3 independent experiments. N = 8. *P<0.05. **P<0.01. Adopted from Paik and colleagues, Infection and Immunity, 
2019. 
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All other mutants tested caused proliferation of T cells (Figure 17), indicating that in 
the C57Bl/6J mouse background, S. aureus culture supernatants drive SEl-Q-dependent 
T cell proliferation. To test if EPS-induced MΦs retain their ability to inhibit T cell 
activation during S. aureus infection, we co-cultured F4/80+ cells from PBS- or EPS-
treated mice with splenocytes from naïve mice and stimulated them with S. aureus 
culture supernatant as in Figure 17. While co-culture with F4/80+ cells from PBS-
treated mice had proliferated and CD25+CD44+ activated CD4+ and CD8a+ T cells, co-
culture with F4/80+ cells from EPS-treated mice had reduced T cell proliferation and 
activation (Figure 18C and D), suggesting that even in the presence of pro-
inflammatory conditions, EPS-induced peritoneal MΦs retain the ability to limit T cell 
activation induced by S. aureus SEl-Q. To test if EPS also affects the activity of SAg in 
vivo, we stimulated splenocytes from EPS-treated mice 3 days after i.p. EPS injection 
with S. aureus culture supernatant ex vivo.   
Figure 19: Effect of EPS In Vivo on Splenic T Cell Proliferation Induced by 
S. aureus SEl-Q. Mice were treated with PBS or EPS by i.p. injection and splenocytes 
were harvested 3 days later and labeled with CTV. CTV-labeled splenocytes were 
stimulated with 33% S. aureus culture supernatant for 4 days and assessed for 
proliferation by flow cytometry. Proliferative index = % events within “proliferated” 
gate. Each triangle represents data from 1 mouse. Bars represent mean. Data pooled 
from 3 independent experiments. N = 7. *P<0.05. ****P<0.0001. Adopted from Paik 
and colleagues, Infection and Immunity, 2019. 
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We found that splenocytes from EPS-treated mice had reduced proliferation of both 
CD4+ and CD8a+ splenocytes (Figure 19), indicating that EPS limits the activation of T 
cells by SEl-Q in vivo. Together, these data suggest that EPS induced MΦs, while they 
have enhanced antimicrobial capacities like that of M1 MΦs, retain their ability to limit 
T cell activation like that of M2 MΦs. 
Induction of Hybrid M1-M2 Macrophages by EPS 
 MΦs have been classically described in two polarized states: pro-inflammatory 
M1 MΦs that mediate antibacterial immunity and anti-inflammatory M2 MΦs that 
mediate wound healing (Murray et al., 2014). EPS-induced peritoneal MΦs have 
previously been reported to be M2 MΦ (Paynich et al., 2017), but our data indicate that 
these MΦs also have enhanced antibacterial capacities like that of M1 MΦs. In reality, 
MΦs are flexible in nature, and their phenotypes depend on the signals they receive 
from the environment (Gautier et al., 2012; Murray et al., 2014). Recently, hybrid states 
of MΦs have been reported (O’Carroll et al., 2014). We hypothesized that EPS-induced 
MΦs might represent such a hybrid-type, displaying both M1- and M2-like qualities. To 
test this, we assessed the expression of the classical M1 marker, iNOS, and the M2 
markers, CD206 and Arg-1, on EPS-induced MΦs. We found that, as previously reported, 
CD11bhighF4/80high LPMs from EPS-treated mice had increased expression of CD206 
and Arg-1 than LPMs from PBS- or ΔEPS-treated mice (Figure 20). In addition, LPMs 
from EPS-treated mice had increased expression of iNOS than LPMs from PBS- or 
ΔEPS-treated mice (Figure 20), indicating that the EPS-induced peritoneal MΦs are 
hybrid MΦs that express both M1 and M2 markers. 
 
95 
 
 
 
Effect of EPS on S. aureus-Induced Local Inflammation In Vivo 
 Upon entering the bloodstream, S. aureus disseminates to and seeds virtually all 
organs, setting off a complex cascade of events thought to lead to inflammation, tissue 
damage, and organ failure. We demonstrated that EPS might protect hosts from 
systemic S. aureus infection in part by MΦs that better control S. aureus growth and 
also limit inappropriate activation of T cells by S. aureus SAg, but many other 
mechanisms of protection may be at play given the complex pathophysiology of S. 
Figure 20: Phenotype of EPS-Induced Peritoneal MΦs. Peritoneal 
CD11bhighF4/80high cells from PBS-, ΔEPS, and EPS-treated mice were analyzed 3 days 
after i.p. EPS injection by flow cytometry for M1 and M2 marker expression. A. 
Representative flow cytometry plots. Solid line (PBS), dotted line (ΔEPS), dashed line 
(EPS). B. MFI normalized to cells from PBS-treated mice. Each triangle represents data 
from one mouse. Data pooled from 3 independent experiments. N = 10 (PBS), 5 (ΔEPS), 
8 (EPS). Data analyzed using 1-way ANOVA with Bonferroni’s multiple comparisons 
test. **P<0.01. ***P<0.001. Adopted from Paik and colleagues, Infection and 
Immunity, 2019. 
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aureus bloodstream infection. We first focused on the observation that EPS-treated 
mice had reduced serum levels of IFN-γ at 1 d.p.i. (Figure 4). IFN-γ is the classic 
defining cytokine of type I immunity (Cher and Mosmann, 1987; Mosmann et al., 1986), 
and is associated with enhancing immunity against intracellular pathogens such as L. 
monocytogenes and Mycobacterium tuberculosis (Buchmeier and Schreiber, 1985; 
Flynn et al., 1993). Therefore, the observation that EPS-treated mice had reduced 
disease burden and reduced serum levels of IFN-γ during S. aureus infection seemed 
paradoxical, given the apparent importance of IFN-γ in antimicrobial immunity. 
However, neutralization of IFN-γ during S. aureus bloodstream infection was reported 
to improve survival in mice (Nakane et al., 1995), and infection of IFN-γ-deficient mice 
also results in improved survival compared to wild-type mice (Sasaki et al., 2000), 
suggesting that under certain circumstances including S. aureus bloodstream infection, 
IFN-γ has a role in promoting pathogenesis. A significant producer of IFN-γ is the T 
helper 1 (TH1) cell (Cher and Mosmann, 1987; Mosmann et al., 1986), and a major S. 
aureus factor that can stimulate T cells is SAgs (Peavy et al., 1970). Since EPS-induced 
MΦs limit activation of T cells by SEl-Q in vitro (Figure 18), and splenocytes from 
EPS-treated mice proliferate less in response to SEl-Q (Figure 19), we hypothesized 
that a principal mechanism underlying protection by EPS in this model is the inhibition 
of IFN-γ induced by S. aureus SAgs. 
 To assess the extent of the effects of EPS on limiting inflammation during S. 
aureus bloodstream infection in vivo, including the induction of IFN-γ, we measured 
the levels of cytokines and chemokines in the organ homogenates from PBS- and EPS-
treated mice. In the spleen, EPS-treated mice had reduced levels of IL-1α, IL-6, IFN-γ, 
MCP-1, and TNF, and increased levels of RANTES than PBS-treated mice (Figure 21).   
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IL-2 levels were low in both PBS- and EPS-treated mice and no differences were 
observed between the two groups (Figure 21). In the liver, levels of IFN-γ and MCP-1 
were reduced in EPS-treated mice compared to PBS-treated mice while RANTES levels 
were increased (Figure 22). A small decrease, though not statistically significant, in IL-
1α levels were observed in the liver of EPS-treated mice compared to PBS-treated mice 
(Figure 22).  
Figure 21: Effect of EPS on Splenic Cytokines and Chemokine Levels 
During S. aureus Bloodstream Infection at 1 d.p.i. Levels of cytokines and 
chemokines were determined from spleen homogenates from PBS- or EPS-treated mice 
systemically infected with S. aureus at 1 d.p.i. by CBA. Each triangle represents data 
from one mouse. Bars represent mean. Data pooled from 2 independent experiments. 
N = 8. **P<0.01. ****P<0.0001. 
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No differences in IL-6 and TNF levels were observed between the two groups, and IL-2 
levels were equally low in both groups. In the kidney, the only molecule showing a 
difference between the two groups was RANTES, which was increased in EPS-treated  
mice compared to PBS-treated mice (Figure 23).   
Figure 22: Effect of EPS on Hepatic Cytokine and Chemokine Levels During 
S. aureus Bloodstream Infection at 1 d.p.i. Levels of cytokines and chemokines 
were determined from liver homogenates from PBS- or EPS-treated mice systemically 
infected with S. aureus at 1 d.p.i. by CBA. Each triangle represents data from one mouse. 
Bars represent mean. Data pooled from 2 independent experiments. **P<0.01. 
***P<0.001. 
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A small decrease in MCP-1 levels in EPS-treated mice compared to PBS-treated mice 
was observed, although it did not reach statistical significance (Figure 23). IFN-γ and 
IL-2 levels in the kidney in both groups were deficient, and no differences were observed 
between the two groups (Figure 23). A much higher level of IL-6, compared to the 
spleen and liver, was observed in both groups in the kidney (Figure 23). Across the 
three organs, no differences in IL-1β, IL-10, IL-12p70, IL-17A, KC, MIP-1α, MIP-1β, and 
Figure 23: Effect of EPS on Renal Cytokines and Chemokines Levels During 
S. aureus Bloodstream Infection at 1 d.p.i. Levels of cytokines and chemokines 
were determined from kidney homogenates from PBS- or EPS-treated mice systemically 
infected with S. aureus at 1 d.p.i. by CBA. Each triangle represents data from one mouse. 
Bars represent mean. Data pooled from 2 independent experiments. **P<0.01. 
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G-CSF were observed between PBS- and EPS-treated mice (data not shown). 
Together, these data suggest that EPS alters local inflammation during systemic S. 
aureus infection, reducing levels of cytokines and chemokines in the spleen and liver but 
not in the kidney. We also confirmed that EPS reduced IFN-γ levels in the spleen and 
liver but not in the kidney. 
Effect of Superantigen on the Pathogenesis of Systemic S. aureus Infection 
 EPS limits the induction of IFN-γ both systemically and locally during S. aureus 
infection, and IFN-γ-deficient mice have improved survival upon systemic infection with 
S. aureus (Sasaki et al., 2000). S. aureus SAgs are major virulence factors thought to 
drive polyclonal activation of T cells (Peavy et al., 1970), the significant producers of 
IFN-γ (Cher and Mosmann, 1987; Mosmann et al., 1986). This ability to induce 
inappropriate activation of T cells have been the focus of studies on SAgs (Bonventre et 
al., 1984), and the role of SAgs in S. aureus pathogenesis have not been extensively 
studied. One study assessed the role of SAg using S. aureus Newman, that encodes SEA 
(Baba et al., 2008). In this study, Xu and colleagues infected mice C57Bl/6Crl (Charles 
River strain) mice with sea-deficient mutant S. aureus and found that levels of IFN-γ 
and IL-12 were reduced in both in the serum and liver at 8 h.p.i. compared to mice 
infected with wild-type S. aureus (Xu et al., 2014). In addition, CFU S. aureus in the 
liver and heart, but not the kidney and the lung, were reduced in sea mutant infected 
mice compared to wild-type infected mice at 8 h.p.i. (Xu et al., 2014). We noticed that 
this pattern of reduced IFN-γ levels early during infection, in the serum and the liver but 
not in the kidney, along with reduced bacterial burden in the liver but not in the kidney, 
was strikingly similar to that we observed in EPS-treated, S. aureus-LAC infected mice.   
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Figure 24: Role of SEl-Q on Systemic and Local Cytokine and Chemokine 
Levels During S. aureus Bloodstream Infection at 1 d.p.i. Mice were infected 
with wild-type (JE2) or SEl-Q-deficient mutant (selq::erm) S. aureus and levels of 
cytokines and chemokines in the serum (A) and spleen (B), liver (C), and kidney (D) 
homogenates collected on 1 d.p.i. were determined by CBA. Each triangle represents data 
from one mouse. Bars represent mean. Data pooled from 3 independent experiments. N 
= 11 (A), 7 (B-D). 
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We reasoned that given our hypothesis that EPS functions in part by limiting SAg-
induced activation of T cells in vivo, the protective phenotype of EPS should be 
reproduced by infecting mice with a SAg-deficient mutant in our system as well. 
We found that in the C57Bl/6J background, only SEl-Q is the active SAg at least under 
in vitro conditions (Figure 17), so we tested this idea by infecting C57Bl/6J mice with 
the JE2 strain (wild-type for the transposon library mutants) or the seq-deficient library 
mutant (seq::erm) we used previously. However, we found that the levels of IFN-γ and 
IL-12p70 were not different in all tissues tested between JE2-infected and seq::erm-
infected mice (Figure 24), inconsistent with the sea-deficient mutant as reported by 
Xu and colleagues (Xu et al., 2014). While EPS-treated mice had reduced levels of MCP-
1 in the serum, spleen, and liver, the SEl-Q-deficient mutant-infected mice did not have 
reduced MCP-1 levels in all tissues tested compared to wild-type-infected mice (Figure 
24). IL-2 levels were low in all tissues in both groups (Figure 24). We also assessed the 
bacterial load in the organ homogenates at 1 d.p.i. and found no difference in CFU S. 
aureus between wild-type- and SEl-Q-deficient mutant-infected mice in all tissues 
tested (Figure 25), another discrepancy compared to sea mutants described by Xu and 
Figure 25: Role of SEl-Q on Bacterial Burden During S. aureus Bloodstream 
Infection at 1 d.p.i. Mice were infected with wild-type (JE2) or SEl-Q-deficient 
(seq::erm) S. aureus and CFU S. aureus in organ homogenates were determined at 1 
d.p.i. Each triangle represents data from one mouse. Data pooled from 3 independent 
experiments. N = 11. 
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colleagues and EPS-treated mice that had reduced CFU S. aureus in the spleen and liver. 
Together, these data suggest that during infection with S. aureus LAC in the C57Bl/6J 
mouse background, SEl-Q does not drive IFN-γ production and does not promote 
bacterial survival early during infection. 
Superantigen-Independent Induction of Interferon Gamma by S. aureus 
 We hypothesized that two possibilities could explain why the SEl-Q-deficient 
mutant did not show reduced IFN-γ production as predicted based on a past study on 
SEA (Xu et al., 2014). The first possibility stems from the differences in the two strains 
of S. aureus used between the SEA study and our study. S. aureus Newman encodes 
SEA and SEl-X (Baba et al., 2008; Wilson et al., 2011), but only SEA is responsible for 
driving T cell activation in this strain (Xu et al., 2014). In contrast, S. aureus LAC 
encodes SEl-K, -Q, and -X along with USA300_1559, a putative type A enterotoxin, 
though only SEl-Q was responsible for T cell proliferation in vitro in the C57Bl/6J 
background (Figure 17). Still, the other three SAgs could be active in vivo, which would 
explain why the SEl-Q single-deficient mutant was able to induce IFN-γ during infection 
(Figure 24). However, only SEl-Q had activity in vitro in S. aureus LAC just as only 
SEA had activity in S. aureus Newman, making it somewhat unlikely that the other SAgs 
could function in vivo at least in the C57Bl/6J background. 
 Another possibility is that S. aureus has a SAg-independent mechanism for 
inducing host IFN-γ responses. One thing we noticed was that in vivo, IL-2 levels were 
not elevated during infection with S. aureus across our experiments. IL-2 is the T cell 
growth factor produced by T cells upon activation to support its proliferation (Mier and 
Gallo, 1980), so the lack of IL-2 elevation during infection at 1 d.p.i. seemed to suggest 
that the production of IFN-γ at this point may not be driven by T cells. Another relevant 
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observation was made in a study that looked for endotoxin-induced IFN-γ responses in 
mouse splenocytes. In this study, Varma and colleagues stimulated splenocytes from 
BALB/c mice in vitro with LPS and a few different heat-killed bacteria, including S. 
aureus, which resulted in the production of IFN-γ (Varma et al., 2002). The way in 
which heat-killed S. aureus was prepared was not described by the authors, but SAgs are 
not expected to be produced by heat-killed S. aureus, though there may have been some 
residual SAgs in the preparation. 
 To confirm that heat-killed S. aureus can induce IFN-γ from splenocytes, we 
isolated splenocytes from naïve C57Bl/6J mice and stimulated them with either 33% S. 
aureus culture supernatant as previously for SEl-Q-based stimulation, or heat-killed S. 
aureus, prepared after washing any secreted proteins away, at MOI 10 and measured 
the levels of cytokines and chemokines in the culture supernatants. At 24 hr, we found 
that cultures stimulated with S. aureus culture supernatant from AH1263 or JE2 had 
detectable IL-2 levels while the supernatant from SEl-Q deficient mutant did not 
(Figure 26A). Low levels of IFN-γ were also detectable in the wild-type supernatant-
stimulated cultures (Figure 26A), indicating that at 24 hr, S. aureus culture 
supernatant causes a SEl-Q-dependent induction of IL-2 and a little IFN-γ, presumably 
from T cells. T cell proliferation induced by S. aureus culture supernatant can be 
detected by 4 days after stimulation in vitro (Figure 17), so we also measured cytokines 
from the supernatant-stimulated cultures at 96 hr. At this time point, high levels of IFN-
γ could be detected in cultures stimulated with the two wild-type S. aureus supernatants 
but not in the SEl-Q-deficient mutant (Figure 26B). At this time point, IL-2 levels in 
the stimulated wells did not differ from the untreated cultures (Figure 26B), indicating 
that IL-2 was no longer produced by 96 hr post stimulation. In contrast, the cultures 
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stimulated with heat-killed S. aureus produced IFN-γ levels at 24 hr, and this effect was 
also observed using heat-killed SEl-Q-deficient mutant S. aureus (Figure 26C), 
indicating that SEl-Q was not required for IFN-γ production in response to heat-killed S. 
aureus.   
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With the heat-killed S. aureus, a small increase in IL-2, although not statistically 
Figure 26: Role of SEl-Q on S. aureus Culture Supernatant- or Heat-Killed 
S. aureus-Induced Stimulation of Mouse Splenocytes. Splenocytes from mice 
were stimulated with 33% S. aureus culture supernatant (A and B) or heat-killed S. 
aureus at MOI 10 (C). Levels of cytokines in culture supernatant at 24 hr (A and C) and 
96 hr (B) were assessed by CBA. Error bars represent SD. Representative data from 3 (A 
and B) or 4 (C) independent experiments. N = 3. Data assessed using 1-way ANOVA 
with Bonferroni’s multiple comparisons test. **P<0.01. ***P<0.001. 
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significant, was observed with all strains tested (Figure 26C). Together, these data 
suggest that S. aureus harbors an alternative, SAg-independent mechanism to induce 
IFN-γ from mouse splenocytes in vitro. 
Mechanism of SAg-Independent Induction of IFN-γ by S. aureus 
 To elucidate the underlying mechanism by which heat-killed S. aureus induces 
IFN-γ, we first tested for the cell types required for the production of IFN-γ in vitro. The 
major producers of IFN-γ that can be found in the spleen are T cells, NKT cells, NK cells, 
and myeloid cells, though the latter is considered a minor contribution (Emoto et al., 
1999; Fukao et al., 2000; Mosmann et al., 1986; Scharton and Scott, 1993; Yeaman et al., 
1998).   
Figure 27: Splenic Cell Types Required for the Induction of IFN-γ by 
Heat-Killed S. aureus. Total, CD3-, NK1.1-, or CD11b-depleted splenocytes from 
mice (3.5 x 105) were stimulated with heat-killed S. aureus at MOI 10 for 24 hr. IFN-γ 
levels in culture supernatants were assessed by CBA. Each triangle represents data 
from one mouse. Bars represent mean. Data pooled from 4 independent experiments. 
N = 7 (total splenocytes), 5 (CD3-), 4 (other groups). Data were analyzed using 1-way 
ANOVA with Bonferroni’s multiple comparisons test. **P<0.01.  
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To test if these cells are required for heat-killed S. aureus-induced IFN-γ, we depleted 
splenocytes of CD3+ (T and NKT cells), NK1.1+ (NK and NKT cells), or CD11b+ (myeloid 
cells) cells and stimulated them with heat-killed S. aureus in vitro. We found that while 
depletion of CD3+ cells resulted in only a minor reduction in IFN-γ levels, depletion of 
NK1.1+ or CD11b+ cells completely abrogated IFN-γ production (Figure 27), suggesting 
that NK cells and myeloid cells are required. 
 Given that NK cells are a typical IFN-γ-producing cell type while myeloid cells 
are thought to be minor contributors (Fukao et al., 2000; Scharton and Scott, 1993; 
Yeaman et al., 1998) , we reasoned that the myeloid cells might be playing a supportive 
role in NK cell-mediated production of IFN-γ.   
Figure 28: Role of MyD88 on Induction of IFN-γ by Heat-Killed S. 
aureus. Splenocytes from MyD88-deficient mice were stimulated with heat-killed 
S. aureus at MOI 10 for 24 hr. IFN-γ levels were assessed by CBA. Each triangle 
represents data from one mouse. Bars represent mean. Data for wild-type group 
was pooled from at least 6 independent experiments including historical data for 
comparison. MyD88 data pooled from 3 independent experiments. N = 4. Data 
analyzed using Mann Whitney U-test. **P<0.01. 
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We hypothesized that for its supportive functions, myeloid cells would interact with S. 
aureus through its PRRs, mainly TLR2, to cause IFN-γ production. To test this, we 
isolated splenocytes from MyD88-deficient mice and stimulated them with heat-killed S. 
aureus. Here, we found that the levels of IFN-γ induced by heat-killed S. aureus were 
completely abrogated in MyD88-deficient mice compared to historic data on IFN-γ 
induction in wild-type splenocytes (Figure 28), suggesting that recognition of S. 
aureus through PRRs was required. 
 The finding that the induction of IFN-γ requires both NK cells and myeloid cell 
activation by S. aureus through PRRs could result from cytokine-dependent activation 
of IFN-γ production, as previously reported for NK cells (Chan et al., 1991). To test if 
Figure 29: Role of IL-12 on Heat-Killed S. aureus-Induced IFN-γ 
Production by Splenocytes. Splenocytes from mice were stimulated with heat-
killed S. aureus at MOI 10 in the presence of neutralizing anti-IL12p40, anti-IL-18, or 
isotype control antibodies for 24 hr. Levels of IFN-γ in culture supernatants were 
determined by CBA. Error bars represent SD. Representative data from 3 independent 
experiments. N = 3. Data analyzed using 1-way ANOVA with Bonferroni’s multiple 
comparisons test. **P<0.01. 
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IFN-γ induction by heat-killed S. aureus occurs through cytokine-dependent activation 
of NK cells, we neutralized the two known IFN-γ-inducing cytokines IL-12 and IL-18 
using antibodies when stimulating splenocytes with heat-killed S. aureus. We found that 
neutralization of IL-12p40 but not IL-18 or the addition of irrelevant antibody (isotype) 
reduced IFN-γ levels in cells stimulated with heat-killed S. aureus (Figure 29). 
Together, these data suggest that S. aureus can induce IFN-γ through a SAg-
independent mechanism, by activating NK cells to produce IFN-γ through IL-12. 
Effect of EPS on SAg-Independent Induction of IFN-γ by S. aureus 
 Our data suggest that EPS reduces IFN-γ levels during systemic S. aureus 
infection, and that this IFN-γ is induced likely through both SAg-dependent and SAg-
independent processes. This indicates that EPS interferes with IL-12-dependent 
activation of NK cells by S. aureus, but no evidence to date exists to support the idea 
that EPS affects NK cell functions. To test this, we treated mice with EPS by i.p. injection 
and isolated the total splenocytes the next day. We stimulated these splenocytes ex vivo 
with heat-killed S. aureus to see if EPS reduces NK cell-derived IFN-γ production. While 
splenocytes from PBS-treated mice produced IFN-γ in response to heat-killed S. aureus, 
splenocytes from EPS-treated mice essentially did not produce IFN-γ (Figure 30). In 
addition, splenocytes from EPS-treated mice produced reduced levels of the pro-
inflammatory cytokine IL-6 and higher levels of the anti-inflammatory cytokine IL-10 
compared to cells from PBS-treated mice (Figure 30). No differences in IL-2 
production were observed (Figure 30).   
111 
 
 
 
We then asked if this alteration of splenic cytokine response, especially the reduction in 
IFN-γ, requires TLR4 by performing the same experiment with TLR4-deficient mice. 
We found that in TLR4 KO mice, the reduction in IFN-γ and IL-6, along with the 
Figure 30: Effect of EPS on Heat-Killed S. aureus-Induced Splenic Cytokine 
Response in Wild-Type and TLR4-Deficient Mice. Splenocytes from PBS- or 
EPS-treated wild-type or TLR4 KO mice were stimulated with heat-killed S. aureus 1 
day after i.p. EPS injection. At 24 hr, levels of cytokines in the culture supernatants were 
determined by CBA. Each triangle represents data from one mouse. Bars represent 
mean. Data pooled from 6 (WT) and 3 (TLR4 KO) independent experiments. N = 14-15 
(WT), 4-6 (TLR4 KO). *P<0.05. ***P<0.001. ****P<0.0001. 
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increase in IL-10 production by EPS in response to heat-killed S. aureus was abrogated 
(Figure 30). These data suggest that EPS reduces NK cell production of IFN-γ in 
response to S. aureus through TLR4. In addition, EPS imprints an anti-inflammatory 
signature on splenic cytokine response to S. aureus through TLR4, reducing pro-
inflammatory IL-6 production and increasing anti-inflammatory IL-10 production. 
Immunostimulatory Properties of EPS 
 EPS bolsters antimicrobial immunity and reduces inflammation by limiting SAg 
stimulation of T cells and by limiting IFN-γ production by NK cells. This “EPS-primed” 
immunity results in reduced bacterial burden and limited inflammation during S. 
aureus bloodstream infection, improving host survival. However, the mechanism by 
which EPS is able to prime host immunity is not clear. To elucidate this mechanism, we 
sought to characterize the basic immunologic properties of EPS. One observation we 
focused on was that the effects of EPS, both from previous studies and from this study, 
required TLR4 (Jones et al., 2014; Paynich et al., 2017). TLR4 is best characterized as 
the signaling receptor for LPS, driving activation of NF-κB and subsequent production 
of pro-inflammatory mediators (Hoshino et al., 1999; Kawai et al., 1999). Given that the 
induction of peritoneal M2 MΦs is TLR4-dependent (Paynich et al., 2017), we 
hypothesized that EPS could be activating TLR4 signaling in peritoneal MΦs. To test 
this, we stimulated peritoneal F4/80+ cells with EPS in vitro and measured the levels of 
cytokines and chemokines in the culture supernatant. We found that EPS treatment 
resulted in induction of many pro-inflammatory cytokines and chemokines as did LPS, 
including IL-6, KC, MIP-1α, MIP-1β, and TNF (Figure 31).   
113 
 
 
 
We also found that EPS stimulated the production of IL-1α, IL-1β, and MCP-1 while LPS 
failed to do so (Figure 31), at least at the concentrations we tested. We also observed 
that the anti-inflammatory cytokine IL-10 was produced by cells stimulated with EPS 
and LPS, though the levels were higher in EPS-treated cells (Figure 31). Paynich and 
colleagues previously reported that the peritoneal F4/80+ cells increased intracellular 
levels of IL-4 and IL-13 upon stimulation using intracellular flow cytometry (Paynich et 
al., 2017), but we did not detect any increase in IL-4 or IL-13 levels in the supernatant of 
these cultures (Figure 31). We also observed that while EPS or LPS did not increase the 
Figure 31: Effect of EPS on Production of Cytokines and Chemokines by 
Peritoneal MΦs. Peritoneal F4/80+ cells (105) from naïve Balb/cJ mice were 
stimulated with EPS or LPS and the levels of cytokines and chemokines in culture 
supernatants were measured at 24 hr using CBA. Error bars represent SD. 
Representative data from 4 independent experiments. N = 3. Data analyzed using 1-way 
ANOVA with Bonferroni’s multiple comparisons test. **P<0.01. ***P<0.001. 
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expression, some baseline level of IL-12p70 production by these cells was detected 
(Figure 31). 
 We next tested if EPS activates NF-κB activation. Paynich and colleagues 
previously reported that treatment of RAW 264.7 cells increases their expression of M2 
MΦ markers(Paynich et al., 2017) , suggesting that EPS also activates RAW 264.7 cells. 
To test if EPS activates NF-κB, we utilized RAW 264.7 cells with a chromosomal 
integration of a secreted embryonic alkaline phosphatase (SEAP) gene whose expression 
is driven by NF-κB or activator protein 1 (AP-1), allowing estimation of NF-κB or AP-1 
activation by measuring SEAP activity levels. We stimulated these reporter cells with 
EPS for 24 hr and measured the activity of SEAP in culture supernatants.   
Figure 32: Effect of EPS on NF-κB Activation. RAW-SEAP cells were stimulated 
with either LPS, EPS, or ΔEPS for 24 hr and the activity of NF-κB reporter, SEAP, was 
measured in culture supernatants using a colorimetric assay. Error bars represent SD. 
Representative data from 4 independent experiments. N = 3. Data analyzed using 1-
way ANOVA with Dunnett’s multiple comparisons test. ***P<0.001. 
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We found that like LPS, EPS induced SEAP activity from these cells in a dose-dependent 
manner (Figure 32), suggesting that EPS activates NF-κB. ΔEPS was not able to induce 
NF-κB activity at any concentrations tested (Figure 32). Together, these data suggest 
that EPS harbors TLR agonistic properties in vitro. 
Mechanism of EPS-Induced IL-4 Receptor Expression 
 EPS induces the expression of M2 MΦ markers both in vitro and in vivo 
(Paynich et al., 2017). One key molecule associated with this effect has been the IL-4 
receptor alpha chain (IL-4Rα), whose expression is increased in EPS-induced peritoneal 
LPMs and also in EPS-treated peritoneal MΦs in vitro (Paynich et al., 2017). IL-4Rα 
forms the IL-4R in complex with the common gamma chain (γc) (Russell et al., 1993), 
and signaling through the IL-4R on MΦs is the best characterized method for alternative 
activation (Stein et al., 1992). Two major cytokines have been demonstrated in the 
literature to increase the expression of IL-4Rα on MΦs, IL-6 and IL-10 (Hutchins et al., 
2012; Mauer et al., 2014), both of which were stimulated from peritoneal MΦs by EPS in 
vitro (Figure 31). To test which of these cytokines drives the increase in IL-4Rα 
expression on MΦs by EPS, we neutralized IL-6 and IL-10 during EPS stimulation of 
peritoneal cells using neutralizing antibodies. In a preliminary experiment, we found 
that neutralization of IL-6 did not affect the increase in IL-4Rα expression by peritoneal 
CD11bhighF4/80high LPMs in vitro (data not shown). However, in the presence of 
neutralizing anti-IL-10 antibodies, EPS did not increase IL-4Rα expression by LPMs 
(Figure 33), indicating that the EPS-driven increase in expression of IL-4Rα and in 
vitro initiation of the M2 polarization requires IL-10.   
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Addition of irrelevant antibody (isotype) to EPS-treated cultures resulted in only a small 
reduction in IL-4Rα expression (Figure 33). 
Mechanism of EPS-Induced Suppression of NK cell IFN-γ Response to S. 
aureus 
 We also sought to elucidate the underlying mechanisms by which EPS limits 
IFN-γ production during S. aureus infection. Paynich and colleagues had previously 
reported that EPS-induced M2 MΦs inhibit T cell activation through TGF-β and PD-L1 
(Paynich et al., 2017). However, the mechanism by which EPS limits IFN-γ induced by 
heat-killed S. aureus, which we found is driven by cytokine-dependent activation of NK 
cells, is not clear. Given that TLR4 was required for EPS inhibition of NK cell IFN-γ 
Figure 33: Requirement for IL-10 on EPS-Induced Expression of IL-4Rα 
by Peritoneal MΦs. Total peritoneal cells (3 x 105) were stimulated with EPS or 
ΔEPS in the presence or absence of neutralizing anti-IL-10 antibody or isotype control. 
Expression of IL-4Rα on CD11bhighF4/80high cells was assessed 24 hr later by flow 
cytometry. A. Representative flow cytometry data. B. Each symbol represents data 
from one mouse. Bars represent mean. Data pooled from 3 independent experiments. 
N = 4 (ΔEPS), 6 (all others). Data analyzed using 1-way ANOVA with Bonferroni’s 
multiple comparisons test. *P<0.05. ***P<0.001. 
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response to heat-killed S. aureus, we reasoned that some of the effector molecules EPS 
induces through TLR4 activation could also be required for this inhibition. We noticed 
that one cytokine induced by EPS treatment of peritoneal MΦs was IL-10 (Figure 31), 
an anti-inflammatory cytokine discovered because of its ability to inhibit IFN-γ 
production in T cells (Fiorentino et al., 1989). We also noticed that splenocytes from 
EPS-treated mice produced increased levels of IL-10 when stimulated with heat-killed S. 
aureus (Figure 30). We tested if EPS requires IL-10 to suppress IFN-γ responses to 
heat-killed S. aureus by administering neutralizing anti-IL-10 antibodies to mice one 
day prior to EPS treatment. Our preliminary results showed that splenocytes from mice 
treated with both EPS and the neutralizing anti-IL-10 antibody had reduced IFN-γ levels 
just like splenocytes from EPS-treated mice (data not shown), suggesting that IL-10 
was not likely the suppressive factor. 
 We then sought for other potential mediators by which EPS limits IFN-γ 
production and focused on TNF-α that was also induced by EPS (Figure 31). TNF-α 
was originally discovered as a factor induced in serum after stimulation with endotoxin 
(Aggarwal et al., 1985; Carswell et al., 1975). TNF-α is generally associated with potent 
pro-inflammatory activity (Osborn et al., 1989b), and is a clinically relevant target in 
many inflammatory diseases. However, TNF-α has also been implicated in 
immunosuppression, especially against T cells (Speiser et al., 1996), and its activity is 
recognized to be more complex.   
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To test if TNF-α was required for the inhibitory effects of EPS on heat-killed S. aureus-
induced IFN-γ, we administered neutralizing anti-TNF-α antibody to mice 1 day prior to 
EPS treatment. Splenocytes from these mice were stimulated with heat-killed S. aureus, 
and the levels of IFN-γ were measured in the culture supernatants 24 hr later. While 
cells from EPS-treated mice produced less IFN-γ compared to PBS-treated mice as we 
observed before, cells from EPS- and anti-TNF-α antibody treated mice did not produce 
less IFN-γ than PBS- and anti-TNF-α-treated mice (Figure 34), suggesting that EPS 
limits IFN-γ induced by heat-killed S. aureus, driven by NK cells, through TNF-α. 
 
Figure 34: Requirement of TNF-α for EPS Inhibition of IFN-γ Induced by 
Heat-Killed S. aureus. Mice were treated with neutralizing anti-TNF-α antibody 1 
day prior to i.p. treatment with PBS or EPS. At 24 hr, splenocytes were harvested and 
stimulated with heat-killed S. aureus at MOI 10. Levels of IFN-γ were determined 
from culture supernatants at 24 hr by CBA. Each triangle represents data from one 
mouse. Bars represent mean. Data pooled from 2 independent experiments. N = 3. 
****P<0.0001. 
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Recruitment and Activation of Immune Cells by EPS 
 Another aspect of EPS we noticed was that EPS-treated peritoneal MΦs 
produced high levels of chemokines KC, MCP-1, MIP-1α, and MIP-1β (Figure 31). 
Chemokines are known to be responsible for the recruitment of various immune cells to 
the tissue (Anisowicz et al., 1987; Martins-Green and Feugate, 1998), and since EPS 
induces the production of chemokines, we hypothesized that EPS could promote 
immune cell recruitment into tissues in vivo.   
Figure 35: Effect of EPS on Neutrophil Recruitment to the Spleen. WT or 
TLR4-deficient mice were treated i.p. with PBS or EPS. The splenic myeloid 
compartment was assessed by flow cytometry 1 day later. A. Representative flow 
cytometry plots showing CD11b+CD11c- splenic myeloid compartment. B. Pooled 
quantification of % Ly6C+Ly6G+ PMNs and % Ly6C+Ly6C- monocytes from the 
CD11b+CD11c- compartment. Each triangle represents data from one mouse. Bars 
represent mean. Data pooled from 4 independent experiments. N = 9 (WT), 7 (TLR4 
KO). ****P<0.0001. 
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In fact, recruitment of CD11b+Ly6C+Ly6G- monocytes and CD11b+Ly6C+Ly6G+ PMNs 
has been observed in the peritoneal cavity 1 day following i.p. EPS injection (Paynich, 
unpublished data). EPS-treated mice have reduced bacterial load in the spleen and liver 
during systemic S. aureus infection, so we tested if EPS can recruit immune cells to the 
spleen in vivo 1 day after i.p. EPS treatment. We found that while neutrophils 
represented about 50% of the splenic CD11b+CD11c- myeloid compartment in PBS-
treated mice, more than 75% of this compartment was neutrophils in EPS-treated mice 
(Figure 35), suggesting that EPS induces neutrophil recruitment in the spleen. We also 
observed that while in PBS-treated mice 40% of the CD11b+CD11c- myeloid cells were 
Ly6C+Ly6G- monocytes, this compartment was reduced to about 15% in EPS-treated 
mice (Figure 35). We also tested if this recruitment depends on EPS activation of TLR4 
using TLR4-deficient mice. We found that EPS-treated TLR4-deficient mice did not 
have increased percentages of Ly6C+Ly6G+PMNs compared to PBS-treated TLR4-
deficient mice (Figure 35), suggesting that EPS recruits neutrophils to the tissue 
through TLR4 signaling. The reduction in % Ly6C+Ly6G- monocytes by EPS did not 
occur in TLR4-deficient mice as well (Figure 35).  
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 Given that EPS activates MΦs to produce cytokines and chemokines (Figure 
31), and that EPS recruits neutrophils to tissues (Figure 35), we wondered if EPS could 
also activate neutrophils for the production of cytokines and chemokines. We tested this 
by isolating bone marrow neutrophils (BM-PMNs) using gradient centrifugation and 
stimulating them with EPS in vitro. We found that stimulation with EPS and LPS, but 
not ΔEPS, of BM-PMNs led to the production of IL-6, MIP-1α, and TNF (Figure 36). In 
addition, production of these molecules required TLR4, as shown by the observation 
that treatment of TLR4-deficient BM-PMNs with EPS and LPS did not induce the 
production of these cytokines (Figure 36). Together, these data suggest that EPS can 
recruit and activate neutrophils through TLR4. 
Figure 36: Effect of EPS on Cytokine and Chemokine Production by 
Neutrophils. Bone marrow neutrophils (105) isolated from WT or TLR4 KO mice were 
stimulated with 5 μg/mL EPS or ΔEPS, or 10 ng/mL LPS for 24 hr. Levels of cytokines 
and chemokines in culture supernatants were determined by CBA. Error bars represent 
SD. Representative data from 2 independent experiments. N = 3. Data analyzed using 1-
way ANOVA with Bonferroni’s multiple comparisons test. ***P<0.001. 
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CHAPTER FOUR 
DISCUSSION 
How Probiotics can Become Therapies 
Barriers to Probiotic Therapy 
 Microbes are gaining an appreciation for their ability to influence many host 
physiologic processes, especially the immune system. The use of microbes in order to 
benefit the host is a concept first characterized by Metchnikoff more than 100 years ago 
(Metchnikoff, 1908), and the practice of this is represented today by the large probiotic 
industry. It is relatively easy for the general public to access an array of probiotic 
products, but the majority of these products are food supplements, and only a limited 
number of probiotics have been approved for use in clinical settings for specific therapy. 
In 2010, the Panel on Dietetic Products, Nutrition and Allergies of the European Food 
Safety Authority gave negative opinions to all health claim submissions related to 
probiotics (Rijkers et al., 2011). 
 The reasons behind the difficulty of getting probiotics to the mainstream clinical 
settings are many and complex, including things such as the discrepancy in the field on 
how to measure health benefits. Still, the primary barrier is that the mechanistic basis 
for how probiotics, and microbes for that matter, confer health benefits are poorly 
understood. Especially concerning is the lack of knowledge on the molecular mediators 
that microbes produce to confer its benefits. Getting new drugs into the bedside relies 
on understanding their pharmacokinetic 
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properties, which allow for the prediction of drug efficacy, tissue distribution, adverse 
effects, and clearance; all are critical parameters required for clinicians to consider when 
tailoring their therapeutic approach to patients. Without identification of the molecules 
that microbes use to benefit hosts, characterization of the pharmacokinetic parameters 
of the probiotic is difficult, and so is predicting its efficacy and the adverse effects. There 
are reports of detrimental traits such as metabolic syndrome that can be conferred by 
the transfer of microbiota from one individual to another in animal models (Ridaura et 
al., 2013), demonstrating a need to understand the underlying mechanisms by which 
microbes affect host physiology. 
 However, this is not to downplay the prospect of microbial therapies. In fact, 
penicillin, the most famous and arguably the most successful medical therapy, is derived 
from a microbe (Fleming, 1929). Given the full range of physiologic systems that 
microbes are being demonstrated to affect, we suspect that studying microbes’ probiotic 
benefits will reveal many novel therapeutic targets and agents that, if their mechanisms 
are elucidated, could be used to improve patient care in many disciplines. 
 In this study, we characterized the use of an EPS molecule derived from the 
probiotic bacterium, B. subtilis, in a model of systemic infection by S. aureus, to prevent 
hosts from succumbing to the disease. We found that EPS does this by stimulating the 
immune system through TLR4, which results in bolstering antimicrobial immunity 
while limiting specific aspects of host inflammatory processes, ultimately reducing 
disease burden and improving survival. However, the structure of EPS is yet unknown, 
and means to detect EPS reliably in vivo do not exist. Therefore, it is currently not 
possible to tract the levels of EPS after administration to hosts in vivo, preventing 
studies from elucidating its pharmacokinetic properties. Developing the tools to reliably 
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detect EPS in vivo would significantly advance our goal of developing EPS into a novel 
therapy for clinical use, since we will be able to understand better the tissue distribution 
of EPS, which will help us predict how EPS affects different host tissue sites, and 
clearance of EPS from the hosts, which will help avoid potential adverse effects of EPS. 
Clinical Considerations for EPS Therapy in Sepsis 
 We demonstrated that pre-treatment of mice with EPS improved outcomes from 
S. aureus bloodstream infection that occurred one day later. In the C. rodentium-
induced colitis model, Jones and colleagues demonstrated that B. subtilis spores could 
be administered to mice as late as 3 days post exposure to C. rodentium (Jones and 
colleagues, unpublished data), suggesting that B. subtilis could potentially be used as a 
treatment for infectious colitis. However, we did not test if EPS could be administered to 
mice after exposure to S. aureus for protection. In this model, EPS-treated mice had 
signs of protection that could be detected as early as 6 h.p.i. (Figure 6C), and immune 
cells isolated from EPS-treated mice respond differently to S. aureus ex vivo by 1 day 
after EPS treatment (Figure 10 and 30), suggesting that EPS primes the host 
immunity in a way better suited for survival when challenged by S. aureus. In addition, 
the peak disease symptoms occur 10 d.p.i. in C. rodentium-induced colitis, so the 
administration of B. subtilis spores at 3 d.p.i. in this is still prior to the development of 
disease symptoms. Sepsis patients often present to the healthcare setting after the 
development of symptoms which rapidly deteriorate, making it a challenge for clinicians 
to identify patients rapidly and to immediately treat them (Rhodes et al., 2017; Singer et 
al., 2016). Therefore, testing if EPS could be used as a treatment for patients with an 
established bloodstream infection is clinically relevant. 
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 Still, the pre-treatment model can be a successful therapy in many situations 
regarding sepsis. One major risk factor for developing bloodstream infections is invasive 
procedures. S. aureus is a major concern for these patients since S. aureus is normally 
found on patients on the skin and anterior nares (Gorwitz et al., 2008). During invasive 
procedures, S. aureus on the skin can get access into the bloodstream, a concern that is 
managed by antimicrobial prophylaxis (Bratzler et al., 2013). 
 Invasive procedures are performed on a daily basis, close to 40 million episodes 
reported between 2009-2014 in the UK (Abbott et al., 2017). We reason that EPS could 
be used prior to an invasive procedure, to prime the patient’s immune system against 
potential systemic S. aureus infection and improve outcomes. As it will be discussed 
later, this approach with EPS may have some limitations given that we have not tested 
EPS against other potential bloodstream pathogens; the protective mechanism of EPS 
on S. aureus infection may not work, or even be detrimental, in infections by other 
causes. Once again, a better understanding of the mechanisms underlying EPS 
protection from S. aureus, and potentially from other etiologic agents, will help develop 
EPS into specific therapies that ultimately benefit humanity. 
EPS Protection from S. aureus Bloodstream Infection: Role of IFN-γ 
The Duality of IFN-γ: Initial Observations 
 Systemic infection is a complex challenge for the host. The host must mount 
aggressive pro-inflammatory immune responses to remove the invading pathogen, but 
in doing so, limit overt inflammation. As we discussed previously, S. aureus harbors 
numerous mechanisms to subvert host immunity, rendering the pro-inflammatory 
responses ineffective. This persistence inflammation damages the surrounding tissue 
and impedes organ functions, causing severe conditions such as sepsis. 
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 We initiated this study under the premise that EPS, through its anti-
inflammatory properties, could reduce inflammation during S. aureus infection to 
improve disease outcomes. However, we found that the effects of EPS are more complex, 
inducing hybrid MΦs that perform both pro- and anti-inflammatory functions. In 
addition, EPS prevented the induction of IFN-γ during disease, a paradoxical result 
given the canonical view of IFN-γ as a cytokine that enhances antimicrobial functions of 
phagocytes (Held et al., 1999). Consistent with our observation, some studies 
demonstrated that in S. aureus bloodstream infection, IFN-γ plays a detrimental role for 
the host since neutralization of IFN-γ using antibodies or the infection of IFN-γ-
deficient mice led to improved survival and reduced bacterial load (Nakane et al., 1995; 
Sasaki et al., 2000). EPS-treated mice had reduced IFN-γ levels both in the serum and 
in organs after infection with S. aureus, leading us to conclude that by limiting IFN-γ 
production, EPS reduces the detrimental effects of IFN-γ during pathogenesis, reducing 
disease burden. However, the specific reason as to how the reduction in IFN-γ levels 
correlates with improved disease outcomes in systemic S. aureus infection is not 
apparent. 
 Since its discovery, IFN-γ has been characterized as a molecule driving immune 
response against intracellular pathogens (Wheelock, 1965). IFN-γ mediates its effects 
through its receptor, which is a heterodimer of IFN-γ receptor 1 (IFN-γR1) and IFN-γR2 
(Basu et al., 1988; Hemmi et al., 1989; 1994; Soh et al., 1994). The activation of the IFN-
γR activates the Janus kinase-signal transducer and activator of transcription (JAK-
STAT) pathway that stimulates the expression of various genes involved in immune 
responses (Igarashi et al., 1994; Sakatsume et al., 1995). In spite of the studies showing 
that the absence of IFN-γ led to improved survival and reduced bacterial load (Nakane 
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et al., 1995; Sasaki et al., 2000), the general consensus is that IFN-γ plays a protective 
role during S. aureus infection. This is because the treatment of MΦs with IFN-γ in vitro 
augments their activation (Held et al., 1999; Murray et al., 1985), and treatment of 
neutrophils with IFN-γ in vitro enhances their capacity to kill S. aureus (Edwards et al., 
1988). In vivo, immunization of mice through primary infection with a low inoculum of 
S. aureus protects mice from subsequent re-challenge with S. aureus 8 weeks later, and 
this protection is abrogated in IFN-γ-deficient mice (Sasaki et al., 2006), suggesting that 
IFN-γ mediates protection in vivo. In addition, systemic administration of recombinant 
IFN-γ to mice reduces mortality during S. aureus bloodstream infection (Zhao et al., 
1998), consistent with the consensus view that IFN-γ plays a protective role. 
 However, a closer look into the studies of S. aureus infection involving IFN-γ 
reveals a more complicated story. Zhao and colleagues initially reported that the 
administration of recombinant IFN-γ protected mice from S. aureus bloodstream 
infection (Zhao et al., 1998). In contrast, this group previously reported that IFN-γR-
deficient mice have increased arthritis severity during systemic infection by S. aureus, 
but also noted that at later points of infection, fewer IFN-γR-deficient mice succumbed 
to disease compared to WT mice, suggesting a pathological role of IFN-γ signaling (Zhao 
and Tarkowski, 1995). These results were corroborated by another group that 
administered neutralizing anti-IFN-γ antibodies to C57Bl/6 mice during infection and 
found improved survival (Nakane et al., 1995). Also, Sasaki and colleagues used IFN-γ-
deficient mice and showed improved survival and reduced bacterial load during S. 
aureus bloodstream infection (Sasaki et al., 2000), providing a view that contradicts the 
general view that IFN-γ is protective.  
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The Duality of IFN-γ: Role of Neutrophils 
 There is an apparent paradox regarding the protective and pathogenic roles of 
IFN-γ during S. aureus bloodstream infection. Although the underlying reason for this 
duality of IFN-γ remains unclear, one hypothesis to explain this can be derived from a 
critical observation made in IFN-γ-deficient mice. When Sasaki and colleagues assessed 
the kidney of infected IFN-γ-deficient mice for histopathology, they noticed smaller and 
fewer abscesses, with neutrophils present but the borders unclear (Sasaki et al., 2000). 
Usually, abscess from S. aureus infections show a necrotic focus containing viable 
bacteria with neutrophils surrounded by a fibrous capsule. Under the premise that 
abscess is a host mechanism to contain the bacterial infection, such finding of an 
abscess with unclear borders would implicate incomplete control of bacterial 
dissemination. However, this is not the case, since these mice had improved survival. In 
addition, abscess formation is also promoted by the bacteria as well, since bacterial 
factors from S. aureus are required (Cheng et al., 2009; Lam et al., 1963). This suggests 
that S. aureus might utilize the abscess as a way to promote its own pathogenic program. 
 One target of S. aureus manipulation of host response is the neutrophil. The 
infected site becomes concentrated with neutrophils as they are recruited to clear the 
pathogen. These neutrophils augment their antimicrobial functions through NETosis 
(Brinkmann et al., 2004). Ironically, NETosis has been implicated in S. aureus immune 
evasion. Thammavongsa and colleagues assessed renal abscesses from S. aureus-
infected mice using immunohistochemical staining and found that the inner parts of the 
abscess only contained Ly6G+ neutrophils. In contrast, F4/80+ MΦs were concentrated 
around the periphery of the abscess, excluded from the central infected foci 
(Thammavongsa et al., 2013). These investigators also observed that in mice infected 
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with mutants deficient in nuclease (Nuc) and adenosine synthase A (AdsA), F4/80+ cells 
were found within the abscess, indicating that this mutant S. aureus failed to exclude 
MΦs from the abscess. This was mediated by S. aureus converting host DNA released 
from neutrophils during NETosis into deoxyadenosine, known to be toxic to MΦs 
(Thammavongsa et al., 2013). Not surprisingly, infection with one of these mutants, 
adsA, resulted in reduced CFU S. aureus in the kidney (Thammavongsa et al., 2009). It 
should be noted that NETosis is probably not required for S. aureus to obtain DNA from 
neutrophils since S. aureus can also use the pore-forming toxin LukED to directly kill 
neutrophils (Alonzo III et al., 2012a) and release DNA from neutrophils. Therefore, it 
can be inferred that while neutrophils play a critical role in containing the initial 
infection by S. aureus, they also serve as a pool of materials that S. aureus have adapted 
to utilize for immune evasion. 
 This view that the neutrophils are utilized by S. aureus during pathogenesis is 
supported by the studies assessing the role of neutrophils in systemic S. aureus infection. 
The initial studies utilized in vivo depletion of neutrophils using anti-Gr-1 antibodies 
that demonstrated that 10 of 13 neutrophil-depleted mice had died from bloodstream 
infection by S. aureus by 2 d.p.i. compared to 0 of 14 deaths in control mice (Verdrengh 
and Tarkowski, 1997). It should be noted here that the extreme sensitivity of neutrophil-
depleted mice in the study by Verdrengh and Tarkowski may be due to the fact the 
authors likely depleted both monocytes and neutrophils since anti-Gr-1 antibody (RB6-
8C5) targets both Ly6C+ monocytes and Ly6G+ neutrophils. Still, another study has used 
anti-Ly6G antibody (1A8) to specifically deplete neutrophils in vivo, which also 
rendered mice more prone to death during S. aureus bloodstream infection (Alonzo III 
et al., 2012a). The presumed protective role of neutrophils in S. aureus infection came 
130 
 
 
 
into question when investigators unexpectedly observed that an influx of neutrophils 
correlated with increased CFU S. aureus (Lowrance et al., 1994). In a study using an 
anti-Gr-1 antibody to limit, but not deplete, neutrophils in vivo, Gresham and colleagues 
found a decrease in bacterial burden during systemic S. aureus infection (Gresham et al., 
2000). Combined with the observation that S. aureus readily survives within leukocytes 
(Rogers and Tompsett, 1952), these data indicate that neutrophils, while required for 
host survival during S. aureus disease, also serve as a niche for S. aureus survival. 
The Duality of IFN-γ: Linking IFN-γ with Neutrophils 
 The observation linking the alteration of abscesses in IFN-γ-deficient mice and 
neutrophils came from a study in which McLoughlin and colleagues observed that 
TCRα/β-deficient mice had reduced numbers of S. aureus within abscesses and reduced 
local levels of CXC motif chemokines such as KC (CXCL1) and MIP-2 (CXCL8), which 
correlated with reduced myeloperoxidase (MPO) activity in tissues (McLoughlin et al., 
2006). They also observed that IFN-γ-deficient mice had slightly reduced levels of KC at 
6 h.p.i. and MIP-2 at 48 h.p.i., with reduced MPO activity (McLoughlin et al., 2008), 
suggesting that IFN-γ promotes neutrophil recruitment through local production of 
CXC motif chemokines, leading to increased bacterial burden within the abscess. 
Similarly, the study of sea mutant demonstrated that sea-infected mice had reduced 
levels of IFN-γ in the liver, which correlated with a reduced number of hepatic abscesses 
(Xu et al., 2014). This study also reported that the number of CD11b+Ly6G+ neutrophils 
was reduced in the liver by 96 h.p.i., consistent with the view that IFN-γ promotes 
neutrophil recruitment (Xu et al., 2014). These data indicate that IFN-γ contributes to 
recruitment of neutrophils during S. aureus infection, thereby increasing the cells S. 
aureus can target for its own survival within the infected site. 
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The Duality of IFN-γ: Role of Macrophages 
 While the studies of neutrophils reveal the nature of S. aureus-induced abscess 
as a potential survival mechanism, they only reported a reduction in the number and 
size of abscesses during infection. As yet, there are no data to directly explain how in 
IFN-γ-deficient mice, the abscess structure was less organized, and the borders 
obscured (Sasaki et al., 2000). The periphery of the abscess is described by a fibrous 
capsule that surrounds the necrotic region (Kobayashi et al., 2011), and the excluded 
MΦ are located just outside the periphery of the abscess (Thammavongsa et al., 2013). 
MΦs are known to express a variety of matrix metalloproteinases (MMP) upon both 
classical and alternative activation (Huang et al., 2012), and these MMPs mediate 
breakdown of extracellular matrix components (Gross and Lapiere, 1962; Wart and 
Birkedal-Hansen, 1990). We suggest that in IFN-γ-deficient mice, the reduction in 
neutrophil numbers in the abscess leads to reduced S. aureus-induced toxicity against 
MΦs, thereby increasing MΦ presence around the abscess. These MΦs could utilize their 
MMPs to break down the fibrous capsule surrounding the abscess to gain access to the 
abscess; indeed, a corresponding increase in F4/80+ cells within abscesses can be 
observed when S. aureus cannot produce deoxyadenosine to exclude MΦs 
(Thammavongsa et al., 2013). This MMP-mediated breakdown of the abscess border 
may explain why the abscess borders are obscure in IFN-γ-deficient mice, and may also 
signify that in these mice, the abscess is more accessible by immune cells, further 
enhancing host responses to S. aureus. Assessing the status of extracellular matrix 
components in IFN-γ-deficient mice during S. aureus infection could reveal if the 
breakdown in the fibrous capsule is responsible for the obscure borders.  
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Proposed Model of the Role of IFN-γ During S. aureus Pathogenesis 
 In conclusion, abscess formation, and the role of IFN-γ during S. aureus 
infection are complex processes that require further studies to elucidate. At present, we 
propose the following model (Figure 37) for the role of IFN-γ in S. aureus pathogenesis. 
S. aureus induces an early IFN-γ response from T or NK cells that leads to the local 
production of CXC motif chemokines such as KC (CXCL1) in the tissues, which 
promotes neutrophil recruitment and initiates abscess formation (Figure 37A). The 
source of CXCL1 is not known (Figure 37A). Within the abscess, PMNs take up S. 
aureus for killing, but S. aureus survives within PMNs. The more PMNs take up the 
bacteria, the more S. aureus survives within the PMNs, increasing the CFU S. aureus 
within the abscess (Figure 37B). PMNs augment their antimicrobial functions through 
NETosis, which releases chromatin to trap the invading bacteria, but S. aureus utilizes 
this DNA for its own survival, killing MΦs that are additionally recruited (Figure 37B). 
S. aureus also uses leukotoxins to kill neutrophils, releasing more DNA to kill MΦs 
(Figure 37B).   
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These processes, stemming from the initial IFN-γ production, form an abscess that 
Figure 37: Proposed Model for the Role of IFN-γ and Abscess Formation 
During S. aureus Pathogenesis. A. S. aureus stimulates IFN-γ production which 
promotes PMN recruitment through chemokine production. Dashed arrow indicates 
that the source of CXCL1 is not known. B. S. aureus readily survives within PMNs after 
phagocytosis. S. aureus utilizes DNA from PMNs to evade MΦ-mediated immunity. C. 
S. aureus excludes MΦs from the abscess outside the fibrous capsule, creating an 
immune-privileged site for bacterial persistence. 
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restricts access by immune cells, allowing S. aureus an immune-privileged environment 
to persist within the host (Figure 37C). 
Proposed Effect of EPS Suppression of IFN-γ on S. aureus Infection 
 We demonstrated that EPS prevents the production of IFN-γ during S. aureus 
infection in vivo. Based on the proposed role of IFN-γ in S. aureus pathogenesis 
(Figure 37), we suggest that EPS disrupts the formation of abscesses, thereby reducing 
bacterial load (Figure 38). With the reduction in IFN-γ levels, the recruitment of 
neutrophils to the site of infection would be disrupted, and there would be a 
corresponding decrease in CFU S. aureus persisting within neutrophils (Figure 38A).   
Figure 38: Proposed Model of the Effect of EPS on S. aureus within 
Abscesses. A. EPS inhibits IFN-γ during S. aureus infection, disrupting neutrophil-
mediated abscess formation. B. Reduced neutrophil recruitment to abscesses reduces 
MΦ toxicity and subsequent exclusion by S. aureus. C. EPS-induced hybrid MΦs 
penetrate abscesses through MMPs, disrupting the abscess capsule to render it more 
accessible by other MΦs. D. EPS-induced hybrid MΦs restrict S. aureus growth within 
the abscess through increased ROS levels. Dashed arrows indicate disruption of process 
by EPS. Yellow circles represent S. aureus. 
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Furthermore, there would be a decrease in the amount of deoxyadenosine produced by S. 
aureus using neutrophil DNA due to a reduction in neutrophil recruitment, which would 
reduce toxicity against MΦs (Figure 38B). This, in turn, could increase MΦ access into 
the abscess where bacteria are present, reducing S. aureus numbers (Figure 38B). 
Since activated MΦs express MMPs (Huang et al., 2012), EPS-activated MΦs may also 
have increased MMP expression to penetrate the abscess better (Figure 38C). We also 
demonstrated that EPS-induced MΦs had increased antimicrobial activity through ROS 
production (Figure 13-15), which would contribute to better pathogen control once the 
cell takes up S. aureus within the abscess (Figure 38D). Visualization of the abscesses 
in EPS-treated mice during S. aureus infection, particularly the periphery of the 
abscesses and the surrounding extracellular matrix components, will help test the 
validity of this model. 
How IFN-γ Can Contribute to Protection from S. aureus 
 There is one key observation we made that creates a discrepancy for the 
proposed model for EPS-mediated protection from S. aureus infection. We proposed 
that the reduction in IFN-γ levels in EPS-treated mice disrupted the recruitment of 
neutrophils to the abscess, which would then correlate with reduced CFU S. aureus 
(Figure 38A). However, we observed that EPS recruits neutrophils to tissues (Paynich, 
unpublished data and Figure 35). One explanation for this apparent discrepancy can 
be found in yet another discrepancy, the finding that mice treated with recombinant 
IFN-γ are protected from S. aureus bloodstream infection (Zhao et al., 1998). In this 
case, recombinant IFN-γ was administered to mice systemically (Zhao et al., 1998), 
which would theoretically activate all cells expressing the IFN-γR. While S. aureus 
survives within neutrophils, and the literature suggests that neutrophils contribute to S. 
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aureus persistence, IFN-γ-activated neutrophils readily kill S. aureus (Edwards et al., 
1988). Enhancing the bactericidal capacity of individual neutrophils in vivo, e.g., by 
systemic administration of recombinant IFN-γ (Zhao et al., 1998), should reduce the 
initial burden of S. aureus at the infected sites, leading to improved outcomes. We 
observed that EPS activates BM-PMNs (Figure 36), so EPS could systemically enhance 
their antimicrobial activities against S. aureus in vivo, which would lead to the better 
killing of S. aureus by PMNs, thereby reducing overall bacterial burden independent of 
the effects of EPS on IFN-γ and abscess formation. 
The Source of IFN-γ During S. aureus Infection In Vivo 
 Perhaps reflective of the important role IFN-γ plays during S. aureus 
pathogenesis, S. aureus harbors two classical and two alternative mechanisms to induce 
host IFN-γ production. The two classical mechanisms are Ag-mediated activation of 
cognate T cells and SAg-mediated polyclonal activation of T cells. In both cases, T cells 
are activated and undergo proliferation and produce effector cytokines. Experimentally, 
the activation of mouse T cells with CP8, a capsular polysaccharide Ag of S. aureus, 
resulted in IFN-γ production 72 hr post stimulation (McLoughlin et al., 2008). In our 
studies, high levels of IFN-γ were detected 96 hr after stimulation with SEl-Q containing 
culture supernatants (Figure 26B). However, the in vitro kinetics of IFN-γ do not 
match the kinetics of IFN-γ levels during S. aureus bloodstream infection in vivo. 
Nakane and colleagues reported that during systemic S. aureus infection, serum IFN-γ 
was detectable at low levels at 1 d.p.i., undetectable in the following couple days, and 
then peaked at much higher levels by 5 d.p.i (Nakane et al., 1995). We also detected IFN-
γ in the serum at 1 d.p.i. (Figure 4), but IFN-γ was not detectable at 3 d.p.i. (data not 
shown), confirming that IFN-γ is produced in a biphasic manner during S. aureus 
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bloodstream infection: an early low-level response at 1 d.p.i. and a surge in levels later in 
infection, between 3 and 5 d.p.i. SAg-induced IFN-γ in vitro was detected at 96 hr post 
stimulation (Figure 26A and B), more in line with the timing of the in vivo surge later 
in infection. In contrast, the level of IFN-γ at 24 hr after stimulation with SAg was 
relatively low (Figure 26A), so it is not likely that the activation of T cells through the 
two classic mechanisms is responsible for the early IFN-γ response observed at 1 d.p.i. 
in vivo. 
 Mice infected with the SEA-deficient mutant, compared to WT, reportedly had 
lower IFN-γ levels during infection (Xu et al., 2014), but we did not observe this with 
our SEl-Q-deficient mutant (Figure 24). One possible explanation for this is that 
because each SAg has specificities for a specific TCR Vβ sequence, the activation profile 
of the SEA and SEl-Q would be different. Therefore, SEA could activate resident cells in 
the liver that bear the TCR Vβ that SEA recognizes, while SEl-Q would not. Xu and 
colleagues also observed that in the Newman strain, sea is encoded in the same immune 
evasion cluster of β-hemolysin converting phage that encodes other immune evasion 
molecules, especially those involved in evading neutrophil-mediated immunity (Xu et al., 
2014). This suggests that sea may be co-regulated in a way that promotes expression 
during neutrophil influx early in the disease. In contrast, the seq gene is only neighbored 
by the sek gene, so SEl-Q may not be expressed in the manner sea is expressed in vivo. 
Still, the decrease in IFN-γ level in the sea-infected mice was only partial (Xu et al., 
2014), consistent with the view that S. aureus can induce IFN-γ through other means. 
 S. aureus has alternative mechanisms to induce IFN-γ responses that are more 
rapid. We found that the stimulation of splenocytes with heat-killed S. aureus-induced 
IFN-γ that was in low but detectable levels at 24 hr post stimulation (Figure 26C). The 
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production of IFN-γ through this method required NK1.1+ cells, CD11b+ cells, MyD88 
signaling, and IL-12 (Figure 27-29), suggesting that S. aureus activates myeloid cell 
production of IL-12 that activates NK cells for the production of IFN-γ. Another pathway 
may involve a specific subset of T cells. Ag-experienced CD8+ T cells were demonstrated 
to produce IFN-γ within 6 hr of stimulation with Pam3CSK4 or resiquimod (R-848), 
TLR1/2 and TLR7 agonists, respectively (Salerno et al., 2016). Since S. aureus 
stimulates immune cells though TLR2, it is possible that these CD8+ T cells could be 
activated by S. aureus directly through TLR2, leading to rapid production of IFN-γ. In 
our hands, depletion of NK1.1+ cells (NK and NKT cells) resulted in complete abrogation 
of IFN-γ production, but depletion of CD3+ cells (T and NKT cells) resulted in only a 
slight decrease that was not statistically significant (Figure 27). Based on these data, 
we suggest that NK cells are the primary mediators of the early IFN-γ response to S. 
aureus infection. We cannot rule out the possibility that NKT cells and T cells, especially 
certain subsets of CD8+ T cells, make a minor contribution to the rapid IFN-γ response 
to S. aureus, and studies utilizing NK cell-depleted mice would allow us to determine if 
non-NK cells contribute. However, we favor the idea that the NK cells are the major 
contributors since in mice infected with L. monocytogenes, another Gram positive 
pathogen, NK1.1+ cells were the dominant IFN-γ-producing compartment at 19 h.p.i., an 
early time point in infection (Thäle and Kiderlen, 2005). 
EPS Suppression of IFN-γ Production Through TNF-α 
 EPS suppressed splenic IFN-γ production in response to heat-killed S. aureus 
(Figure 30), and this required TNF-α (Figure 34). TNF-α has been classified as a pro-
inflammatory cytokine since its discovery as an endotoxin-induced serum factor 
(Carswell et al., 1975). However, TNF-α has a much more complex set of functions, 
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mediated through TNF receptor 1 and 2 (TNFR1/2). When activated, TNFR1 recruits an 
adaptor protein called TNFR type 1-associated death domain protein (TRADD) which 
mediates two seemingly counteractive signaling pathways: Fas-associated death domain 
protein (FADD)-mediated caspase activation leading to apoptosis and TNFR-associated 
factor 2 (TRAF2)-mediated NF-κB and AP-1 activation leading to pro-inflammatory 
gene expression and cell survival (Hsu et al., 1995; 1996). However, most cells are 
resistant to apoptosis when stimulated with TNF-α alone (Sugarman et al., 1985), 
though the reason for this is still not understood. Therefore, the general view is that 
TNFR1 mediates pro-inflammatory activation and survival of cells. However, a study 
showed that TNFR1-deficient mice had increased percentages of CD8+ T cells after 
immunization (Speiser et al., 1996), indicating that TNFR1 promotes peripheral deletion 
of cytotoxic T cells. In addition, TNFR1 signaling was demonstrated to induce myeloid-
derived suppressor cells (MDSC) that induced T cell anergy during S. aureus peritonitis 
(Ledo et al., 2018), indicating an immunosuppressive role. TNFR2 differs from TNFR1 
in that it lacks the death domain. Because of this, TNFR2 was initially thought to only 
mediate cell survival (Tartaglia et al., 1991). However, a later study showed that TNFR2 
could also mediate cell death (Holler et al., 1992), indicating that the signals induced by 
TNFR2 are also complicated. While TNFR1 is expressed ubiquitously, TNFR2 
expression is more limited, generally to the immune system and the nervous system 
(Ware et al., 1991; Yang et al., 2002). Predominant expression of TNFR2 is found on the 
maximally suppressive subset of Treg cells (Chen et al., 2008), and TNF is thought to 
increase survival and expansion of this Treg cell compartment to promote 
immunoregulation in response to inflammation (Grinberg-Bleyer et al., 2010). Since 
EPS induces TNF-α production, we think that some of the immunosuppressive effects of 
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EPS, especially the increase in Treg cells (Paynich et al., 2017) and the reduced response 
to S. aureus SEl-Q (Figure 19), may be mediated in part through TNFRs. TNF-α is also 
crucial for survival during S. aureus bloodstream infection (Nakane et al., 1995), 
suggesting that TNF-α-mediated effects of EPS likely play a role in protection from S. 
aureus infection. Studies using TNFR1- and TNFR2-deficient mice will help us test this 
hypothesis.  
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 TNFR1 and TNFR2 are both expressed on NK cells, but there is no explanation 
as to why EPS would require TNF-α to suppress IFN-γ production by the NK cells. This 
is because TNF-α was shown to mediate the opposite for NK cells, as the addition of 
TNF-α or a TNFR2 agonist enhances IFN-γ production stimulated by IL-2 and IL-12 in 
human NK cells (Almishri et al., 2016). Therefore, we suggest that EPS-induced TNF-α 
does not directly act on the NK cell itself. We think that there are three possible 
mechanisms by which EPS-induced TNF-α limits IL-12-dependent activation of NK cells 
in response to S. aureus. First, TNF-α could act on the myeloid compartment to limit 
their IL-12 production in response to S. aureus (Figure 39A), leading to reduced 
activation of NK cells and their IFN-γ production. While we could not detect differences 
in IL-12p70 levels in spleen, liver, and kidney of PBS- and EPS-treated mice during S. 
Figure 39: Proposed Model for the Role of TNF-α in EPS Suppression of 
NK Cell IFN-γ Production. A. EPS-induced TNF-α directly inhibits myeloid IL-12 
production in response to S. aureus, reducing NK cell activation. B. EPS-induced 
TNF-α indirectly inhibits myeloid production of IL-12 in response to S. aureus, 
through a yet unidentified mediator cell. C. EPS-induced IFN-γ inhibits NK cell 
sensitivity to IL-12, likely through a yet unidentified mediator cell. The mediator could 
consist of multiple cell types and signaling pathways. 
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aureus infection (Figure 21-23), we did observe reduced serum levels of IL-12p70 in 
EPS-treated mice at 1 d.p.i. (Figure 4), suggesting that EPS has the capacity to limit IL-
12 production. Another possibility is that EPS-induced TNF-α acts on a yet unidentified 
mediator cell, perhaps an MDSC, that then inhibits the production of IL-12 in response 
to S. aureus, leading to reduced NK cell activation (Figure 39B). It could also be that 
this mediator cell act on NK cells to reduce their sensitivity to IL-12, such as 
downregulating IL-12R levels on NK cells (Figure 39C), leading to reduced NK cell 
activation by IL-12. Identifying the source of IL-12 during S. aureus infection in vivo 
that is responsible for the activation of NK cells and assessing the expression of IL-12R 
on NK cells will help elucidate this mechanism further. 
EPS Protection from S. aureus Bloodstream Infection: Role of Macrophages 
Antimicrobial Mechanisms of Hybrid Macrophages: ROS 
 EPS-induced MΦs were previously characterized as anti-inflammatory M2 MΦs 
that limit T cell activation (Paynich et al., 2017). Our results showed that EPS-induced 
MΦs are hybrid MΦs with both M1- and M2-like qualities, able to restrict S. aureus 
growth through ROS and limit T cell activation by S. aureus SEl-Q. In mediating 
opsonophagocytic killing, MΦs use a variety of mechanisms to kill bacteria; the two 
major mechanisms are RNS and ROS production. While RNS did not explain the 
enhanced restriction of S. aureus by EPS-induced MΦs, RNS was produced by these 
MΦs, suggesting that RNS contributes to the restriction of S. aureus growth (Figure 
16). In demonstrating that ROS was responsible for the enhanced restriction, we used 
DPI, an irreversible inhibitor of NADPH oxidase (Cross and Jones, 1986). However, DPI 
is known to have off-target effects that lead to inhibition of mtROS production as well 
(Li and Trush, 1998), so we cannot identify the source of ROS responsible for restriction 
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of S. aureus growth. However, recent studies have highlighted the close relationship 
between mtROS, M2 MΦs, and killing of S. aureus, leading us to think that mtROS play 
a vital role in the restriction of S. aureus growth. 
 ROS production from the mitochondria is thought to occur as a byproduct of 
mitochondrial metabolic processes since increasing mitochondrial respiration increases 
MΦ ROS levels (Arsenijevic et al., 2000). One key feature of M2 MΦ differentiation is 
fatty acid oxidation (Huang et al., 2014), a mitochondrial metabolic process. Therefore, 
M2 MΦs are expected to produce higher levels of mtROS, and indeed, EPS-induced 
MΦs had higher mtROS levels (Figure 14B). A recent study showed that during S. 
aureus infection, MΦs recruit mtROS-containing vesicles derived from the 
mitochondria to the S. aureus-containing phagosomes (Abuaita et al., 2018), suggesting 
that mtROS are involved in the MΦ response to internalized S. aureus. The importance 
of the mitochondria in MΦ-mediated immunity is further highlighted by the discovery 
that S. aureus alpha-toxin drives the mitochondria away from S. aureus-containing 
phagosomes (Cohen et al., 2018), indicating that S. aureus evades the mitochondria to 
promote its survival within the MΦ. While EPS-induced MΦs also increase their mtROS 
levels upon infection with S. aureus, we do not know if EPS-induced MΦs utilize mtROS 
to restrict S. aureus growth, Examination of the mtROS and their recruitment within 
EPS-induced MΦs will help us determine if EPS-induced MΦs use mtROS for restriction 
of S. aureus growth. 
Antimicrobial Mechanisms of Hybrid Macrophages: Other Potential 
Mechanisms 
 While ROS was required for restriction of S. aureus growth by EPS-induced 
MΦs, we cannot rule out the possibility that other mechanisms also contribute. One 
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particular way MΦs can capture intracellular pathogens for killing is through autophagy, 
but it is not clear if autophagy benefits MΦs in their response to internalized S. aureus. 
In fact, accumulation of autophagosomes was associated with enhanced survival of S. 
aureus in BMDCs (O’Keeffe et al., 2015), suggesting that autophagy may be detrimental 
for the host. However, this result is in part due to S. aureus manipulating the autophagic 
processes. S. aureus is known to activate the mammalian target of rapamycin (mTOR) 
through to transit into autophagosomes which prevents its maturation to promote 
persistence (Schnaith et al., 2007). M2 MΦ differentiation involves the activation of the 
mTOR pathway, which drives cells to rely on mitochondrial metabolism (Huang et al., 
2016). Therefore, we hypothesize that EPS-induced MΦs may have an altered state of 
mTOR activation, which could alter the autophagic response to S. aureus infection. In 
addition, EPS-induced MΦs could promote maturation of the autophagosomes, leading 
to enhanced restriction of S. aureus within the cells. Consistent with this model, TLR4 
has been implicated in promoting autophagy through Toll-IL-1R domain-containing 
adaptor-inducing IFN-β (TRIF) signaling, so we think that EPS could also do this 
through TLR4-TRIF signaling. We will need further studies utilizing S. aureus mutants 
that cannot induce autophagy or autophagy-deficient MΦs to test if this process is 
involved in EPS-mediated protection. 
Induction of Hybrid Macrophages by EPS 
 Unlike the effector functions of EPS-induced hybrid MΦs, the mechanisms 
underlying the induction of these cells by EPS is poorly understood. Paynich and 
colleagues previously demonstrated that treatment of peritoneal MΦs with EPS in vitro 
results in increased expression of M2 MΦ markers (Paynich et al., 2017), but these MΦs 
do not recapitulate all of the functions of MΦs isolated from EPS-treated mice (data 
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not shown). To understand why these in vitro-stimulated MΦs did not function like 
EPS-induced MΦs in vivo, we need to consider the dynamic nature of peritoneal MΦ 
subsets. The majority of peritoneal cavity MΦs at steady state are CD11bhighF4/80high 
LPMs (Ghosn et al., 2010). Therefore, in vitro experiments assessing the effect of EPS 
on MΦs were performed on LPMs. However, the peritoneal cavity becomes dominated 
by CD11b+F4/80+/low SPMs after EPS treatment in vivo (Paynich, unpublished data), 
and there is a corresponding decrease in the LPM compartment. By 3 days after EPS 
treatment, the LPM compartment is restored, and the MΦ compartment then consists of 
functional hybrid MΦs. While we do not know the mechanism underlying the induction 
of hybrid MΦs in vivo, we propose a model that potentially explains the process 
considering the dynamics of peritoneal cavity MΦs. 
Ontogeny of Peritoneal Macrophages 
 A hint for the origins of EPS-induced hybrid MΦs can be found in the study of 
peritoneal LPMs and SPMs. Ghosn and colleagues compared the LPMs and SPMs in 
their ability to produce the antimicrobial molecule, RNS, and found that when isolated 
20 hr after i.p. LPS treatment, SPMs increase NO levels higher than that of LPMs; SPMs 
also had higher levels of MHCII (Ghosn et al., 2010). SPMs were shown to be derived 
from the infiltrating CD11b+Ly6C+ monocytes (Ghosn et al., 2010), so it is thought that 
these are cells recruited to mediate antimicrobial responses against invading pathogens. 
EPS induces the infiltration of CD11b+Ly6C+ monocytes into the peritoneal cavity 
(Paynich, unpublished data), so we hypothesize that EPS-induced hybrid MΦs may 
originate from the recruited monocytes like SPMs, which could explain the enhanced 
antimicrobial capacities of these cells. Consistent with this view is that EPS induces the 
production of a variety of chemokines by the peritoneal F4/80+ cells (Figure 31), which 
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would recruit SPMs. It should be noted that in comparing LPMs and SPMs, Ghosn and 
colleagues did not assess ROS production, so we will need to confirm that SPMs have 
increased ROS levels like in EPS-induced MΦs. Also, we will need to confirm if EPS-
induced MΦs are derived from cells in the circulation using fate mapping or adoptive 
transfer approaches. 
Signals Governing EPS-Induced Macrophage Differentiation 
 If EPS-induced MΦs originate from the infiltrating monocytes that are classically 
characterized to mediate pro-inflammatory responses, how is it that these MΦs mediate 
anti-inflammatory functions as well? We think that the answer lies in the signaling 
events that occur after recruitment. Paynich and colleagues demonstrated that 
treatment of peritoneal MΦs increases their expression of IL-4Rα (Paynich et al., 2017), 
indicating that EPS sensitizes cells to activation by IL-4 or IL-13. While we have not 
assessed if this also occurs on the recruited SPMs, the increase in IL-4Rα depends on 
IL-10 (Figure 33), a cytokine produced by type I IFNs, resulting from TLR4-TRIF 
signaling (Chang et al., 2007). Since EPS activates NF-κB through TLR4 (Figure 32) 
and induces cytokine production multiple cell types (Figure 31 and 36), we think that 
EPS could be activating IL-10 production from the recruited SPMs as well, thus 
increasing their IL-4Rα expression. If not, IL-10 produced by the LPMs within the 
peritoneal cavity could act on the recruited SPMs to increase their IL-4Rα expression. 
Signaling through the IL-4R is the classic mechanism for alternative activation of MΦs 
(Murray et al., 2014), so we think that by increasing IL-4Rα expression on the SPMs, 
EPS makes the SPMs prone to alternative activation, leading to their immunoregulatory 
functions. 
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 Paynich and colleagues demonstrated that EPS treatment increases intracellular 
levels of IL-4 and IL-13 on LPMs (Paynich et al., 2017), but we could not detect secretion 
of IL-4 and IL-13 after treatment of peritoneal LPMs with EPS in vitro (Figure 31). In 
addition, i.p. administration of EPS results in the initial disappearance of the LPMs as 
the SPMs get recruited (Paynich, unpublished data), leading us to think that a different 
cell is the source of IL-4 or IL-13. We do not yet know this source, but a number of 
different cell types within the peritoneal cavity are known to produce IL-4 and IL-13, 
leading us to think that these cells could be the source by which EPS drives the 
induction of hybrid MΦs. Amongst these cells, we think that eosinophils, basophils, type 
2 innate lymphoid cells (ILC2), and B cells are the likely cells since they are involved in 
type 2 immune responses defined by IL-4 and IL-13. Interestingly, iNKT cells in the liver 
were demonstrated to produce IL-4 after a sterile injury to drive M2 differentiation of 
the recruited monocytes and promote wound healing (Liew et al., 2017), consistent with 
the view that an accessory cell drives M2 differentiation in EPS-treated mice. It should 
be noted that we cannot rule out the possibility that signals other than IL-4 and IL-13 
drive EPS induction of hybrid MΦs, so we need to consider other signals that could 
contribute. 
 Such an alternative signal to consider for hybrid MΦ differentiation by EPS is 
MCP-1 (CCL2). During murine systemic infection, MCP-1 is produced early and is 
thought to mediate the recruitment of monocytes through its receptor CCR2 (Kurihara 
et al., 1997), thereby promoting inflammation. However, during systemic infection, 
MCP-1 was associated with immunosuppression and increased mortality (Tsuda et al., 
2004). Blockade of MCP-1 in MΦs enhanced M1-associated gene expression while it 
reduced M2-associated genes, suggesting that MCP-1 promotes M2 polarization of MΦs 
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(Sierra-Filardi et al., 2014). EPS induces MCP-1 production by peritoneal LPMs (Figure 
31), so MCP-1 could contribute by not only recruiting monocytes to the peritoneal cavity, 
but also promote their M2 polarization in vivo. In addition, EPS-treatment results in 
abrogated serum MCP-1 levels during S. aureus infection (Figure 4). This reduction in 
MCP-1 during infection may promote MΦs to take on antimicrobial capacities rather 
than fully adopting M2 polarization as in EPS-treated mice, leading to their hybrid state 
capable of both antimicrobial and immunoregulatory functions. In addition, CCR2-
deficient mice show impaired IFN-γ production in response to immunization with 
Mycobacterium bovis (Peters et al., 2000), another parallel observation consistent with 
the abrogation of both MCP-1 and IFN-γ during S. aureus infection by EPS. 
Proposed Model of the Induction of Hybrid Macrophages by EPS 
 Taking the above information into account, we propose the following model for 
EPS induction of hybrid MΦs in the peritoneal cavity. EPS initially activates TLR4-
MyD88 signaling on LPMs, inducing the production of chemokines that lead to 
recruitment of SPMs that have increased antimicrobial capacities (Figure 40A) (Ghosn 
et al., 2010). EPS also activates TLR4-TRIF signaling, which causes IL-10 production, 
driving the expression of IL-4Rα on recruited SPMs (Figure 40B). A yet unidentified 
accessory cell provides IL-4 and IL-13, activating the SPMs and promoting their M2 
differentiation (Figure 40C). Activation through IL-4Rα converts MΦ metabolism to 
mitochondria-driven metabolism (Huang et al., 2016), and TLR4 signaling also 
increases mtROS (West et al., 2011), which contributes to M2 MΦ differentiation 
(Formentini et al., 2017) (Figure 40C). Due to the origin and the differentiation 
pathway of EPS-induced MΦs, we propose that they harbor qualities of both M1 and M2 
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MΦs, able to restrict S. aureus growth and limit T cell activation, making these hybrid 
MΦs (Figure 40D). 
Mechanism Underlying Inhibition of Superantigen-Mediated T Cell 
Activation 
 EPS-induced MΦs inhibit T cells stimulated through the TCR, using anti-CD3ε 
antibodies (Paynich et al., 2017). In this model, EPS-induced MΦs inhibit T cells 
through the inhibitory cytokine TGF-β and the co-inhibitory molecule PD-L1 (Paynich et 
al., 2017). However, the culture supernatant of S. aureus we used for SEl-Q-mediated 
stimulation of T cells contains S. aureus lipoproteins that drive pro-inflammatory 
activation of immune cells. In addition, S. aureus is known to subvert adaptive 
Figure 40: Proposed Model for the Induction of Hybrid MΦs by EPS. A. EPS 
activation of TLR4-MyD88 on LPMs induce chemokine production, recruiting SPMs 
that have increased antimicrobial capacities. B. EPS activation of TLR4-TRIF induces 
IL-10 that act on recruited SPMs to increase their IL-4Rα expression. C. An accessory 
cell produces IL-4 and IL-13 that activates the SPMs through IL-4/13R, driving M2-like 
differentiation. EPS may also increase fatty acid oxidation through IL-4Rα-mTORC2 
signaling, and also mtROS through TLR4, promoting M2 differentiation. D. The EPS-
induced MΦs have both increased antimicrobial capacities to restrict S. aureus growth 
like M1 MΦs and capacity to limit T cell activation like M2 MΦs, a characteristic of 
hybrid MΦs. 
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immunity by altering the expression of co-stimulatory molecules on Ag-presenting cells 
(Sanchez et al., 2017). Therefore, EPS-induced MΦs could use other mechanisms to 
inhibit T cells in the presence of S. aureus-derived factors due to the pro-inflammatory 
signals they receive. We will need to confirm that TGF-β and PD-L1 mediate this 
inhibition or reassess the mechanisms of inhibition to understand inhibition of SAg-
mediated activation of T cells by EPS-induced MΦs. 
Tissue-Specific Protection from S. aureus Infection by EPS 
Role of Interferon-Gamma 
 EPS-treated mice have reduced bacterial burden in the spleen and liver, but not 
in the kidney (Figure 6A and B). While we do not understand the mechanism behind 
this, we suggest that it may be due to the differences in immune cells among these 
tissues. DCs dominate the immune cell population within the kidney (Kaissling and Hir, 
1994; Zheng et al., 2006). This is in contrast to the spleen and the liver that harbor 
many MΦs and lymphocytes. Nakane and colleagues observed that IFN-γ levels in the 
kidney remain at baseline levels throughout the infection (Nakane et al., 1995), and we 
observed that renal IFN-γ levels in S. aureus-infected mice at 1 d.p.i. are barely 
detectable (Figure 23). Therefore, we think that the inhibitory effect of EPS on T and 
NK cells, and the resulting IFN-γ, in the kidney is minimal, since the kidney does not 
harbor so many of these cells. Consistent with this view, sea-infected mice had reduced 
IFN-γ levels in the liver but not in the kidney (Xu et al., 2014), suggesting that IFN-γ 
differentially contributes to pathogenesis among organs, which could explain the lack of 
EPS effects in the kidney. It should be noted that IFN-γ-deficient mice had reduced 
bacterial load in the kidney, and the observation on abscess formation was made from 
the kidney (Sasaki et al., 2000), suggesting that IFN-γ plays an overall pathogenic role 
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in the kidney as well. Therefore, we suggest that EPS does not affect kidney 
pathophysiology. 
Role of Myeloid Cells 
 Another possibility for the failure of EPS to reduce bacterial load in the kidney 
may have to do with the myeloid compartment. As discussed, DCs are the dominant 
immune cell in the kidney (Kaissling and Hir, 1994). Renal DCs are thought to rapidly 
recruit neutrophils upon recognition of infection such as uropathogenic E. coli (Tittel et 
al., 2012). In the case of S. aureus infection, this rapid recruitment of neutrophils may 
promote abscess formation, thereby increasing S. aureus survival. In contrast, the liver 
harbors Kupffer cells, unique tissue resident MΦs, that clear activated neutrophils and 
cellular debris (Brown et al., 2001). Clearance of neutrophils would reduce abscess 
formation within the hepatic tissue and not only help clear the bacteria, but also 
maintain MΦ access to the invading pathogen. Resident MΦs were recently shown to 
cloak pathogens from recognition by neutrophils, preventing the initiation of abscess 
formation and subsequent tissue damage (Uderhardt et al., 2019). This process may also 
be occurring in the liver through Kupffer cells, reducing abscesses. In addition, 
peritoneal LPMs have been demonstrated to be directly recruited to the liver during 
sterile injury, where the LPMs mediated uptake of necrotic tissue debris and promoted 
wound healing (Wang and Kubes, 2016); this may be another way the liver could recruit 
more MΦs during S. aureus infection to clear neutrophils, suppress abscesses, and 
promote wound healing. The spleen also contains specialized resident MΦs, some of 
them known to mediate immunity against bloodborne pathogens (Geijtenbeek et al., 
2002), and these could also contribute to clearing activated neutrophils and provide 
additional immunity against S. aureus. Additionally, EPS could enhance the 
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antimicrobial capacities of MΦs in these tissues to further accentuate the difference in 
responses in these tissues compared to the kidney. 
Activation of TLR4 by EPS 
Classic and Modern Views on the Effect of Lipopolysaccharide in Immunity 
 EPS has broad anti-inflammatory effects that confer host protection against a 
variety of diseases where inflammation plays a role, including infectious diarrhea (Jones 
et al., 2014; Paynich et al., 2017), allergic eosinophilia (Swartzendruber et al., 2019), and 
sepsis. However, we found that EPS also stimulates immune cells through TLR4, leading 
to the activation of NF-κB and pro-inflammatory cytokine production. The best-
characterized ligand for TLR4 is LPS, an inducer of pro-inflammatory responses, and 
the model causative agent of sepsis (Hoshino et al., 1999). However, a closer look at the 
literature on LPS indicates that TLR4 can mediate immunoregulatory responses in vivo. 
The first evidence of this was observed when Uchiyama and colleagues found that while 
LPS administration at the time of immunization enhanced antibody responses, pre-
injecting mice with LPS 3 days prior to immunization reduced antibody responses 
(Uchiyama et al., 1984). Since then, this phenomenon of has been studied in the context 
of LPS-induced endotoxemia model and has been termed sepsis-induced 
immunosuppression or immunoparalysis. Generally, the primary mechanistic focus 
from these studies has been the induction of CD11b+Gr-1+ MDSCs in vivo (Greifenberg 
et al., 2009; Wilde et al., 2009). Therefore, the underlying mechanism for how LPS 
administration results in a suppressed host immunity is poorly understood outside of 
the induction of MDSCs. Because EPS also activates TLR4, we think that some of the 
immunoregulatory mechanisms of EPS could also explain sepsis-induced 
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immunosuppression. This also suggests that the classic view of TLR4 signaling in 
mediating pro-inflammatory responses need to be re-examined. 
 The modern view of immunity is that the immune system, like virtually all other 
physiologic systems in the body, is subject to extensive homeostatic mechanisms. Such 
an idea has been highlighted in studies of inflammation that claim the need to balance 
pro- and anti-inflammatory responses. However, these processes need to be recognized 
as part of the same process. We hypothesize that LPS-induced immunosuppression, and 
even EPS-primed immunity, demonstrate this phenomenon: an initial pro-
inflammatory response activated through TLR4 that results in host countermeasures to 
limit and resolve inflammation. MDSCs would also fit into this view since MDSCs are 
known to be induced through inflammatory mediators such as IL-1β (Elkabets et al., 
2010), representing a host response to inflammation that limits or resolves 
inflammation. 
 Clinically, sepsis-induced immunosuppression is a primary concern, since many 
patients that survive the initial inflammatory phase are vulnerable to superinfections, 
presumably due to the immunosuppressed state that ensues later in the disease. 
Therefore, agents that limit inflammation have not been well-accepted by the field, in 
part due to concerns of worsening the immunosuppressed state of sepsis patients. 
However, we suggest that limiting inflammation during the early phase of sepsis can not 
only improve patient survival, but also reduce the ensuing anti-inflammatory response 
that occurs in response to the initial inflammation, essentially a reflex response. In 
addition, priming the host through TLR4, as shown in our EPS-treated mice, bolsters 
antimicrobial immunity, indicating that the immunoregulatory effect of TLR4 does not 
impair antimicrobial immunity to S. aureus. Therefore, limiting inflammation during 
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the acute phase of sepsis using a TLR4-based immunotherapeutic agent such as EPS 
may be a novel strategy to preserve host immunity during the late phase of sepsis. The 
effect of EPS treatment on preserving host immunity during the late phase of sepsis will 
need to be examined, but EPS limits activation of T cells by S. aureus SAg which 
normally results in deletion of certain T cells from the repertoire, thereby providing 
some evidence for EPS preserving host immunity. 
EPS and LPS 
 EPS and LPS both activate signaling through TLR4. However, LPS is produced 
as a part of the gram negative cell wall while EPS is produced by the gram positive B. 
subtilis, as a part of its biofilm matrix. Therefore, the structure of EPS, while not known, 
is expected to be quite dissimilar compared to LPS. While the idea of two dissimilar 
molecules acting through the same receptor seems unlikely, TLR4 is known to mediate 
signaling by a vast array of ligands, many of them endogenous ligands such as 
fibrinogen (Smiley et al., 2001), hyaluronan (Jiang et al., 2005), and S100 proteins 
(Vogl et al., 2007). The diversity of ligands for TLR4 is possible because TLR4 often 
works in conjunction with co-receptors, such as CD14 and MD-2 that mediate LPS 
recognition. Therefore, we hypothesize that EPS has a distinct receptor that acts as a co-
receptor on TLR4 to initiate EPS-induced TLR4 signaling, a potential difference from 
LPS which uses LPS-binding protein, CD14, and MD-2 (Ryu et al., 2017). While the 
signal itself induced through TLR4 is very similar between EPS and LPS, there may be 
some differences if a different co-receptor is used because this can affect the 
downstream adaptors that are recruited or the amount of TLR4 that is endocytosed to 
mediate TLR4-TRIF signaling. These differences may lead to EPS being used in 
potentially different therapeutic scenarios than other TLR4-targeting agents. The 
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elucidation of EPS structure, and the identification of the EPS receptor, will help us 
understand the biology of EPS-induced signaling, which may even reveal a novel aspect 
of TLR4 biology. 
Other Cell Types that Could Mediate Protection by EPS in S. aureus 
Infection 
 Given that EPS activates TLR4 signaling on both MΦs and neutrophils, we 
hypothesize that many other cell types contribute to EPS-mediated protection from 
sepsis, given that they express the yet unidentified EPS receptor. The following are a 
short, incomplete list of cell types that could be affected by EPS during S. aureus 
bloodstream infection. 
Basophils: Basophils have been demonstrated to protect mice from sepsis induced by 
cecal ligation and puncture through TNF, and these cells express TLR4 (Piliponsky et al., 
2019). TNF-α is crucial for survival during S. aureus infection (Nakane et al., 1995), and 
we hypothesize that EPS could potentially induce TNF-α production by basophils, 
thereby contributing to protection from sepsis. 
Eosinophils: Eosinophils have recently been implicated in protection from S. aureus 
sepsis, through a mechanism that is poorly understood (Krishack et al., 2019). We have 
some evidence that EPS increases the percentage of eosinophils within tissues (Paynich, 
Fleming-Trujillo, unpublished data), and we suggest that eosinophils could mediate EPS 
protection from sepsis. 
Endothelial cells: The major pathologic feature of sepsis, cardiovascular collapse, is 
thought to initiate from endothelial dysfunction. Endothelial cells were demonstrated to 
be activated by LPS through TLR4, but this does not lead to endothelial dysfunction as 
presumed previously (Menghini et al., 2014). Instead, activation of endothelial cells 
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leads to protection from sepsis, presumably from efficient recruitment of neutrophils to 
the site of infection (Andonegui et al., 2009). We think that EPS could also activate 
endothelial cells through TLR4, thereby contributing to protection from sepsis. 
Platelets: Platelets have been demonstrated to mediate host defense against S. aureus. 
One mechanism that bears uncanny similarity to EPS is the ability to enhance 
macrophage uptake and restriction of S. aureus growth, mediated through IL-1β 
production by platelets (Ali et al., 2017). Platelets express TLR4 (Andonegui et al., 2005), 
and stimulation of platelets with LPS leads to the production of IL-1β (Brown et al., 
2013). Therefore, we think that EPS could enhance antimicrobial activities of MΦs 
through TLR4-mediated activation of platelets. In addition, activated platelets have 
been shown to directly kill S. aureus by releasing a yet unidentified antimicrobial 
product (Ali et al., 2017), which could also be a way EPS could promote antimicrobial 
immunity against S. aureus. 
Concluding statement 
 Sepsis is one of the most dramatic manifestations of infection. Patients are 
treated immediately and aggressively, but their conditions can rapidly deteriorate, 
leading to high mortality rates. S. aureus is the leading cause of sepsis, and it is 
incredibly challenging to treat, given its broad antimicrobial resistance profile and an 
uncanny ability to subvert the immune system to persist and even promote its own 
survival. Therefore, novel agents and strategies to combat systemic S. aureus infection 
are critically needed. Probiotics represent a vast potential for developing new therapies, 
but the mechanisms by which they benefit hosts are not known. 
 In this study, we demonstrated that EPS derived from the probiotic, B. subtilis, 
can protect hosts from S. aureus bloodstream infection. EPS does this by priming host 
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immunity through TLR4, which improves antimicrobial functions of MΦs, and limits 
inflammation induced during infection. This EPS-primed immunity prevents S. aureus 
from optimally subverting the host processes for its own pathogenic program, leading to 
reduced disease burden and improved host survival. By priming high-risk patients with 
EPS, we suggest that we can benefit patients undergoing invasive procedures by limiting 
severity during subsequent infection that occurs in high frequency. Still, EPS has the 
potential to affect many other aspects of host physiology beyond the few cell types we 
presented here, so there could be other scenarios in which EPS could be beneficial. By 
increasing our understanding of the structure, host receptor, and the molecular 
pathways of EPS, we will be able to bring EPS, and more broadly TLR4-targeting 
therapy, to the healthcare industry. In addition, we will be able to open the door to 
microbial therapy, a novel sector of therapeutics with a vast potential to benefit 
humanity.
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